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II. SUMMARY/RESUMEN 
 
Introduction 
 
Melanoma is an extremely aggressive type of cancer, whose incidence continues to 
increase worldwide. Despite of new recently approved therapies, melanoma remains highly 
resistant to treatment and relapses are frequently seen in clinical practice. Thus, the 
identification of new mechanisms of melanoma progression and translation of this knowledge 
into the identification of potential therapeutic targets are still strictly necessary. 
Aggressive cancers, and melanoma tumors are no exception, are characterized by an 
exacerbated cell metabolism, which frequently results in the production of misfolded proteins. 
In fact, tumor cells tend to be significantly more dependent on the continuous clearance of 
damaged proteins than their normal counterparts. Therefore, this intrinsic characteristic of 
cancer cells could represent a point of vulnerability for the development of improved 
therapies.  
One of the least understood aspects in melanoma is the modulation of the proteasome 
and the autophagosome machineries, the main mediators of the degradation of damaged 
proteins and protein aggregates. This PhD Thesis focuses on Sequestosome 1/p62. 
Sequestosome 1/p62 is a multifunctional protein involved in proteasomal and autophagosomal 
degradation with key roles in other tumor types, but unknown in melanoma. Importantly, p62 
has also been described as an adaptor protein activating multiple signaling cascades, again, 
virtually unexplored in melanoma. Therefore, p62 is an attractive candidate to be 
characterized in melanoma tumors. 
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The main objectives of this study are: (1) to analyze the expression of 
Sequestosome1/p62 protein in benign melanocytic tumors and melanomas at different stages 
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Results 
 
Tissue microarrays revealed a notable overexpression of p62 in melanoma specimens, 
particularly at invasive stages. In contrast, melanocytic nevi were virtually negative for p62 
expression. Comparative genomic hybridization and expression analyses in a large panel of 
melanoma cell lines support that p62 expression is regulated at transcriptional levels without 
amplification of its genomic locus.  Moreover, in vitro studies with senescent melanocytes 
and in vivo analyses with melanoma mouse models support that p62 expression is induced 
during the malignant transformation of melanocytes. 
Mechanistically, genetic depletion of p62 was found to inhibit cellular proliferation, 
leading to an invariable senescence-like phenotype in melanoma cells, but not in their normal 
melanocytic counterparts. Invasion assay and skin reconstruct experiments showed that p62 
expression also contributes to melanoma invasion capacity. The lack of p62 expression in 
melanoma cells does not block autophagosome formation. Instead, transcriptomic analyses 
revealed new roles of p62 in multiple cellular pathways that modulate cell cycle, DNA 
replication and cellular invasion.  
Corroborating the physiological impact of p62 in melanoma progression, the absence 
of p62 in melanoma cells inhibits tumor growth in mouse xenograft model. Furthermore, 
survival analyses performed in melanoma patients demonstrated that the expression of p62 in 
primary tumors is associated to an increased risk for the development of metastasis.  
 
Conclusions  
 
This multidisciplinary study supports for the first time that Sequestosome1/p62 protein 
is required for melanoma progression. Indeed, Sequestosome1/p62 protein represents a point 
of vulnerability for melanoma cells and, consequently, it may represent a potential target for 
melanoma treatment. 
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Introducción 
 
 
Melanoma es un tipo muy agresivo de cáncer, cuya incidencia sigue aumentando en 
todo el mundo. A pesar de los tratamientos recientemente aprobados para pacientes con 
enfermedad metastásica, melanoma sigue siendo un tumor extremadamente resistente y 
recidivas son frecuentes en la práctica clínica. La identificación de nuevos mecanismos de 
progresión del melanoma y la implementación de esos conocimientos en la identificación de 
nuevas dianas terapéuticas sigue siendo estrictamente necesaria. 
Melanoma, como otros tumores agresivos, se caracteriza por un metabolismo celular 
exacerbado que requiere la degradación continua de proteínas dañadas.  De hecho, las células 
tumorales suelen ser significativamente más dependientes de la degradación de dichas 
proteínas que sus homólogas normales. Esa característica, intrínseca a células cancerosas, 
puede representar un punto de vulnerabilidad para el desarrollo de nuevas terapias. 
Uno de los aspectos menos comprendidos del melanoma es la modulación del sistema 
proteasomal y autofagosomal, principales mediadores de la degradación de proteínas dañadas 
y agregadas. Esta tesis doctoral se centra en Sequestosome1/p62. Sequestosome1/p62 es una 
proteína multifuncional implicada en la degradación proteasomal y autofagosomal de 
proteínas, con funciones claves en otros tipos de tumores, pero todavía desconocidas en 
melanoma. Además, p62 funciona como una proteína adaptadora que activa distintas vías de 
señalización intracelulares implicadas en tumorigenesis. Por lo tanto, la propiedad 
multifuncional de Sequestosome1/p62 combinada con la necesidad de nuevas estrategias en el 
tratamiento del melanoma, señalizan p62 como un atractivo candidato para ser caracterizado 
en este tumor. 
 
Objetivos 
 
Los objetivos principales de este estudio son: (1) analizar la expresión de la proteína 
Sequestosome 1/p62 en tumores melanocíticos benignos y malignos en las diferentes etapas 
de progresión tumoral; (2) determinar la función de la proteína Sequestosome 1/p62 a través 
de estudios in vitro con líneas celulares de melanoma, y; (3) establecer el impacto fisiológico 
de Sequestosome1/p62 in vivo utilizando el modelo de xenoinjerto de ratón y análisis de 
supervivencia en pacientes con melanoma. 
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Resultados 
 
Análisis inmunohistoquímicos en matrices tisulares de lesiones melanocíticas revelan 
que p62 está ausente en nevus intradérmicos, mientas que en los melanomas está 
significativamente sobreexpresada, particularmente en estadios tardíos (metástasis). 
Hibridación genómica comparativa y análisis de la expresión en un gran panel de líneas 
celulares de melanoma revelan que la expresión de p62 está regulada en niveles 
transcripcionales sin amplificación de su locus genómico. Además, estudios in vitro en 
melanocitos senescentes y en modelos de melanoma de ratones sugieren que la expresión de 
p62 es inducida durante la transformación maligna de melanocitos. 
La inactivación dirigida de p62 mediante RNA interferente conduce a un bloqueo en la 
proliferación celular e inducción de senescencia prematura en células de melanoma, efectos 
que no se observaron en melanocitos normales. Ensayos de invasión celular in vitro y en piel 
artificial demuestran que p62 también contribuye a la capacidad invasiva de las células de 
melanoma. Curiosamente, la pérdida de expresión de p62 en células de melanoma no impide 
la formación de autofagosomas, sino que interfiere con una variedad de vías celulares que 
modulan el ciclo celular, la replicación del ADN y la invasión celular.  
Corroborando el impacto fisiológico de p62 en la progresión del melanoma, la 
depleción de p62 se tradujo en un bloqueo significativo de la progresión tumoral en modelos 
de xenoinjertos. Por otra parte, los análisis de supervivencia en pacientes con melanoma han 
demostrado que la expresión de p62 en tumores primarios se asocia a un mayor riesgo de 
desarrollo de metástasis. 
 
Conclusiones 
 
El presente estudio de carácter multidisciplinario apoya por primera vez que la 
proteína Sequestosome1/p62 es necesaria para la progresión del melanoma. De hecho, 
Sequestosome1/p62 representa un punto de vulnerabilidad de las células de melanoma y, en 
consecuencia, podría representar una potencial diana terapéutica en el manejo de los pacientes 
con melanoma.  
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III. ABBREVIATIONS 
 
aa Amino acid 
AD Alzheimer's disease  
AJCC American Joint Committee on Cancer  
AKT Serine/threonine protein kinase Akt  
ALK Anaplastic lymphoma receptor tyrosine kinase 
aPKC Atypical protein kinase  
Atg7 Autophagy related 7 
BAP1 Breast cancer 1-associated protein 1  
BECN1 Beclin 1, autophagy relate 
BRAF v-raf murine sarcoma viral oncogene homolog B1 
BSA Bovine serum albumin  
CDK1 Cyclin-dependent kinase 1  
CDKN2A Cyclin-dependent kinase inhibitor 2A  
cDNA Complementary DNA 
CGH Comparative Genomic Hybridization  
CI Confidence intervals 
CNIO Centro Nacional de Investigaciones Oncológicas 
CO2 Carbon Dioxide  
CTLA-4 Cytotoxic T-lymphocyte antigen-4  
DAPI 4,6-diamidino-2-phenylindole  
DFS Disease Free Survival  
DMEM Dulbecco’s Modified Eagle’s Medium 
DNA Deoxyribonucleic acid 
dsRNA Double-stranded RNA 
EDTA Ethylenediaminetetra-acetic acid 
EGFP Enhanced green fluorescent protein 
EGFR Epidermal growth factor receptor 
ERK1 Extra-cellular signal-regulated kinase-1  
FBS Fetal Bovine Serum 
FDA Food and Drug Administration  
FDR False discovery rate  
FGM Fibroblast growth medium 
GBM Glioblastoma multiforme 
GNAQ Guanine nucleotide binding protein (G protein), q polypeptide  
GSEA Gene Set Enrichment Analysis  
H&E  Hematoxylin and eosin 
HD Huntington's disease  
HMGA2 High-Mobility Group A2  
HR Hazard ratio 
IAP Inhibitor of apoptosis protein  
IF Immunofluorescence 
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IHC Immunohistochemistry 
KEAP1 Kelch-like ECH-associated protein 1  
KEGG Kyoto Encyclopedia of Genes and Genomes 
KGM Keratinocyte growth medium 
KIR Keap-interacting region  
KIT Tyrosine-protein kinase Kit  
LC3 Microtubule-associated protein 1 light chain 3  
LIR LC3-interacting region  
MAPK Mitogen-activated protein kinase  
MC1R Melanocortin receptor-1  
MGM Melanocyte growth medium 
MITF Microphthalmia-associated transcription factor  
mRNA Messenger RNA 
mTOR  Mammalian target of rapamycin  
NCCN National Comprehensive Cancer Network 
NF-kB  Nuclear factor of kappa light polypeptide gene enhancer in B-cells 
NRAS  v-ras neuroblastoma RAS viral oncogene homolog 
NRF2 Nuclear factor (erythroid-derived 2)-like 2 
OCT  Optimal Cutting Temperature  
OS Overall Survival  
P Probability values  
PB1 Phox and Bpem 1  
PBS  Phosphate-Buffered Saline 
PBS-T Phosphate-Buffered Saline with Tween 
PDB Paget Disease of the Bone  
PI3K Phosphatidylinositol 3-kinase  
pIC Polyinosine-polycytidylic acid  
PKC Protein kinase C  
PTEN Phosphatase and tensin homolog 
pUb Polyubiquitin  
RAC1 Ras-related C3 botulinum toxin substrate 1  
RB Retinoblastoma 
RGP Radial Growth Phase 
RIP1 Receptor-interacting protein-1  
RNA Ribonucleic acid 
RNAi RNA interference  
ROS Reactive oxygen species  
RT Room Temperature 
RT-qPCR Real-time reverse transcription polymerase chain reaction 
SA-β-Gal Senescence-Associated β-Galactosidase  
SD Standard deviation 
SEM Standard error of estimate of mean value 
shRNA Short hairpin RNA  
SQSTM1 Sequestosome1/p62 
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TMA  Tissue Microarrays 
TNF Tumor necrosis factor 
TRAF6 TNF receptor-associated factor 6 
TSC Tuberosis sclerosis complex 
Ub Ubiquitin 
UBA Ubiquitin-associated domain  
UPS Ubiquitin-proteasome system  
VGP  Vertical Growth Phase 
WB Western Blotting (Immunoblotting)  
WHO  World Health Organization Classification 
WT Wild Type 
ZIP Zeta-interacting protein  
ZZ Zing finger  
3D-SR Three-Dimensional Human Skin Reconstruct 
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1. INTRODUCTION 
 
1.1. Melanoma 
 
Melanocytes are dendritic cells derived from neural crest precursors. The neural crest 
cells give rise to unpigmented melanoblasts that home to specific destinations, where they 
ultimately form mature pigment-producing melanocytes. Mature melanocytes can be found in 
the skin, hair matrix, eye, inner ear, mucous membranes and central nervous system. In 
normal skin, these cells reside along the basal layer of the epidermis and in the hair bulb, with 
an approximated 1:10 ratio to basal keratinocytes (Dupin et al., 2003; Zabierowski et al., 
2010). 
The major function of melanocytes is to produce and transport melanin to surrounding 
keratinocytes. The pigment melanin confers protection of the mitotically active keratinocytes 
against the effects of ultraviolet light and is responsible for the visible pigmentation of the 
skin, hair, and eyes. 
Defects in melanocytes can lead to numerous pigment disorders. Additionally, an 
abnormal proliferation of melanocytes can generate benign indolent neoplasias, known as 
melanocytic nevi, or a malignant tumor, melanoma.  
Distinct categories of melanocytic neoplasms are distinguished by the current World 
Health Organization (WHO), which includes a list of lesions with different clinical and 
morphological profiles (LeBoit et al., 2006; Whiteman et al., 2011). 
Common nevi are melanocytic lesions frequently found in population. This benign 
neoplasm originates as a focus of melanocytic proliferation within the lower layers of 
epidermis (junctional nevus) that progress to the presence of cells in both epidermis and 
dermis (compound nevus) and lately, it is confined to the dermis (dermal nevus). The 
likelihood of common nevi undergoing malignant transformation is quite remote. Their main 
relevance lies as a confounding factor in the diagnosis of melanomas or as a prognostic factor, 
since an increased number is correlating with a greater risk for melanoma development 
(Swerdlow et al., 1986; Holly et al., 1987).  
Dysplastic nevi are junctional or compound melanocytic neoplasms characterized by 
architectural and cytological atypia. Clinically, dysplastic nevi may occur as sporadic lesions 
or associated to familial syndrome. Dysplastic nevus syndrome affects a group of patients 
with large numbers of atypical nevi, familial history of melanoma and an increased risk of 
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developing melanoma (Carey et al., 1994; Tucker et al., 1997). The malignant transformation 
of dysplastic nevi is quite controversial (Cook et al., 1985; Skender-Kalnenas et al., 1995). 
However, they may represent a confounding factor in the diagnosis of melanomas (Roth et al., 
1991). 
Malignant melanocytic tumors represent the most problematic group of skin cancers 
for patients and physicians. The first recorded description of melanoma in history appeared in 
the writings of Hippocrates in the 5th century, BC (Urteaga et al., 1966; Rebbeca et al, 2012). 
The original description of melanoma as an entity is attributed to René Laennec, who named 
this disease as ‘melanose’ in 1812 (Laennec, 1812). Later on, in 1838, the distinguished 
pathologist Robert Carswell was credited with the creation of the term ‘melanoma’, a word 
derived from the ancient Greek melas, ‘dark’ and oma, ‘tumor’ (Carswell, 1838; Rebbeca et 
al., 2012).  
Since then, it has become clear that melanoma is a complex cancer, with an impressive 
aggressiveness and heterogeneity of its clinical, histological and genetic presentation. 
Although less common than basal or squamous cell carcinoma of the skin, melanomas are 
much more frequently fatal due to their intrinsic tendency to promote metastasis and extreme 
resistance to therapy. Already in 1840, the British surgeon Samuel Copper described that 
advanced stages of melanomas were untreatable, ‘the only chance for benefit depends upon 
the early removal of the disease…’ (Copper, 1840; Rebbeca et al., 2012). Unfortunately, this 
assertion is still largely true to this day. 
 
1.1.1. Incidence and mortality of melanoma patients 
 
Cancer is a major public health problem in many parts of the world. Melanoma is the 
fifth and sixth most incident cancer type in both males and females, respectively (Siegel et al., 
2012). The incidence of melanoma continues to increase dramatically. It is increasing in men 
more rapidly than any other malignancy and, in woman more rapidly than any other 
malignancy except lung cancer (NCCN, 2013).  
In the year 2012, an estimated 76,250 new cases of melanoma were diagnosed and 
about 9,180 patients died of melanoma in the United States (Siegel et al., 2012). The lifetime 
risk of developing the disease in the year 2005 for a person born in the United States was 1 in 
55 (NCCN, 2013).  
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The levels of melanoma incidence vary considerably worldwide. Rates are higher in 
populations where Caucasians predominate (about 80% of the cases diagnosed in 2002 
occurred in the predominantly white populations of Northern America, Australia, New 
Zealand and Europe), and lower in countries where inhabitants are of mainly Asian or African 
origin (LeBoit et al., 2006). 
The median age of the patients at diagnosis of melanoma is 59 years (NCCN, 2013). It 
is one of the most aggressive types of cancer. In fact, melanoma ranks second to adult 
leukemia in terms of loss of years of potential life, per death (NCCN, 2013).  
As with other malignancies, the outcome of melanoma initially depends on the stage at 
the time of diagnosis. The TNM classification and stage groupings for melanoma patients 
depend of histopathological and clinical aspects of the disease. Supplemental Tables 1 and 2 
(page 131) summarize the recent revision of the staging system for cutaneous melanoma by 
the American Joint Committee on Cancer (AJCC) (Balch et al., 2009). The thickness of 
primary tumor, also named Breslow index (Breslow A, 1970), and the presence of ulceration 
and mitotic figures are the most relevant histological predictors for metastatic disease.  
In general, the prognosis of melanoma patients is excellent for patients who present at 
the diagnosis with localized disease and primary tumors 1.0 mm or less in thickness, with 5-
year and 10-year survival rates ranging from 97% to 93%, respectively. Unfortunately, this 
panorama changes with the increase of tumor thickness. In patients staged as T4bN0M0 
(tumor thickness more than 4 mm with ulceration), 5-year and 10-year survival rates decrease 
to 53% and 39% respectively. Moreover, the likelihood of regional nodal involvement 
increases with increasing tumor thickness. When regional nodes or in transit metastases are 
present, 5-year survival decrease to 78%, 59%, and 40% for patients with stage IIIA, IIIB, and 
IIIC, respectively. When distant metastases are present, survival rates are extremely low. 
Thus, one-year survival rates among stage IV patients are 62% for M1a, 53% for M1b, and 
33% for M1c melanomas (Balch et al., 2009). 
 
1.1.2. Clinical, histological and genetic aspects of melanoma 
 
Melanoma is a heterogeneous disease. It displays considerable variation at different 
levels: clinical presentation, histology, genetic alterations and patient outcome.  
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According to anatomical site, histopathology and degree of sun damage, there are four 
major types of cutaneous melanomas (Lentigo maligna, Superficial spreading, Nodular and 
Acral lentiginous) and two types of extracutaneous melanomas (Mucosal and Ocular).  
Lentigo maligna melanoma appears mostly in head and neck region in elderly people 
and is related to chronic sun exposure. Superficial spreading melanoma is the most common 
type of melanoma in Caucasians patients. Legs and back are the anatomic sites most 
frequently involved and this type is related to intermittent exposition to sunlight. Nodular 
melanoma usually presents as a rapidly growing nodule on sites that are intermittently 
exposed to sunlight. This is the most aggressive type of cutaneous melanoma and is 
histologically characterized by the absence of radial growth phase. Acral lentiginous 
melanomas arise on sites protect from the sunlight, including the palm of the hand, sole of the 
foot or under the nails. It is the predominant type of melanoma in Afro-Caribbean and 
Oriental patients (LeBoit et al., 2006). Mucosal melanomas may originate in any mucosa, but 
mostly in nasal and oral cavity, anorectum, vulva and vagina. Compared with cutaneous and 
ocular melanoma, mucosal melanomas have the lowest percent of five-year survival 
(Mihajlovic et al., 2012). Melanoma can also originate from melanocytes of the uvea, 
encompassing intraocular structures such as the iris, ciliary body, and choroid (Laver et al., 
2010; Whiteman et al., 2011).  
Most cutaneous melanomas present as an initial intraepidermal proliferation that 
subsequently evolves to the invasion of basement membrane and dermal proliferation. The 
metastatic capacity of melanoma cells occurs when these cells reach the dermis and are able 
to invade lymph or blood vessels.  
The first stage of skin melanoma progression is known as radial growth phase (RGP). 
In this phase, melanoma cells are confined to the epidermis (in situ melanoma) or involve 
papillary dermis as small nests composed of less than 15 cells without proliferative or 
metastatic capacity (Gimotty et al., 2005). The next step in melanoma progression is named 
vertical growth phase (VGP). In this phase, melanoma cells are located in the dermis and are 
able to proliferate and generate metastasis (Barnhill et al., 1993). Significant change in gene 
expression profile occurs in the transition from radial to vertical growth phase. Such alteration 
encourages proliferation, suppression of apoptotic programs, capacity for vascular invasion 
and metastatic spread (Alonso et al., 2004; Hoek, 2007). 
Many studies performed over several years on benign nevi and melanoma tumors have 
tried to identify the mechanisms involved in malignant transformation of melanocytes. 
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Comparative genomic hybridization (CGH) of melanocytic neoplasms has identified multiple 
genomic regions with changes in DNA copy number in melanoma tumors and absence or a 
restricted set of chromosomal aberration in melanocytic nevi (Curtin et al., 2005; Bauer et al., 
2006).  
Numerous genes have been implicated in melanoma development and progression. 
The v-raf murine sarcoma viral oncogene homolog B1 (BRAF) and the v-ras neuroblastoma 
RAS viral oncogene homolog (NRAS) genes are the most common targets for somatic 
mutations in melanoma. A point mutation in the BRAF gene (predominantly V600E, where 
valine is substituted for glutamic acid at amino acid 600) is detected in around 40-60% of 
melanoma patients (Goel et al., 2006; Ribas et al., 2011). In the RAS family, NRAS is the most 
frequently affected gene. Its mutation occurs in approximately 10-20% of melanoma patients 
(Goel et al., 2006). Both BRAF and NRAS mutations seem to be mutually exclusive and lead 
to the constitutive activation of the mitogen-activated protein kinase (MAPK) pathway with 
the consequent induction of proliferative and survival programs (Mercer et al., 2003).  
Although BRAF and NRAS mutations are a critical step in melanoma initiation, they 
are not exclusively expressed in malignant lesions of melanocytes. BRAFV600E mutation is 
found in 82% of common nevi (Pollock et al., 2003) and NRAS mutation in 56% of congenital 
nevi (Chin et al., 2006). In fact, the overexpression of such oncogenes in cultured 
melanocytes triggers a nonproliferative but viable state named senescence (Michaloglou et al., 
2005; Denoyelle et al., 2006). Since the induction of senescence triggered by oncogenes is an 
intrinsic cellular mechanism against malignant transformation, the transformation of 
melanocytes must be invariably accompanied by additional deregulation, including the loss-
of-function of tumor suppressors, as the inhibitor cyclin-dependent kinase 4 (p16INK4a) and the 
phosphatase and tensin homolog (PTEN) (Tsao et al., 2004; Dankort et al., 2009).  
The inactivation of p16INK4a protein, taken as whole, is detected in 30–70% of 
melanomas (Sharpless et al., 2003). P16INK4a is a tumor suppressor gene product involved in 
cell cycle regulation and induction of senescence (Hansson et al., 2010). Loss of p16INK4a 
function promotes retinoblastoma (RB) inactivation, resulting in unconstrained cell cycle 
progression (Serrano et al., 1993). This protein is coded by the cyclin-dependent kinase 
inhibitor 2A gene (CDKN2A) and approximately 20-40% of familial melanomas harbor 
germline mutations in this gene.  
The allelic loss or altered expression of PTEN gene is observed in 20% and 40% of 
melanoma, respectively (Chin et al., 2006; Goel et al., 2006). PTEN inactivation leads to the 
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activation of the phosphatidylinositol 3-kinase/ serine/threonine protein kinase Akt 
(PI3K/AKT) pathway, which enhances melanoma cell survival and proliferation (Robertson et 
al., 2005). 
Additional mutations have also been described in melanoma tumors. Mutations in the 
receptor tyrosine-protein kinase Kit (cKIT) gene occur more frequently in acral, mucosal and 
cutaneous melanomas with chronic sun-induced damage (Curtin et al., 2006). Somatic 
mutation in the heterotrimeric G protein α-subunit (GNAQ) gene has been found in 46% of 
uveal melanoma (Van Raamsdonk et al., 2009). Another study on uveal melanomas has 
identified an inactivating somatic mutation in the gene encoding the breast cancer 1-
associated protein 1 (BAP1) (Harbour et al, 2010). Recently, the sequencing of 147 
melanomas has demonstrated mutation in the ras-related C3 botulinum toxin substrate 1 
(RAC1) gene in 9.2% of sun-exposed melanomas (Kraurhammer et al., 2012). RAC1 is a 
small G-protein in the Rho family that promotes cell-cell adhesion and regulates cell motility 
in response to extracellular signals (Kimura et al 2006; Sanz-Moreno et al., 2008; Leve et al., 
2012). Interestingly, this mutation was the third most frequent in sun-exposed melanoma after 
BRAF and NRAS mutations (Kraurhammer et al., 2012).  
Many other genetic aberrations, as microphthalmia-associated transcription factor 
(MITF) amplification (Garraway et al., 2005), genetic polymorphisms in the melanocortin 
receptor-1 (MC1R) and germline inactivation of the retinoblastoma 1 (RB1) gene (Fletcher et 
al., 2004), have been related to melanoma tumors and illustrate the extreme genetic 
heterogeneity of this disease. 
 
1.1.3. The influence of autophagy in melanoma progression 
 
Besides the aforementioned genetic alterations, melanoma progression also involves 
development of other events, such as adaptive responses to nutrient deprivation, hypoxia and 
anticancer drugs. 
Macroautophagy (herein referred to as autophagy) is a lysosomal proteolytic process 
involved in the degradation of protein aggregates and cytoplasmic organelles. It can be 
stimulated by numerous forms of cellular stress, as nutrient deprivation, hypoxia, oxidative 
and endoplasmic reticulum stresses, protein aggregates and damaged organelles (Kroemer et 
al., 2010).  
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In autophagy, cytosolic substrates are engulfed by a double-layered membrane called 
autophagosome. The autophagosome microtubule-associated protein 1 light chain 3 (LC3) is 
an important constituent of autophagosomes. The cytosolic form LC3-I is cleaved by 
proteases to expose a C-terminal glycine residue, which is then conjugated to a 
phosphatidylethanolamine group to generate the isoform LC3-II that is tightly bound to the 
autophagosomal membrane. Subsequently, the autophagosome structure fuses with the 
lysosome, whereby the protein content is degraded by lysosomal proteases (Mehrpour et al., 
2010).  
Deregulation of autophagy has been described in different types of human cancers. 
Under biological stress, autophagy can promote survival of tumor cells by eliminating toxic 
substrates and supplying metabolic precursors. Paradoxically, autophagy can work as a tumor 
suppressor and promotes tumor cell death by induction of self-destroying programs (Levine et 
al, 2008).  
In melanoma tumors, the activation of autophagy seems to be an adaptive mechanism 
for tumoral progression (Hersey et al., 2008; Checinska and Soengas, 2011). 
Immunohistochemical and electron microscopy studies of melanoma specimens have 
identified high levels of autophagy in the invasive front of primary melanomas (Lazova et al., 
2010). The expression of LC3 protein in primary tumors was also strongly associated with the 
development of metastasis and shorter survival of melanoma patients (Han et al., 2011). 
Additionally, the inhibition of autophagy through RNA interference (RNAi) or drug treatment 
induced cellular death of aggressive melanoma cells (Ma et al., 2011). Autophagy can also 
protect cells against drug-induced stress, thus representing a mechanism of melanoma 
chemoresistance (Marino et al., 2010; Ma et al., 2011).  
Nevertheless, as in other type of cancers, autophagy could work as a tumor suppressor 
and induces cellular death. Unlike the previously mentioned studies, another study has found 
that mRNA expression of two autophagy-related genes, beclin 1 (BECN1) and LC3, 
significantly decreases with tumor progression (Miracco et al., 2010). In addition, treatment 
of melanoma cells with dsRNA mimic polyinosine-polycytidylic acid (pIC) engendered 
hyperactivity of autophagy machinery with subsequent cell death through self-degradation 
(Tormo et al., 2009; Alonso-Curbelo et al., 2010). 
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1.1.4. The need for new melanoma treatment strategies  
 
Melanoma is a very complex and heterogeneous disease, with multiple events 
involved in tumor initiation and progression. Despite all knowledge generated in last years, 
additional studies are still necessary for full comprehension of its pathogenesis (Soengas et 
al., 2003). 
While melanoma can be curable when removed at early stages, the prognosis is grim 
in the context of metastatic disease. In fact, the overall long-term survival in patients with 
distant metastatic melanoma is less than 10% (NCCN, 2013). Metastases of melanoma may 
appear many years after the diagnosis, in different organs and usually, do not respond to 
treatment.  
This type of cancer is characterized by the resistance to all forms of conventional 
treatments (radio-, immuno-and chemotherapy). During a long time, dacarbazine, which 
presents very disappointing response rates, was the unique single-agent approved by the Food 
and Drug Administration (FDA) for treating metastatic melanoma (Serrone et al., 2000). 
Other therapies used in clinical practice, as Interferon alfa-2b and Interleukin-2 also showed 
disappointing responses and failed to demonstrate prolonged overall survival (Atkins et al., 
1999; Kirkwood et al., 2000). 
After many years dedicated to the comprehension of genetic and immunologic 
alterations of melanoma tumors, recently, new strategies for melanoma treatment are 
emerging (Márquez-Rodas et al., 2011; Espinosa el at., 2012). Targeted therapies aimed to the 
frequently mutated oncogene BRAF (Chapman et al., 2011) and the cytotoxic T-lymphocyte 
antigen-4 (CTLA-4) (Hodi et al., 2010), were recently approved by the FDA. However, 
although both drugs have improved overall and disease free survival in phase III clinical 
trials, these are only effective on a fraction of affected patients. In addition, tumor resistance 
and relapses appear in most of patients treated with these drugs (Hodi et al., 2010; Chapman 
et al., 2011; Kudchadkar et al., 2012).  
Many other clinical trials currently underway also demonstrate partial or 
unsatisfactory results. Therefore, unfortunately, melanoma remains highly resistant to current 
available treatments. This clinical picture, associated with an increasing incidence, justifies 
efforts for the discovery of new mechanisms of melanoma progression and translation of such 
insights into therapeutic strategies. The identification of new targets and generation of drugs, 
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used as single-therapy or in combination with the current ones, would be of great benefit for 
melanoma patients. 
 
1.2. Sequestosome 1/p62 protein 
 
In eukaryotic cells, large amounts of damaged/misfolded proteins are constantly 
produced. Furthermore, the exposure of cells to stress, principally oxidative stress, increases 
the production of misfolded proteins that need to be refolded or degraded.  
Aggressive cancers, and melanoma is not an exception, are characterized by an 
exacerbated cellular metabolism. High metabolism associated to stressful microenvironment, 
such as nutrient deprivation, hypoxia and low pH, dramatically enhance the production of 
misfolded proteins in cancer cells (Schröder et al., 2005; Moenner et al., 2007; Kirkin et al., 
2009).  Thus, tumor cells appear to be significantly more dependent on the continuous 
clearance of damaged proteins than their normal counterparts. In fact, therapeutic drugs 
targeting systems of protein degradation, such as the ubiquitin-proteasome system (UPS) and 
autophagy, are a strategy used for the treatment of patients with cancer (Linder et al., 2005; 
Amaravadi et al., 2007; Mujtaba et al., 2011; Yang et al., 2011).  
Since tumor cells present an intrinsic ability to overcome stressful conditions 
(Moenner et al., 2007), an understanding of the mechanisms by which tumor cells adapt to 
adverse environment is essential for developing a well-targeted therapy. Recently, the 
multifunctional protein Sequestosome 1/p62 has been emerging as a new promoter of tumor 
survival (Duran et al., 2008; Mathew et al., 2009; Duran et al., 2011). P62 protein is involved 
in proteasomal and autophagosomal degradation with key roles in other tumor types, but 
unknown in melanoma. Additionally, p62 works as an adaptor protein activating several 
intracellular signaling pathways involved in metabolism, antioxidative response, 
inflammation, and ultimately, tumorigenesis (Puissant et al., 2012).  
One of the least understood aspects in melanoma is the modulation of protein 
degradation machineries. Therefore, the multifunctional property of Sequestosome1/p62 
protein combined with the need for new melanoma treatment strategies turns p62 an attractive 
candidate to be characterized in melanoma tumors. 
 
 
 
Introduction	  
___________________________________________________________________________	  
29 
	  
used as single-therapy or in combination with the current ones, would be of great benefit for 
melanoma patients. 
 
1.2. Sequestosome 1/p62 protein 
 
In eukaryotic cells, large amounts of damaged/misfolded proteins are constantly 
produced. Furthermore, the exposure of cells to stress, principally oxidative stress, increases 
the production of misfolded proteins that need to be refolded or degraded.  
Aggressive cancers, and melanoma is not an exception, are characterized by an 
exacerbated cellular metabolism. High metabolism associated to stressful microenvironment, 
such as nutrient deprivation, hypoxia and low pH, dramatically enhance the production of 
misfolded proteins in cancer cells (Schröder et al., 2005; Moenner et al., 2007; Kirkin et al., 
2009).  Thus, tumor cells appear to be significantly more dependent on the continuous 
clearance of damaged proteins than their normal counterparts. In fact, therapeutic drugs 
targeting systems of protein degradation, such as the ubiquitin-proteasome system (UPS) and 
autophagy, are a strategy used for the treatment of patients with cancer (Linder et al., 2005; 
Amaravadi et al., 2007; Mujtaba et al., 2011; Yang et al., 2011).  
Since tumor cells present an intrinsic ability to overcome stressful conditions 
(Moenner et al., 2007), an understanding of the mechanisms by which tumor cells adapt to 
adverse environment is essential for developing a well-targeted therapy. Recently, the 
multifunctional protein Sequestosome 1/p62 has been emerging as a new promoter of tumor 
survival (Duran et al., 2008; Mathew et al., 2009; Duran et al., 2011). P62 protein is involved 
in proteasomal and autophagosomal degradation with key roles in other tumor types, but 
unknown in melanoma. Additionally, p62 works as an adaptor protein activating several 
intracellular signaling pathways involved in metabolism, antioxidative response, 
inflammation, and ultimately, tumorigenesis (Puissant et al., 2012).  
One of the least understood aspects in melanoma is the modulation of protein 
degradation machineries. Therefore, the multifunctional property of Sequestosome1/p62 
protein combined with the need for new melanoma treatment strategies turns p62 an attractive 
candidate to be characterized in melanoma tumors. 
 
 
 
Introduction	  
___________________________________________________________________________
	   	   	  
30 
	  
1.2.1. Structure and domains of Sequestosome 1/p62 protein  
 
P62 was first described by Joung and collaborators in 1996 (Joung et al., 1996). It was 
cloned as a novel human cDNA encoding a 62 kDa protein able to bind to p56lck, a T-cell-
specific Src family tyrosine kinase. Independently, Puls and co-workers identified p62 as a 
cytosolic protein capable to interact with the atypical protein kinase C (PKC) member PKC-ζ 
(Puls et al., 1997). On this occasion, p62 was referred as zeta-interacting protein (ZIP). 
Currently, p62 is also named Sequestosome1 because of its ability to sequester aggregates of 
proteins inside the cytosol (Shin et al., 1998).  
The Sequestosome1 human gene (SQSTM1) is located on the long (q) arm of 
chromosome 5 at position 35. More precisely, it is located from base pair 179,233,388 to base 
pair 179,265,078. It codes manly for two protein isoforms composed of 440 and 356 amino 
acids. Using protein immunoblot analysis, the main isoform identified presents around 62 
kDa.  
P62 mRNA is ubiquitously expressed in a variety of normal tissues (Joung et al., 
1996). This protein is essentially located in the cytoplasm and can present different patterns of 
distribution: diffuse or forming small bodies or large aggregates of protein (Lamark et al., 
2003; Bjørkøy et al., 2005). A minor number of publications have also referred the nuclear 
localization of p62 protein (Bjørkøy et al., 2005; Pankiv et al., 2009).  
The functions of p62 are associated to two major processes: protein degradation and 
activation of signaling pathways. The structure and domains of p62 are illustrated in 
Figure1.  
The N-terminal Phox and Bpem 1 domain (PB1, aa. 21-103) is responsible for the 
self-oligomerization of p62 and the interaction of p62 with the S5a proteasome subunit 
(Seibenhener et al., 2007). Through PB1 domain, p62 also interacts with atypical protein 
kinase (aPKC), regulating the nuclear factor of kappa light polypeptide gene enhancer in B-
cells (NF-kB) pathway (Moscat et al., 2006; Saio et al., 2009) and with extra-cellular signal-
regulated kinase-1 (ERK1), being involved in adipogenesis (Lee et al., 2010). The zing finger 
domain (ZZ, aa. 128-163) is responsible for p62 interaction with the receptor-interacting 
protein-1 (RIP1) and regulation of NF-kB pathway (Geetha et al., 2002; Moscat et al., 2006). 
The region between the ZZ and TRAF6-binding (TBS) domains (aa. 167-230) harbors the 
domain responsible for the association with Raptor protein, involved in the mammalian target 
of rapamycin (mTOR) pathway (Duran et al., 2011). Through TBS domain (TBS, aa. 225-
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250), p62 interacts with TNF receptor-associated factor 6 (TRAF6) and activates NF-kB 
pathway (Sanz et al., 2000; Durán et al., 2004). The LC3-interacting region domain (LIR, aa. 
321-345) is responsible for the interaction between p62 and the autophagy related protein 
LC3. Next, the Keap-interacting region (KIR, aa. 346-359) binds kelch-like ECH-associated 
protein 1 (Keap1) and activates the antioxidative response through nuclear factor (erythroid-
derived 2)-like 2 (Nrf2) activation (Komatsu et al., 2010). Finally, through the C-terminal 
ubiquitin-associated domain (UBA, aa.386-440), p62 binds to ubiquitinated proteins and 
target them for proteasomal or autophagosomal degradation (Kirkin et al., 2009). 
 
 
 
 
 
 
 
 
 
 
 
 
 
1.2.2. Interaction of Sequestosome 1/p62 protein with protein degradation systems 
 
The ubiquitin-proteasome system and autophagy process are the major routes for 
intracellular protein recycling. Both systems are essential for the maintenance of cellular 
homeostasis, especially under stressfull conditions.  
Ubiquitination is a common type of posttranslational modification of proteins. It 
involves covalent attachment of the 76 amino acid peptide ubiquitin (Ub) to proteins, as mono 
or polyubiquitin (pUb) chains. Ubiquitination participates in different cellular processes, as 
	  
Figure 1. Schematic presentation of the domains and the main interactions/functions of p62 
protein. Through diverse domains, p62 can interact with proteasomal and autophagosomal 
degradation systems and regulates different intracellular pathways (modified from Puissant et al., 
2012).   
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protein degradation, endocytosis, signal transduction and DNA repair (Kirkin et al., 2009). 
The addition of polyubiquitin chains, in which Ub is linked via lysine 48, targets the 
substrates for degradation by the proteasome system (Seibenhener et al., 2004).  
The ubiquitin-proteasome system is responsible for the degradation of defective or 
misfolded proteins. Thus, the recognition of polyubiquitinated substrates by the proteasome 
complex plays an essential role in degradation of toxic proteins. Through the interaction with 
S5a proteasome subunit by PB1 domain and the interaction with pUb proteins by the UBA 
domain, p62 can bind ubiquitinated proteins and delivers them for proteasomal degradation.  
As mentioned before, autophagy is a catabolic process involved in intracellular 
degradation of proteins aggregates and organelles through the lysosomal machinery. During a 
long time autophagy was considered an unspecific proteolytic system of cytoplasmic 
substrates. However, the discovery of p62 added new evidences of the specificity of 
autophagosomal degradation (Kirkin et al., 2009).  
P62 can form ubiquitylated and non-ubiquitylated aggregates into the cytoplasm 
(Watanabe et al., 2011). Through LIR domains, p62 interacts with LC3 protein and transports 
protein aggregates (either ubiquitinated or not) to autophagosomal degradation, thereby being 
itself degraded by lysosomal proteases (Figure 2).  
 
 
 
 
 	  
Figure 2. Schematic figure 
showing the function of p62 
in sequestosome formation 
and autophagosome 
degradation. P62 binds and 
sequester aggregates of 
proteins in the cytosol 
(sequestosome formation). 
Through the interaction with 
LC3 protein located in the 
membrane of autophagosomes, 
p62 delivers aggregated 
proteins for lysosomal 
degradation (modified from 
Puissant et al., 2012). 
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In summary, p62 is able to interact with the two major proteolytic systems, UPS and 
autophagy. Because of its ability to form cytoplasmic bodies of proteins and interact with 
LC3 protein, p62 is considered the missing link between protein aggregation and autophagic 
clearance (Bjørkøy et al., 2005; Bjørkøy et al., 2006). 
 
1.2.3. Implication of Sequestosome 1/p62 protein in cellular functions  
 
Sequestosome1/p62 also works as an adaptor protein. The adaptor proteins are 
proteins without enzyme activity that act by forming complexes with other signaling 
molecules and are required for the efficient regulation of intracellular pathways.  
The first signaling pathway related to p62 protein was the NF-kB pathway. NF-kB is 
a transcription factor governing the expression of genes involved in immuno response, 
inflammation, embryonic development, apoptosis, cell cycle, and oncogenesis (Hayedn et al., 
2004). Through the interaction with different proteins of NF-kB pathway (as aPKC, RIP1 and 
TRAF6) p62 has been associated to the regulation of osteoclastogenesis (Duran et al., 2004), 
inflammation (Martin et al., 2006; Kim et al., 2009) and tumorigenesis (Duran et al., 2008; 
Ling et al., 2012). 
P62 also works as an adaptor protein in Keap1-Nrf2 signaling pathway. The 
transcription factor Nrf2 plays a central role in the protection of cells against oxidative stress. 
It controls the expression of various detoxifying and antioxidant defence enzymes and 
proteins (Taguchi et al., 2011). Through a specific domain, p62 can bind Keap1 and competes 
with the interaction between Nrf2 and Keap1, resulting in the stabilization of Nrf2 and 
transcriptional activation of target genes. Therefore, the constitutive activation of Nrf2 by p62 
confers resistance of tumor cells to oxidative stress and contributes to tumor progression 
(Komatsu et al., 2010; Copple et al., 2010; Lau et al., et al 2010). 
The mTOR signaling pathway, a coordinator of cell growth and metabolism, is also 
regulated by P62.  mTOR can be activated by different stimuli, like nutrients, hypoxia and 
growth factors, in order to control cell growth, proliferation and motility. The deregulation of 
mTOR pathway has been demonstrated in different types of cancer (Pópulo et al., 2012). 
Through the interaction with Raptor protein, p62 activates mTOR pathway in response to 
amino acids stimulation and contributes to tumorigenesis (Duran et al., 2011; Moscat et al., 
2011).   
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Another critical function of p62, recently described, is its involvement in cell cycle. 
Linares and collaborators have shown that p62 is phosphorylated by the cyclin-dependent 
kinase 1 (CDK1) on threonine 269 and serine 272 during early mitosis phase (Linares et al, 
2011). The phosphorylation of p62 permits the cells to properly continue through mitosis and 
is responsible for restraining cell growth and tumor progression On the other hand, the lack of 
CDK1-mediated phosphorylation of p62 promotes a faster exit from mitosis and enhances cell 
proliferation and tumorigenesis (Linares et al, 2011).  
Recently, p62 has also been linked to apoptosis. The programmed cell death by 
apoptosis participates in various biological processes such as development, maintenance of 
tissue homeostasis and as a natural barrier to cancer progression. It initiates with the 
activation of normally latent proteases (caspase-8 and caspase-9), which promotes a cascade 
of proteolysis culminating in cellular death (Hanahan et al., 2011). Jin and colleagues have 
demonstrated the co-localization of p62 and caspase-8 into ubiquitinated cytoplasmic foci.  
Furthermore, the aggregation of caspase-8 promoted by p62 was responsible for the full 
activation of this protease and the consequent induction of apoptosis (Jin et al., 2009). 
It has also been demonstrated the involvement of p62 in energy homeostasis and 
adipogenesis through the interaction with ERK1 protein. P62 antagonizes basal ERK activity 
and its loss conducts to the hyperactivation of ERK and adipogenesis. In fact, p62-deficient 
mice develop late-onset obesity that leads to insulin resistance and impaired glucose tolerance 
(Rodriguez et al., 2006; Lee et al., 2010). 
In summary, in the last years, many works describing the function of p62 as an 
adaptor protein have been emerging in the literature. Through its different domains, p62 is 
able to interact and regulate diverse signaling pathways and, consequently, interfere with 
critical cellular functions. 
 
1.2.4. Association of Sequestosome 1/p62 protein with human diseases 
 
P62 has been associated to different human diseases. One of the most well described 
entities related to p62 is the Paget Disease of the Bone (PDB) (Layfield et al., 2004; Rhodes 
et al., 2008). PDB is a common skeletal disorder characterized by disorganized bone 
resorption due to increased osteoclastic activity. Mutations in the SQSTM1 gene have been 
described in approximately 40% of familial and 8% of sporadic cases of Paget Disease. More 
than 20 different mutations have been identified and almost all of them affect the UBA 
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domain of p62 (Morissette et al., 2006; Najat et al., 2009; Michou et al., 2011). There are 
limited data about the functional consequence of SQSTM1 mutations in PDB. Although it is 
not a consensus, SQSTM1 mutations seem to interfere with osteoclastogenesis through 
deregulation of NF-kB signaling pathway (Durán et al., 2004; Layfield et al., 2004; Rea et al., 
2006; Kurihara et al., 2007). Corroborating the influence of p62 in bone homeostasis, p62 
knockout mice present increased bone density with defective osteoclastic function (Durán et 
al., 2004). 
Abundant expression of p62 has also been identified in cytoplasmic inclusions of 
neurodegenerative diseases (Nagaoka et al., 2004; Bjørkøy et al., 2005).  
Alzheimer's disease (AD) is the most common neurodegenerative disease 
characterized by progressive impairment in memory and cognition. Accumulation of 
polyubiquitinated tau protein in neuronal cells is one of the major histopathological features 
of AD. Immunohistological studies of parietal cortical samples of patients with AD showed 
that p62 co-localizes with tau-positive inclusions in neuronal cells (Kuusisto et al., 2002). 
Moreover, Babu and collaborators have described that p62 interacts with polyubiquitinated 
tau through its UBA domain (Babu et al., 2005). The study of p62 knockout mice performed 
by these authors also revealed a pathological accumulation of tau protein in neurons, 
associated to a massive neuronal degeneration, which suggests a protective role of p62 in 
Alzheimer's disease (Babu et al., 2005).  
Huntington's disease (HD) is an inherited autosomal dominant neurodegenerative 
disorder characterized by late onset of motor dysfunctions, psychiatric disturbances and 
ultimately, death of patients. HD is caused by the expression of mutant forms of huntingtin 
protein that accumulates in the cytoplasm being deleterious to neuronal cells (Bano et al., 
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bodies in hepatocellular carcinoma; and Rosenthal fibers in astrocytoma (Stumptner et al., 
2002; Zatloukal et al., 2002; Stumptner et al., 2007). In sporadic inclusion-body myositis, 
p62 is overexpressed at protein and mRNA levels and accumulates within p-tau containing 
inclusion bodies in muscle fibers (Nogalska et al., 2009).  
Although the relevance of p62 aggregates in human diseases has not been fully 
elucidated, many studies indicate that it represents a protective mechanism developed by the 
cells. Through the ability of p62 to sequester toxic proteins and deliver misfolded proteins to 
proteasomal and autophagosomal degradation, p62 could prevent cell death and, 
consequently, contributes to cellular survival. 
 
1.2.5. The role of Sequestosome 1/p62 in tumorigenesis 
 
The overexpression and accumulation of p62 has been described in different types of 
human cancers (Thompson et al., 2003; Kitamura et al., 2006; Duran et al., 2008).  
As already mentioned for other diseases, most of the studies indicate a pro-survival 
role of p62. The mechanisms whereby p62 contributes to tumorigenesis are diverse and are 
related to autophagy clearance or cell signaling activation functions. Moreover, the 
involvement of p62 in tumor progression appears to be tissue-specific and its mechanism 
dependent of the type of cancer cell studied.  
Moscat’s group described one of the first implications of p62 in cancer cells in 2008 
(Duran et al., 2008). Using p62 knockout mice, these authors showed that the lack of p62 
inhibits the induction of lung adenocarcinoma by RAS oncogene. They also demonstrated 
that Ras expression increases p62 mRNA levels through the activation of p62 promoter. In 
this context, the lack of p62 impaired NF-kB activation in Ras-transformed cells, which led to 
higher production of reactive oxygen species (ROS) and increased cell death (Duran et al., 
2008). Confirming the involvement of p62 in lung cancer, other authors have performed 
immunohistochemical and survival analyses of p62 expression in 109 patients with non-
small-cell lung cancer, including adenocarcinoma, squamous cell carcinoma, and large cell 
carcinoma, and found that the accumulation of p62 was particularly associated with poor 
prognosis in patients with lung adenocarcinoma (Inoue et al., 2012). 
The group of Eileen White has also demonstrated the implication of p62 in 
tumorigenesis (Mathew et al., 2009). Taking in account that some human tumors can present 
mutations in autophagy genes leading to autophagy defects, these authors tried to elucidate 
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how the loss of such survival process could promote tumor growth. Using autophagy-
defective tumor cells, they found that p62 protein accumulates in response to metabolic 
stress. Moreover, they found that the inability to clear p62 through autophagy and the 
consequent accumulation of p62 was responsible for increased DNA damaged response, 
cellular genomic instability and finally, tumor growth. Interestingly, opposite to Moscat’s 
findings in lung carcinoma, these authors suggested that defective autophagy and p62 
accumulation impaired NF-kB activation in hepatocellular carcinoma, demonstrating the 
tissue-specific mechanism of p62 function (Mathew et al., 2009).  
Based on the fact that more than 25% of human hepatocellular carcinomas present 
cytosolic aggregates of p62, and that the induction of Nrf2 anti-oxidative pathway is 
recognized in most of these tumors, Komatsu’s group has studied the link between autophagy 
deficiency, p62 and Nrf2 transcription factor (Inami et al., 2011). Using liver-specific 
autophagy related 7 (Atg7) knockout mice, these authors demonstrated the development of 
hepatocellular tumors in this model. Since Atg7 is an essential gene for autophagy function, 
they found a marked accumulation of p62 in hepatocytes of Atg7-deficient cells. It was 
observed that most of the p62-containing aggregates were also positive for Keap1. The 
sequestration of Keap1 into p62 aggregate structures was responsible for the persistent 
activation of the Nrf2 transcriptional factor leading to an anti-oxidative response and tumor 
progression. Besides the transcriptional regulation proposed by Moscat’s group (Duran et al., 
2008), Jain and coworkers have also demonstrated that p62 is regulated by Nrf2 (Jain et al, 
2010). Under oxidative stress stimulus, Nrf2 transcriptional factor binds to the antioxidant 
response element located in the p62 promoter and regulates the expression of p62 mRNA.  
P62 was also linked to tumorigenesis through its ability to interact with the metabolic 
pathway mTOR. Duran and collaborators have shown that p62 is required for tumor 
proliferation of prostate cancer cells. In fact, the depletion of p62 affected the capacity of 
prostate cancer cells to form solid tumors in xenograft mice models. In this context, the 
inhibition of the survival pathway mTOR was the mechanism whereby the lack of p62 
inhibits tumor growth (Duran et al., 2011).  
The contribution of p62 in tumor growth was also described in tuberosis sclerosis 
complex (TSC). TSC is a genetic disorder characterized by mutations in the tuberous 
sclerosis complex 1 or 2 genes (TSC1 and TSC2). There are multiple clinical manifestations 
including neurologic disease and the formation of nonmalignant hamartomas in different 
organs. P62 was accumulated in angiomyoliomas and pulmonary lymphangioleiomyomatosis 
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of patients with TSC. Further, p62 was important for tumor growth in TSC since the depletion 
of p62 delayed TSC2-null tumor development in xenograft models (Parkhitko et al., 2011).  
Recently, p62 was associated to tumor invasion capacity. Galavotti and coworkers 
have studied the influence of p62 in glioblastoma multiforme (GBM) progression. Using 
glioblastoma stem cells isolated from GBM surgical specimens, they found that the depletion 
of p62 expression inhibits the invasion and migration capacity of such cells. The mechanism 
underlying the role of p62 in invasion was not fully elucidated. However, it appears that p62 
interferes with tumor invasion function through its involvement with autophagy and the 
regulation of energy metabolism (Galavotti et al., 2012). 
P62 was also associated to cancer through the description of a new gene 
translocation. Takeuchi and collaborators reported the fusion of anaplastic lymphoma 
receptor tyrosine kinase (ALK) gene with Sequestosome1 gene in a patient with ALK-positive 
large B-cell lymphoma (Takeuchi et al., 2011). Additionally, 3T3 fibroblasts expressing 
SQSTM1-ALK were able to form solid tumors in nude mice model, demonstrating the 
transforming potential of such translocation. Although there is only one unique case referred 
in the literature, the new SQSTM1-ALK fusion is of great clinical interest since it presents 
oncogenic capacity. 
In summary, the multifunctional protein p62 promotes tumorigenesis by activating 
pro-oncogenic signaling pathways and interfering with the autophagy system. As mentioned 
previously, the involvement of p62 in cancer is quite complex and dependent of the cell type. 
Although p62 has been linked to different types of human cancer, no data about its 
implication in melanoma are available in the literature. Altogether, the involvement of p62 in 
crucial cellular function, as degradation of misfolded proteins and protein aggregates, 
combined with the regulation of oncogenic pathways turn p62 an interesting candidate to be 
studied in melanoma tumors.  
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2. OBJECTIVES 
 
The increasing incidence of melanoma and the tendency for lethal metastasis and 
therapeutic resistance presented by such tumors justify the efforts for the identification of new 
mechanisms of melanoma progression and alternatives of treatment. Melanoma, like other 
aggressive tumors, is characterized by an exacerbated cellular metabolism, which requires 
continuous degradation of proteins. However, the molecular bases that mediate this process 
are poorly characterized and their understanding could provide a platform for the 
development of new drugs. Sequestosome 1/p62, a multifunctional protein involved mainly in 
protein degradation and activation of pro-oncogenic signaling pathways, is an attractive 
candidate to be investigated in aggressive tumors. This multidisciplinary study aims the 
characterization of the Sequestosome 1/p62 protein in melanoma, through the following main 
objectives: 	  
	  
2.1. To analyze the expression of Sequestosome 1/p62 in benign melanocytic tumors and 
melanomas at different stages of progression; 
 
2.2. To determine the function of Sequestosome 1/p62 in melanoma tumors using an in vitro 
approach with melanoma cell lines; 
 
2.3. To establish the physiological impact of Sequestosome 1/p62 in vivo using a xenograft 
model and correlating p62 expression with melanoma patient outcome. 
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3. MATERIALS AND METHODS 
	  
3.1. In vitro experiments	  
3.1.1. Isolation of normal melanocytes, keratinocytes and fibroblasts	  
	  
The sources of tissue for melanocytes, keratinocytes and fibroblasts isolation were 
human neonatal foreskins obtained from routine circumcision and donation by patients treated 
at Hospital Universitario 12 de Octubre and Hospital Niño Jesus, Madrid. 
The skins were washed with 70% ethanol, cut into small pieces and digested by 
Dispase II (Invitrogen, Carlsbad, CA, USA) enzyme at 4oC overnight. The day after, 
epidermal sheets were detached from the dermis by sliding it off with a scalpel blade. 
Epidermal pieces were used for melanocytes and keratinocytes isolation. Dermal pieces were 
separated for fibroblasts isolation. The isolated epidermal sheets were then cut with a scalpel 
blade and digested by 0.25% Trypsin/EDTA (Invitrogen, Carlsbad, CA, USA) at 37oC during 
3 minutes. The cell dispersal solution obtained was centrifuged.  The pellet obtained from the 
epidermis was divided into two parts and resuspended with Melanocyte Growth Medium for 
melanocytes culture or Keratinocyte Growth Medium for keratinocytes culture (Table 1). The 
isolated dermis pieces were cut and digested by Collagenase IV (Invitrogen, Carlsbad, CA, 
USA) at room temperature (RT) during 24 hours. After centrifugation, the cells of the dermis 
were resuspended in Fibroblast Growth Medium for fibroblasts culture (Table 1). All cultures 
were incubated at 37oC/5% of CO2.  
 
Table 1. Culture mediums used for melanocytes, keratinocytes and fibroblasts isolation:	  
Melanocyte Growth Medium  
500 mL 254CF Medium (Cascade Biologics, Portland, OR, USA) 
500 µL of CaCl2 (0.2 mM) 
5 mL of Cascade Biologics Human Melanocyte Growth Supplement (HMGS) 
5 mL of Penicillin/Spreptomycin (100 µg/mL ) 
Keratinocyte Growth Medium  
500 mL 154CF Medium (Cascade Biologics, Portland, OR, USA) 
250 µL CaCl2 (0.1 mM) 
5 mL of Cascade Biologics Human Keratinocyte Growth Supplement (HKGS) 
5 mL of Penicillin/Spreptomycin (100 µg/mL ) 
Fibroblast Growth Medium  
500 mL DMEM with 4500 mg/L glucose (Nova-Tech Inc., Grand Island, NY, USA) 
50 mL FBS (10%) 
5 mL of Penicillin/Spreptomycin (100 µg/mL ) 
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3.1.2. Melanoma cell lines	  
	  
Human melanoma cell lines with different genetic backgrounds were kindly provided 
by two collaborators: Herlyn’s laboratory, The Wistar Institute, Philadelphia and Memorial 
Sloan-Kettering Cancer Center, New York, USA (Table 2). Melanoma cells were cultured in 
Dulbecco’s modified Eagle’s medium (DMEM, Life Technologies, Rockville, MD, USA) 
supplemented with 10% fetal bovine serum (FBS) (Nova-Tech Inc., Grand Island, NY, USA) 
and 100 µg/mL of Penicillin/Streptomycin and incubated at 37oC/5% of CO2. When cells 
were confluent, they were passaged to new plates using 0.05% Trypsin/EDTA solution 
(Invitrogen, Carlsbad, CA, USA).  
Table 2. Human melanoma cell lines used in this study: 
Melanoma cell line BRAF  NRAS PTEN p53 
G-361 wt/mutant (V600E) wt deletion wt 
SK-Mel-5 mutant (V600E) wt wt wt 
SK-Mel-19  mutant (V600E) wt deletion wt 
SK-Mel-28 mutant (V600E) wt mutant mutant 
SK-Mel-29 mutant (V600E) wt wt wt 
SK-Mel-94  mutant (V600E) wt ND wt 
SK-Mel-103 wt mutant (Q61R) wt wt 
SK-Mel-147 wt mutant (Q61R) wt wt 
SK-Mel-173 wt mutant (Q61K) wt wt 
UACC-62 mutant (V600E) wt deletion wt 
UACC-257 wt wt ND wt 
WM-35 mutant (V600E) wt mutant wt 
WM-115 mutant (V600E) wt deletion wt 
WM-164 mutant (V600E) wt wt mutant 
WM-852 wt mutant (Q61R) deletion ND 
WM-902B mutant (V600E) wt ND ND 
WM-1158 mutant (V600E) wt deletion ND 
WM-1366 wt mutant (Q61L) wt ND 
980513 ND ND ND ND 
ND: Not determined     
 
3.1.3. Protein cell lysates, extraction and protein immunoblots 
 
Adherent cells were collected by trypsinization (0.05% Trypsin solution) and total cell 
lysates were obtained by Laemmli extraction. Pellets with 2x106 cells were resuspended in 
70-80 µl of Laemmli Buffer (0.0625 M Tris-HCl pH 6.8, 2% SDS, 10% Glycerol and 5% β-
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mercaptoethanol) and boiled for 5 minutes at 95ºC. Protein concentrations were determined 
using the BCA Protein Assay (Pierce, Rockford, IL). The calibration curves were prepared 
with bovine serum albumin (0, 2, 4, 6, 8 and 10 µg/mL) of Bio-Rad Mix (Bio-Rad, Hercules, 
CA, USA, ref. 500-0001) and the absorbance was read at 595 nm.  
Protein immunoblots were performed according to standard protocols; protein extracts 
were subjected to electrophoresis on sodium dodecyl sulfate polyacrylamide (SDS-PAGE) 
gels using the acrylamide concentration adequate for the size of the detected proteins (10-
15%). Following electrophoresis, the proteins were transferred onto Immobilon®-P Transfer 
membrane (Millipore, Bedford, MA, USA) using Mini Trans-Blot Cell equipment (Bio-Rad, 
Hercules, CA, USA). Transference was performed at 100V during 1 hour at 4ºC. Membranes 
were blocked with 5% Milk in PBS-T (phosphate-buffered saline with 0.1% Tween-20) 
during 1 hour with shaking. Primary antibodies were diluted in 5% Milk PBS-T or 5% BSA 
PBS-T and added to the membrane overnight at 4ºC (Table 3). Membranes were washed and 
incubated with secondary antibody diluted in 5% Milk PBS-T during 2 hours at RT (Table 4).  
Protein bands were detected by the ECL system (GE, Healthcare, Buckinghamshire, UK) and 
quantified using the Java-based image processing program ImageJ. 
 
Table 3. Primary antibodies used for protein immunoblots/Western blot (WB) and 
immunofluoresence (IF): 
 
Common 
Name Antibody 
Catalog 
# Company Type Dilution 
Actin β-Actin (AC-15) A 5441 Sigma-Aldrich mouse WB 1:10.000 
Aurora A Aurora A/AIK (1G4) 4718 Cell Signaling Tech. rabbit WB 1:250 
Aurora B Aurora B/AIM1 3094 Cell Signaling Tech. rabbit WB 1:250 
B-Raf Raf-B (F-7) sc-5284 Santa Cruz Biotech. mouse WB 1:1000 
CDK1 CDK1 sc-54 Santa Cruz Biotech. mouse WB 1:250 
Cyclin A2 Cyclin A2 (H-432) sc-751 Santa Cruz Biotech. rabbit WB 1:250 
Cyclin B1  Cyclin B1 (H-433) sc-752 Santa Cruz Biotech. rabbit WB 1:1000 
EGFR EGFR 2232 Cell Signaling  rabbit WB 1:1000 
HMGA2 HMGA2 ab41878 Abcam rabbit WB 1:200 
p62 p62 lck 610832 BD Biosciences mouse WB 1:1000  IF: 1:100 
Pan-Ras Pan-Ras (Ab-3) Mouse  OP40 Calbiochem mouse WB 1:1000 
Survivin Survivin AF886 RD Systems rabbit WB 1:200 
Tubulin α-Tubulin T 9026 Sigma-Aldrich mouse WB 1:10.000 
Ubiquitin Mono-polyubiquitinylated  
SPA-
205 Assay Designs mouse WB 1:1000 
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Table 4.  Secondary antibodies used for protein immunoblots/Western blot (WB) and 
immunofluoresence (IF): 
 
Common Name Antibody Catalog # Company Type Dilution 
Anti-mouse IgG ECL Anti-mouse IgG NA931V Amersham sheep WB 1:2500 
Anti-rabbit IgG ECL Anti-rabbit IgG NA934V Amersham donkey WB 1:2500 
Anti-mouse IgG 
(H+L) Alexa Fluo 488 Green A11017 Invitrogen goat IF 1:250 
Anti-rabbit IgG 
(H+L) Alexa Fluor 555 Red A31572 Invitrogen donkey IF 1:250 
	  
 
3.1.4. Immunofluorescence analyses in cells lines 
 
Melanocytes and melanoma cells were cultured on cover slips and fixed in 4% 
paraformaldehyde during 15 minutes. Cells were turn permeable with PBS-0.2%Triton-X for 
5 minutes and blocked with PBS-1% BSA. Primary antibodies were added for 1 hour at room 
temperature (Table 3, page 47). After that, the cover slips were rinsed and incubated with 
fluorescent secondary antibodies for 1 hour at room temperature (Table 4). Counterstaining of 
nuclei with 4,6-diamidino-2-phenylindole (DAPI) and mounting of the cover slips were done 
with Prolong Gold 5µg/mL (Invitrogen, Carlsbad, CA, USA) 20 minutes before imaging. 
Negative controls were obtained by omitting the primary antibody. Fluorescence emission 
was imaged using a Leica DMI6000 B fluorescence microscope (Leica Microsystems, 
Wetzlar, Germany). 
 
3.1.5. Lentiviral-mediated gene transfer 
 
Lentiviral supernatants were generated using HEK 293T cells transfected via standard 
protocols of calcium phosphate precipitation: 500µL of HBS solution (280 mM NaCl, 10 mM 
KCl, 1.5 mM Na2HPO4.2H2O, 12 mM dextrose and 50 mM HEPES), 250 nM of CaCl2, 4 µg 
of vector plasmid, and 4 µg of each of the lentiviral packaging constructs (pRSV-REV, 
pMDLg/pRRE and the VSV-G expression plasmid pHCMVG). Media was changed 8 hours 
after transfection and the viral supernatants were collected 24–36 hours later. Cells were 
infected with 1:2-1:4 dilutions of the viral supernatants and 4 µg/mL of Polybreen (Sigma-
Aldrich, Inc St Louis, MO, USA). Infected cells were selected with 1 µg/mL of Puromycin 
(Sigma-Aldrich Inc, St Louis, MO, USA). 
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For genetic depletion of p62, melanoma cells were first infected with 5 different p62 
short hairpin RNA (p62 shRNA) purchased from Sigma-Aldrich (Sigma-Aldrich, Inc St 
Louis, MO, USA). After establishment of the conditions, melanoma cells, melanocytes and 
fibroblasts were infected with p62 shRNA number 1 or p62 shRNA number 5 (Table 5). 
Parallel infections with pLKO vector coding for scrambled shRNA (control shRNA) served as 
negative control (Sigma-Aldrich, Inc St Louis, MO, USA). 
 
Table 5. Target sequences of shRNA used for genetic depletion of Sequestosome 1/p62: 
  Hairpin sequence  
p62shRNA1 CCGGGCCCTCCATTTGTAAGAACAACTCGAGTTGTTCTTACAAATGGAGGGCTTTTT 
p62shRNA5 CCGGCCTCTGGGCATTGAAGTTGATCTCGAGATCAACTTCAATGCCCAGAGGTTTTT 
 
Senescent melanocytes were generated infecting cells with FG12 vector expressing the 
oncogenic BRAFV600E, NRASQ61Ror HRASG12Vmutants. Parallel infections with FG12 vector 
were used as negative control. 
For p62 overexpression, melanoma cells and melanocytes were stably transfected with 
pLV-Cherry-p62 lentiviral vectors. Parallel infections with pLV-Cherry plasmid were used as 
negative control. 
To monitor autophagy, melanoma cells were infected with pLV-puro-EGFP-LC3 and 
pLV-Cherry-p62 lentiviral vectors.  
Fluorescence emission was imaged using a Leica DMI6000 B fluorescence 
microscope (Leica Microsystems, Wetzlar, Germany).  
 
3.1.6. Cell proliferation, viability and colony formation assays 
 
Total cell numbers infected with control shRNA and p62 shRNA vectors were 
estimated by manual counting at different time points. 
For proliferation assay, 5.0 x103 UACC-62 cells were infected with control shRNA 
and p62 shRNA vectors. After 6 days of infection, cells were plated in 96-well optical bottom 
plates and, at the indicated time intervals cells were fixed with 4% paraformaldehyde and 
stained with DAPI. For each time point, the total number of cells was quantified by automated 
high-throughput confocal detection of DAPI-stained nuclei (Invitrogen; Carlsbad, CA, USA) 
using the OPERA HCS platform and the Acapella Analysis Software (Perkin Elmer).   
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For colony formation assays, 1.0x104 UACC-62 cells infected with control shRNA 
and p62 shRNA vectors were seeded onto 6-well plates and were allowed to grow for 20 days.  
The colonies were then stained with crystal violet (0.4g/L), purchased from Sigma-Aldrich 
(Sigma-Aldrich, Inc St Louis, MO, USA). 
 
3.1.7. Real-time reverse transcription polymerase chain reaction 
 
Melanocytes infected with mutants BRAFV600E, NRASQ61R, HRASG12V and control 
FG12 were harvested at day 4 and day 6 post-infection and total RNA was extracted and 
purified using RNeasy Mini-Kit (QIAGEN, Valencia, CA, USA) following the 
manufacturer’s instructions. The concentration of extracted RNA was determined by a 
NanoDrop Spectrophotometer ND-100 (NanoDrop Biotechnologies). 
First-strand cDNA was synthesized from total RNA using the High Capacity cDNA 
Reverse Transcription kit (Applied Biosystems, Foster City, CA). 2µg of total RNA in 10 µl 
of Nuclease- free water were mixed with 10µl of RT Master Mix (2µl of 10x RT buffer and 
10x Random Primers, 0.8 µl 25x dNTPs, 1 µl of 50U/µl MultiScribe RT, 3.2 µl of Nuclease- 
free water and 1 µl of RNAse inhibitor). The samples were processed in a thermocycler with 
the following program: 25 ºC for 10 min, 37 ºC for 120 min, 85 ºC for 5 min and 4 ºC O/N. 
Real-time reverse transcription polymerase chain reaction (RT-qPCR) was done 
mixing 50 ng of total cDNA, 2X Power SYBR® Green PCR Master Mix (Applied 
Biosystems, Foster City, CA) and 10 uM of forward and reverse primers of p62 or 18S (Table 
6). Triplicate samples of each condition were processed in 7500 fast Real-Time PCR System 
(Applied Biosystems, Foster City, CA) following the program: 50 ºC for 2 min, 95 ºC for 10 
min and 30 cycles of 95 ºC for 15 sec and 60 ºC 1 min. 
 
Table 6. Primers used for p62 and 18S amplification: 
mRNA Forward 5’- 3’ Reverse 5’- 3’ 
p62 CGCAGTCTCTGGCGGAGCAG TGGCATCTGTAGGGACTGGAGTTCAC 
18S TTGGAGGGCAAGTCTGGTG CCGCTCCCAAGATCCAACTA 
 
3.1.8. Senescence-associated acidic β-galactosidase activity 
 
Melanocytes, fibroblasts and melanoma cells infected with control shRNA and p62 
shRNA on day 7 post-infection were washed twice with phosphate-buffered saline (PBS; pH 
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7.2), fixed with 0.5% glutaraldehyde in PBS and washed in PBS supplemented with 1 mM 
MgCl2. Cells were stained at 37°C in X-Gal solution (1 mg ml–1 X-Gal, 0.12 mM 
K3Fe[CN]6, 0.12 mM K4Fe[CN]6, 1 mM MgCl2 in PBS at pH 6.0). The staining was 
performed for 4–6 h to minimize the background signal. 
 
3.1.9. Melanoma cells treatment 
 
Melanoma cells were treated with 20 nM of Chloroquine, an autophagy inhibitor that 
blocks lysosome–autophagosome fusion (Solomon et al., 2009), during 7 hours.  
Melanoma cells were treated with 25 nM of Rapamycin, an autophagy stimulator by 
the inhibition of mTOR pathway (Raught et al., 2001), during 7 hours.  
 
3.1.10. Matrigel invasion assay 
 
The invasive capacity of SK-Mel-103 melanoma cells was determined via matrigel 
transwell invasion assays according to manufacturer´s guidelines using boyden chambers 
(0.8µm BD BioCoat™ Matrigel™ Invasion Chambers; from BD Biosciences, San Jose, CA, 
USA). This method consists of a pore membrane with a thin layer of Matrigel substance, 
composed by a protein mixture extracted from the Engelbreth-Holm-Swarm mouse sarcoma, 
which include laminin, collagen IV, heparan sulfate proteoglycans, entactin/nidogen and 
different growth factors.  
Melanoma cells infected with control shRNA and p62 shRNA were serum-starved 
overnight. 1 x 105 cells were harvested and seeded in serum-free DMEM onto the upper 
chamber. DMEM containing 10% FBS was placed in the lower chamber. After incubation 
during 20 hours, invading and non-invading cells were first fixed with 4% paraformaldehyde 
and then stained with DAPI. Single cells were visualized by confocal detection of DAPI-
stained nuclei through the 20x objective of a TCS-SP5-WLL (AOBS-UV) spectral 
microscope (Leica Mycrosystems, Wetzlar, Germany) at Confocal Unit, CNIO. The transwell 
membrane was also visualized by laser reflection. LAS AF Matrix screening Software was 
used for an automated high-throughput acquisition across the total width of the matrigel 
membrane in 9 different fields per experimental condition. IMARIS 6.3 Software was used to 
quantify the percentage of invading cells (normalized to the total cell per field).  
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3.1.11. Three-dimensional human skin reconstruct model	  
	  
The three-dimensional human skin reconstruct model (3D-SR) was developed during a 
3 months stay as Visiting Scientist in the Melanoma laboratory of Dr. Meenhard Herlyn, at 
The Wistar Institute, Philadelphia, USA (Figure 3). 	  
The 3D-SR consists of an artificial dermis with fibroblasts cells embedded in a 
collagen I matrix, an artificial epidermis, which is comprised of stratified and differentiated 
keratinocytes and a functional basement membrane. Skin reconstructs are a handful tool for 
the study of melanoma progression. It recapitulates the environment of melanoma cells and 
allows the study of cell-matrix, cell-cell interactions and melanoma invasion capacity in a 
more physiological system than 2D cultures (Li et al., 2011; Brohem et al., 2011). Due to the 
innovation and complexity of the 3D-SR protocol (Li et al., 2011), it will be described in 
detail. 
	  
Preparation of the dermis:  
First, an acellular layer was prepared mixing the following reagents in a 50 mL tube 
on ice: 0.59 mL 10X EMEM, 50 µl 200mM L-glutamine, 0.6 mL FBS, 120 µl 7.5% sodium 
bicarbonate and 4.6 mL bovine collagen I. 1 mL of the mixture was added into each insert of 
tissue culture trays (Organogenesis, Canton, MA) and incubate for 30 min at room 
temperature for solidification. After that, a cellular layer (“dermis”) was prepared mixing the 
following reagents in a 50 mL tube on ice: 1.65 mL 10X EMEM, 150 µl 200 mM L-
glutamine, 1.85 mL FBS, 350 µl 7.5% Sodium bicarbonate, 14 mL bovine collagen I. Human 
fibroblasts were trypsinized from culture flasks with 0.25% trypsin/EDTA. 0.45 x 106 
fibroblasts were resuspended in 1.5 mL DMEM with 10% FBS and added to the mix. 3 mL of 
the mixture were added to each acellular layer-coated insert.  
The “dermis” was incubated for 45 min at 37 °C in a 5 % CO2 tissue culture incubator. 
After that, DMEM containing 10% FBS was added to the inserts (2 mL inside and 10 mL 
outside of insert in each well of skin reconstruct trays) and it was incubated during 4 days for 
“dermis” contraction.  
After 4 days, DMEM medium was aspirated from both inside and outside of each 
insert and washing medium (HBSS with 1% dialyzed FBS) was added in order to remove the 
regular serum. The “dermis” was incubated for 1 hour at 37 °C. 
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Preparation of the epidermis: 
Human keratinocytes were trypsinized from culture flasks with 0.05% trypsin/EDTA.  
Trypsin was neutralized with soy bean trypsin inhibitor (250 mg/L in 1x phosphate buffered 
saline) and 4.17 x 106 cells/mL were resuspended in skin reconstruct Medium I (Table 7).  
The non-invasive melanoma cell line WM-3211 was selected for the skin reconstruct 
invasion experiment. WM-3211 cells were infected with pLV-Cherry-p62 for p62 
overexpression and pLV-Cherry as control. After infection, melanoma cells were trypsinized 
from culture flasks with 0.05% trypsin/EDTA. Trypsin was neutralized with soy bean trypsin 
inhibitor (250 mg/L in 1x phosphate buffered saline) and 0.83 x 106 cells/mL were 
resuspended in skin reconstruct Medium I. 
Washing medium was removed from both inside and outside of each insert. 
Reconstruct Medium I was added (1.5 mL to the inside and 10 mL to the outside of each 
insert). Next, 600µl cell suspension of keratinocytes and 600 µl cell suspension of melanoma 
cells were mixed. 200 µl of the mixed cell suspension were dropped to the inside of each 
insert. The 3D-SR was incubated for 2 days at 37 °C. 
After 2 days, the Skin Reconstruct Medium I was aspirated from both the inside and 
the outside of each insert. Skin reconstruct Medium II (Table 7) was added to the inserts (2 
mL to the inside and 10 mL to the outside). The 3D-SR was incubated for another 2 days at 
37 °C. 
After 2 days, the Skin Reconstruct Medium II was aspirated from the inside and the 
outside of each insert and 7.5 mL Skin Reconstruct Medium III (Table 7) were added only the 
outside part of the insert. From this point, the surface of reconstructs was exposed to the air, 
favoring the differentiation of the keratinocytes. Medium III was changed every other day 
until day 18 (Figure 3). 
At day 18, the 3D-SR was harvested and fixed in 4% formalin for 4 hours and stored 
in 70% ethanol at 4°C. The artificial skins were embedded in paraffin and cut for 
Hematoxylin and eosin (H&E) staining. 3D-SRs were also submitted to 
immunohistochemistry (IHC) analysis for p62 (antibody clone 3/P62 LCK LIGAND, BD 
Biosystem) and mCherry (antibody DsRED Goat Polyclonal, Santa Cruz Biotechnology, sc-
33354) detection. 
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Table 7. Mediums used for three-dimensional human skin reconstruct: 
  
Medium I 
(100mL) 
Medium II 
 (100mL) 
Medium III 
(300mL) 
DMEM 72.5 mL 72.5 mL 142.5 mL 
F12 (HAM's) 24 mL 24 mL 142.5 mL 
L-glutamine (200 mM) 2 mL 2 mL 6 mL 
Hydrocortisone (269 g/mL) 200 µl 200 µl 600 µl  
ITES (500X) 200 µl 200 µl 600 µl  
O-phosphorylethanolamine (0.05 M) 200 µl 200 µl 600 µl  
Adenine (90 mM) 200 µl 200 µl 600 µl  
Progesterone (2 nM) 200 µl 200 µl 600 µl  
CaCl2 (1 M) 240 µl 240 µl 720 µl 
Triiodothyronine (10 nM)  200 µl 200 µl 600 µl 
Chelexed newborn calf serum  100 µl 0 0 
Newborn calf serum 0 100 µl 6 mL 
 
 
a b 
Figure 3. Three-dimensional human skin reconstruct model. (a, b) The gross appearance of the 
skin reconstructs. (c) H&E staining of normal human skin. (d) H&E staining of three-dimensional 
human skin reconstruct. The epidermis comprises oriented basal layer and differentiated stratified 
cell layers. The dermis contains fibroblasts embedded in a collagen type I matrix. 
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3.1.12. Array comparative genomic hybridization  
 
Array comparative genomic hybridization was performed at the Cytogenetic Unit, 
CNIO. Genomic DNA from melanoma cell lines SK-Mel-28, SK-Mel-103, SK-Mel-173 and 
UACC-62 were extracted using DNeasy Blood & Tissue kit (QIAGEN, Valencia, CA, USA) 
and processed for analysis in Human Genome CGH 4x44k microarrays (Agilent 
Technologies, Palo Alto, CA, USA), as previously described (Barrett et al., 2004). Human 
Genomic female DNA (Promega) was used as the reference DNA for all hybridizations. 
Slides were scanned using an Agilent 2565AA DNA Microarray Scanner (Agilent 
Technologies) and the data were analyzed with Agilent Feature Extraction and CGH Analytic 
software 3.5.14.  
 
 
3.1.13. Microarray hybridization and gene expression analysis 
 
Melanoma cells (SK-Mel-103 and UACC-62) infected with control shRNA and p62 
shRNA were harvested at day 3 and day 6 post-infection and total RNA was extracted with 
Trizol, precipitated with isopropanol and purified using RNeasy Mini-Kit (Qiagen, Valencia, 
CA) following the manufacturer’s instructions. RNA quality was assessed in a 1% agarose-
gel. Samples were hybridized onto 4 x 44K microarray slides (Whole Human Genome, 
Agilent Technologies, Inc., Santa Clara, CA), Universal Human Reference RNA (Stratagene, 
La Jolla, CA) and RNA from each sample were reverse-transcribed using a Low RNA Input 
Fluorescent Linear Amplification kit (Agilent Technologies, Inc.) for 2 h at 40 ºC. Equal 
amounts of Cy3- and Cy5-labeled amplified RNA were hybridized for 17 h at 65 ºC and 10 
rpm. The slides were scanned using a G2565BA Microarray Scanner System (Agilent 
Technologies, Inc.). All experiments were done in triplicate. Data were obtained from 
scanned images using Feature Extraction v9.0 software (Agilent Technologies, Inc.) (Martín-
Sánchez et al., 2011) (Figure 4).  
In collaboration with Bioinformatics Unit of CNIO, data were normalized and 
preprocessed using the Gene Expression Pattern Analysis Suite (GEPAS v3.1, 
http://gepas3.bioinfo.cipf.es). Genes differentially expressed under each condition were 
identified using a method based on the Limma t-test (http://pomelo2.bioinfo.cnio.es). A false 
discovery rate (FDR) of < 0.25 was considered significant. These genes were hierarchically 
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clustered using Cluster/Treeview (http://rana.lbl.gov/EisenSoftware.htm). Functional analysis 
was carried out using Gene Set Enrichment Analysis (GSEA v2.0, 
http://www.broad.mit.edu/gsea) (Subramanian, et al 2005). A list of genes identified by the t-
test was used in a preranked GSEA analysis to obtain pathways enriched in each class. 
Reactome (http://www.reactome.org/), Biocarta (http://www.biocarta.com/), KEGG 
(http://www.genome.ad.jp/kegg/) and GenMAPP were used to generate the gene set database. 
 
 
	  SQSTM1 gene expression data from cDNA microarray hybridization of normal 
melanocytes and melanoma cell lines was performed and provided by Dr. Herlyn’s 
laboratory, The Wistar Institute, Philadelphia, USA. 
 
Figure 4. Experimental design for microarray sample labeling and hybridization. Indicated 
melanoma cells were collected 3 and 6 days after lentiviral infection with control and p62 shRNA. 
cDNA from control and p62 depleted cells were synthesized and labeled with Cy3 (green) or Cy5 (red), 
respectively. cDNA from control and p62 depleted cells were mixed and hybridized in microarrays 
slides. The slides correspond to different cell lines and time points. Green circles represent genes that are 
downregulated and red circles represent genes that are upregulated after p62 depletion. 
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3.2. Animal models 
 
3.2.1. Mouse xenograft model 
 
UACC-62 melanoma cells infected with control shRNA and p62shRNA were 
harvested 72 hours after infection and subcutaneously injected (2.0x106 cells in 0.1 mL of 
PBS) into the flanks of 5 nude mice. SK-Mel-103 melanoma cells infected with control 
shRNA and p62shRNA were harvested 72 hours after infection and subcutaneously injected 
(1.0x106 cells in 0.1 mL of PBS plus 0.05 mL of Matrigel) bilaterally into the back region of 
4 nude mice. Tumours growth was measured blinded to the experimental conditions. Every 
two days the two orthogonal external diameters was determinate using a calliper. Tumour 
volume was calculated by using the standard formula: a x b2 x 0.52; where ‘a’ is the longest 
diameter and ‘b’ is the shortest diameter. When tumours reached a size of 1.5 cm3 mice were 
sacrificed, tumours were surgically excised and processed for histopathological study.  
H&E staining and p62 immunohistochemistry were performed in melanoma xenograft 
samples. Cell perimeters were quantified using an automated scanning microscope and 
computerized image analysis system (Ariol SL-50; Genetix) at the Immunhistochemistry Unit 
of CNIO. 
All experiments with mice were performed at CNIO in accordance with protocols 
revised and approved by the Institutional Ethics Committee of the center. 
 
3.2.2. Melanoma mouse model  
 
Conditional melanocyte-specific BrafV600E and BrafV600E/PtenloxP/loxP mouse models 
were generated as previously described (Dankort et al., 2009). Adult mice were treated with 
intraperitoneal injection of 4 mg of tamoxifen per 30 g of mouse 3 consecutive days for tumor 
induction. When tumors reached a diameter of 1cm they were surgically excised and 
processed for histopathological study. Conditional melanocyte-specific BrafV600E mice were 
able to develop benign melanocytic proliferation, meanwhile conditional melanocyte-specific 
BrafV600E/PtenloxP/loxP mice developed malignant tumors with metastatic capacity. Melanocytic 
lesions were confirmed by histological analysis and by Trp2 immunohistochemical staining 
performed at Comparative Pathology Unit, CNIO. Trp2 (D-18, Santa Cruz Biotechnology) 
and p62 (clone 3/P62 LCK LIGAND, BD Biosystem) immunohistochemical staining were 
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performed with Alkaline phosphatase (in pink) due to the elevated amount of melanin 
presented by such tumours. 
	  
3.3. Analyses in human specimens 
 
3.3.1. Tissue samples 
 
A total of 213 paraffin embedded tissue samples including common melanocytic 
dermal nevi (n=47), dysplastic nevi (n=29), primary radial growth phase melanoma (n =16), 
primary vertical growth phase melanoma (n=26), skin (n=38), lymph node (n=35) and 
visceral (n=22) melanoma metastases were randomly selected from the files of Hospital 
Universitario 12 de Octubre for the construction of Tissue microarrays (TMA). 
For survival analysis, 79 additional paraffin embedded cases of VGP melanomas 
randomly selected from the files of Hospital Universitario 12 de Octubre were analyzed on 
whole tissue-sections. 
For RNA extraction and real time PCR, 10 frozen melanoma specimens, including 2 
vertical growth phase, 4 skin metastatic melanomas and 4 lymph node metastatic melanomas 
were obtained from the Biobank of Hospital Universitario 12 de Octubre, Madrid.  
H&E slides were available for review in all cases. The Breslow’s index, the presence 
of ulceration and histological progression growth phase were defined according to standard 
criteria (Breslow A, 1970; Clark et al., 1989).  
All patients included in this study were treated in the Dermatology Department of the 
Hospital Universitario 12 de Octubre according to standard National Comprehensive Cancer 
Network (NCCN) criteria and this study was performed following the Spanish biomedical law 
14/2007. 
 
3.3.2. Generation of tissue microarrays 
 
For characterization of p62 and Ki67 expression, eight different tissue arrays (2 
melanocytic dermal nevi, 1 dysplastic nevi, 1 RGP melanoma, 1 VGP melanoma, 1 skin 
metastatic melanoma, 1 lymph node metastatic melanoma and 1 visceral metastatic 
melanoma) containing the distinctive histological stages of melanocytic tumors were 
constructed.  
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Tissue microarray method was used because it allows the simultaneous analysis of 
multiple individual tissue samples on a single slide. Using this technology, the experimental 
conditions are more homogeneous and there is a minimal destruction of the original tissue. 
Indeed, the possibility of bias due to non-representative tissue sections is overcomed by the 
presence of duplicated samples and the elevated amount of tumors analyzed (Kononen et al., 
1998; Kallioniemi et al., 2001). 
TMAs were assembled as previously described (Kononen et al., 1998; Kallioniemi et 
al., 2001; Alonso et al., 2004).  Two 1.5-mm-diameter cylinders of tissue were taken from 
representative areas of each paraffin block and arrayed into a new recipient paraffin block 
with a custom-built precision instrument (Beecher Instruments, Silver Spring, MD). Areas 
chosen for the cylinder core had high tumor cellularity. To evaluate the most adequate part of 
each primary tumor, the invasive border of the tumor in large lesions and all tumor cells in 
smaller samples were selected. In addition, normal tissues (skin, tonsil, and reactive lymphoid 
tissue) were placed adjacent to tumoral cylinders to serve as internal controls and to ensure 
the quality of staining slides. Initial sections were stained for hematoxylin and eosin to verify 
the quality of the TMAs (Figure 5). 
 
 
 
 
 
 
	  
Figure 5. Generation of tissue microarrays of melanocytic lesions. (a) Tissue arrayer 
instrument used for array construction (b) Donor paraffin block with melanocytic lesion. (c) TMA 
paraffin block. (d) The gross appearance of TMA slide stained with H&E. 
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3.3.3. Immunohistochemistry 
 
Three-micrometer tissue sections from the TMAs or paraffin blocks were sectioned 
and applied to special immunohistochemistry coated slides (DAKO, Glostrup, Denmark).  
P62 immunohistochemical staining was performed using BondTM Automated System 
(Leica Microsystems) at the Immunohistochemistry Unit of Hospital Universitario 12 de 
Octubre. After incubation with primary antibodies, immunodetection was performed with 
BondTM Polymer Refine Detection (Leica Microsystems), according to the manufacturer’s 
instructions. All sections were counterstained with hematoxylin. Sequestosome1/p62 antibody 
(clone 3/P62 LCK LIGAND, BD Biosystem), was diluted 1:100 and used with sodium citrate 
buffer (pH 6.5). Substantia nigra specimen from a patient with Parkinson disease was used as 
positive control (Layfield et al., 2008).  
Ki 67 (clone MIB-1, Ready-to-use, DAKO) immunohistochemical staining was 
performed at Immunohistochemistry Unit, CNIO, using Dako Autostainer protocol and 
sodium citrate buffer (pH 6.5). Reactive lymphoid tissue was used as positive control.  
P62 staining was blinded evaluated by Drs. José Luis Rodriguez Peralto and Erica 
Riveiro. Staining was considered positive for p62 taking into account both the percentage of 
positive cells and the intensity of its expression. The score system used was: 0 (no 
expression), 1 (week expression or less than 50% of the tumor presenting high intensity) or 2 
(more than 50% of the tumor presenting high intensity). Ki67 percentage of expression was 
determined using an automated scanning microscope and computerized image analysis system 
(Ariol SL-50; Genetix) at the Immunhistochemistry Unit of CNIO. 
 
3.3.4. Immunofluorescence analysis in tissues 
 
For immunofluorescence analyses of human specimens, tissue sections were 
deparaffinized in xylene for 20 minutes, rehydrated through a graded ethanol series and 
washed with phosphate-buffered saline. Antigen retrieval was achieved by a 10-minutes heat 
treatment in a pressure cooker, containing 1 liter of 10 mmol/L sodium citrate buffer (pH 6.5). 
Tissue sections were incubated overnight with anti-S100 antibodies (dilution 1:400, DAKO, 
Z0311) or anti-p62 antibody (dilution 1:150, BD Biosciences, p62 lck) at 4°C in a humidified 
chamber. After that, the slides were rinsed with PBS and incubated with fluorescent 
secondary antibodies for 1 hour at room temperature. Secondary antibodies used were anti-
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positive cells and the intensity of its expression. The score system used was: 0 (no 
expression), 1 (week expression or less than 50% of the tumor presenting high intensity) or 2 
(more than 50% of the tumor presenting high intensity). Ki67 percentage of expression was 
determined using an automated scanning microscope and computerized image analysis system 
(Ariol SL-50; Genetix) at the Immunhistochemistry Unit of CNIO. 
 
3.3.4. Immunofluorescence analysis in tissues 
 
For immunofluorescence analyses of human specimens, tissue sections were 
deparaffinized in xylene for 20 minutes, rehydrated through a graded ethanol series and 
washed with phosphate-buffered saline. Antigen retrieval was achieved by a 10-minutes heat 
treatment in a pressure cooker, containing 1 liter of 10 mmol/L sodium citrate buffer (pH 6.5). 
Tissue sections were incubated overnight with anti-S100 antibodies (dilution 1:400, DAKO, 
Z0311) or anti-p62 antibody (dilution 1:150, BD Biosciences, p62 lck) at 4°C in a humidified 
chamber. After that, the slides were rinsed with PBS and incubated with fluorescent 
secondary antibodies for 1 hour at room temperature. Secondary antibodies used were anti-
Materials	  and	  Methods	  
___________________________________________________________________________	  
61 
	  
	  
rabbit Alexa Fluor 555 (red) or anti-mouse Alexa Fluor 488 (green) (Invitrogen, Carlsbad, 
CA, USA). Counterstaining of nuclei and mounting of slides were done with Prolong Gold 
5µg/mL (Invitrogen, Carlsbad, CA, USA) 20 minutes before imaging. Negative controls were 
obtained by omitting the primary antibody. Fluorescence emission was imaged using a Leica 
DMI6000 B fluorescence microscope (Leica Microsystems, Wetzlar, Germany). 
 
3.3.5. RNA extraction from frozen melanoma specimens 
 
Frozen melanoma biopsies were cut with a cryostat to get 10-20 slides with 10 µm. 1 
ml of Trizol was added to the samples, homogenized with 23 G needles and incubated 5 min 
at room temperature. After that, 200 uL of chloroform was added, homogenized by vortexing 
and incubated at room temperature for 15 min.  The tubes were centrifuged at 12000 rpm 
during 15 min at 4°C. Following centrifugation, the aqueous phases were transferred to clean 
tubes where 600 uL of 70% ethanol at -20 ° C were added to each sample. The product of the 
mixture was transferred to the columns of the kit RNeasy Mini Kit (QIAGEN, Valencia, CA, 
USA) and followed the manufacturer's instructions. The concentration of extracted RNA was 
determined by a NanoDrop Spectrophotometer ND-100 (NanoDrop Biotechnologies) and 
analyzed by 1% TAE agarose gel with DNA SYBERsafe Stain (Invitrogen, Carlsbad, CA, 
USA). First-strand cDNA and RT-qPCR were done as previously described. 
	  
3.4. Statistical and survival analyses  
 
Differential expression of p62 among melanocytic tumors was analyzed by Chi-square 
test (Figure 7b, page 67). P62 mRNA and protein expression between melanocytes and 
melanoma cell lines was compared using Mann-Whitney U test (Figures 8 and 9b, pages 68-
69). Differential expression of p62 mRNA among frozen melanoma speciemens was analyzed 
by one-way analysis of variance (Figure 13b, page 73). Statistical significance of SA-β-Gal 
activity in melanocytes, fibroblasts and melanoma cells depleted for p62 was analyzed by 
Student´s t test (Figure 20c, page 82). Difference on invasion capacity of melanoma cells after 
genetic depletion of p62 was analyzed by Student´s t test (Figure 21, page 83). Statistical 
differences between tumor volumes in xenograft mice model were analyzed by two-way 
analysis of variance (Figure 26a, page 90). The perimeters of melanoma cells in xenograft 
tumors were compared by Student´s t test (Figure 26c, page 90). Differences on Ki67 
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percentages across p62 expression categories were obtained by one-way analysis of variance 
(overall) and Student´s t test (negative versus low versus high) (Figure 27b, page 91). 
For survival analysis, clinical data and immunohistochemical scoring were performed 
blind. P62 IHC staining was quantified by two independent investigators as negative (absence 
of expression) or positive (including low and high intensity of p62 expression). Clinical data 
were compiled only after all analyses were completed. 
The distribution of 105 patients according to p62 expression was analyzed by Chi-
square test (sex, ulceration and clinical staging) and Student´s t test (age and Breslow). 
Five years of follow-up survival data were available in 104 patients with vertical 
growth phase melanoma. Disease Free Survival (DFS) and Overall Survival (OS) curves were 
estimated with Kaplan-Meier product-limit method and survival curves were compared using 
logrank test. The hazard ratio was calculated using Cox regression and adjusted with 
univariate and multivariate models adjusting by Breslow, Clinical Stage and T3 category. 
Distribution of patients into two T3 categories (T≤ T3a stage or T>T3a stage) was performed 
to include both thickness and ulceration status in multivariate analyses. These two subgroups 
were chosen because they present significant differences in survival rates (Balch et al., 2009). 
 - Disease Free Survival was defined as the time interval between diagnosis (made by 
histopathological study of primary melanoma) and the development of the first metastasis. It 
was considered censored for patients who did not present metastasis at last follow-up. 
- Overall survival was defined as the time interval between diagnosis (made by 
histopathological study of primary melanoma) and death due to melanoma. It was considered 
censored for patients who were alive at last follow-up or who died from other causes.  
Probability values (P) equal or less than 0.05 were considered statistically significant 
(*P<0.05, ** P<0.01, *** P<0.001, *** P<0.0001). 
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4. RESULTS 	  
 
4.1. The expression of Sequestosome 1/p62 in melanocytic tumors 
 
4.1.1. Benign and malignant melanocytic tumors express differential levels of p62 
protein 
 
The overexpression of p62 has been described in different types of human cancers 
(Thompson et al., 2003; Kitamura et al., 2006; Duran et al., 2008). However, no data about its 
expression in melanoma tumors are available in the literature.  
First, to address whether p62 could have a role in melanoma, direct 
immunofluorescence for p62 was performed in 3 human benign intradermal nevi and 3 skin 
metastatic melanoma specimens.  Representative pictures of co-staining with S100, a 
melanocytic marker, and p62 are shown in Figure 6. Interestingly, a strong expression of p62 
was observed in metastatic melanoma samples while no expression was detected in benign 
nevi. S100 was clearly positive in both lesions, however.  
Figure 6. Differential expression of p62 protein in nevi and melanoma cells. Melanomas but 
not dermal nevi display enhanced p62 expression, as shown by immunofluorescence staining of 
human specimens (p62 in green, S100 in red and nuclei stained with DAPI in blue signal).  
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Next, to characterize p62 expression in melanoma progression, 8 tissue microarrays 
containing different stages of melanocytic tumors (common melanocytic dermal nevi (n=47), 
dysplastic nevi (n=29), primary radial growth phase melanoma (n =16), primary vertical 
growth phase melanoma (n=26), skin melanoma metastases (n=38), lymph node melanoma 
metastases (n=35) and visceral melanoma metastases (n=22)) were immunohistochemically 
analyzed for p62 by two independent investigators.  
As shown in Table 8 and Figures 7a and 7b, all 47 common dermal nevi analyzed 
were negative for p62 staining. In 9 out of 29 dysplastic nevi (31%), a low expression of p62 
was observed. Interestingly, an increase in frequency and intensity of p62 expression was 
observed in malignant melanocytic lesions (P<0.0001). The study of 16 radial growth phase 
melanomas, showed low expression of p62 in 10 specimens (62.5%) and high expression of 
p62 in 1 case out of 16 (6.25%). Moreover, the expression of p62 was increased with 
melanoma progression. The analysis of 26 vertical growth phase melanomas, an invasive 
form with metastatic capacity (Barnhill et al., 1993), showed low expression of p62 in 16 
samples (61.54%) and high expression of p62 in 6 cases (23.08%). Skin metastatic and lymph 
node metastatic samples presented similar percentage of p62 expression. In skin metastases, 
36.85% cases presented low expression (14/38) and 26.3% high expression of p62 (10/38). In 
lymph node metastases, 34.3% cases presented low expression (12/35) and 28.6% high 
expression of p62 (10/35). Metastatic melanomas to different organs (visceral metastasis) 
presented an increased expression of p62, with 36.4% with low expression (8/22) and 45.4% 
of the cases showing high expression of p62 (10/22).  
 
Table 8. P62 protein expression in benign and malignant melanocytic tumors: 
  p62 Negative p62 Positive low p62 Positive high 
Melanocytic Tumors N/total % N/total % N/total % 
Dermal Nevi 47/47  100 0/47  0 0/47 0 
Dysplastic Nevi 20/29 69 9/29  31 0/29 0 
RGP Melanomas 5/16  31.25 10/16  62.5 1/16  6.25 
VGP Melanomas 4/26  15.38 16/26 61.54 6/26  23.08 
Skin Metastases 14/38  36.85 14/38  36.85 10/38  26.3 
Node Metastases 13/35  37.1 12/35  34.3 10/35  28.6 
Visceral Metastases 4/22  18.2 8/22  36.4 10/22  45.4 
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Figure 7.  The expression of p62 
increases during melanoma 
progression. (a) Representative 
pictures of p62 
immunohistochemistry in tissue 
microarrays containing the indicated 
human benign and malignant 
melanocytic tumors. (b) The bar 
graph shows the corresponding p62 
quantification for 213 melanocytic 
tumors. The staining was classified 
into “Negative, “Low” and “High” 
p62-expressing tumors. N indicates 
the total number of cases analyzed 
in each group (P<0.0001).	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In summary, p62 protein expression was completely negative in common dermal nevi. 
Dysplastic nevi were positive for p62, however less frequently than malignant lesions. 
Additionally, an increased expression of p62 was observed in late stages of melanoma 
progression. Early phase of melanoma progression (radial growth phase) presented less 
expression of p62 comparing to invasive (vertical growth phase melanoma) and advanced 
stages of malignant melanoma (metastatic disease). Altogether, the immunohistochemical 
analysis of melanocytic tumors indicates that the expression of p62 is related to melanoma 
progression (P<0.0001). 
 
 
4.1.2. Normal melanocytes and melanoma cell lines present differential levels and 
cellular distribution of p62 protein  
 
To confirm the expression of p62 in melanoma cells and to establish an in vitro model 
for additional studies of p62 function, thirty-four melanoma cell lines and 4 normal 
melanocytes were cultured and collected for the detection of p62 RNA levels. Total mRNA 
was extracted and submitted to microarray hybridization and gene expression analysis. As 
shown in Figure 8, melanoma cell lines presented a statistically significant overexpression of 
p62 mRNA. In 32 out of 34 melanoma cell lines, a higher amount of p62 mRNA comparing 
to normal melanocytes was observed (P=0.007).  
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Figure 8. Overexpression of p62 at mRNA level in melanoma cells. Microarray hybridization of 
4 normal melanocytes and 34 human melanoma cell lines showing an overall overexpression of 
p62 at mRNA level in melanoma cells (P = 0.007). 
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To analyze protein levels of p62 in cell lines, adherent melanoma and melanocytes 
cells were collected and total protein extracts were analyzed by protein immunoblots. Only 
one band of p62 protein with approximately 62 kDa was detected in melanocytes and 
melanoma cell lines. As shown in Figures 9a and 9b, p62 expression was clearly associated 
with a tumoral phenotype, with 12 out of 19 melanoma cell lines showing higher amounts of 
p62 protein comparing to normal melanocytes (P=0.007).  
 
 
 
 
 
Additionally, p62 localization and pattern of distribution in normal melanocytes and 
melanoma cells lines were assessed by direct immunofluorescence (Figure 10). Melanoma 
cells presented a punctuated pattern consistent with p62 being localized into cytosolic 
speckles or aggregates. In one out of seven melanoma cell lines (WM-1366), it was also 
observed nuclear expression of p62. As previously shown by protein immunoblots, direct 
immunofluorescence confirmed a higher expression of p62 in melanoma cells comparing to 
normal melanocytes. Moreover, normal melanocytes did not present aggregates of p62, but a 
weak and diffuse pattern of cytosolic p62 expression. 
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Figure 9. Overexpression of p62 at 
protein level in melanoma cells. (a) 
Protein immunoblot against p62 of 
total cell extracts isolated from the 
indicated melanoma cell lines and 3 
normal melanocytes. α -tubulin was 
used as loading control. (b) 
Corresponding quantification of 
protein immunoblots showing an 
overall overexpression of p62 in 
melanoma cells (P=0.007).	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cells were collected and total protein extracts were analyzed by protein immunoblots. Only 
one band of p62 protein with approximately 62 kDa was detected in melanocytes and 
melanoma cell lines. As shown in Figures 9a and 9b, p62 expression was clearly associated 
with a tumoral phenotype, with 12 out of 19 melanoma cell lines showing higher amounts of 
p62 protein comparing to normal melanocytes (P=0.007).  
 
 
 
 
 
Additionally, p62 localization and pattern of distribution in normal melanocytes and 
melanoma cells lines were assessed by direct immunofluorescence (Figure 10). Melanoma 
cells presented a punctuated pattern consistent with p62 being localized into cytosolic 
speckles or aggregates. In one out of seven melanoma cell lines (WM-1366), it was also 
observed nuclear expression of p62. As previously shown by protein immunoblots, direct 
immunofluorescence confirmed a higher expression of p62 in melanoma cells comparing to 
normal melanocytes. Moreover, normal melanocytes did not present aggregates of p62, but a 
weak and diffuse pattern of cytosolic p62 expression. 
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Figure 9. Overexpression of p62 at 
protein level in melanoma cells. (a) 
Protein immunoblot against p62 of 
total cell extracts isolated from the 
indicated melanoma cell lines and 3 
normal melanocytes. α -tubulin was 
used as loading control. (b) 
Corresponding quantification of 
protein immunoblots showing an 
overall overexpression of p62 in 
melanoma cells (P=0.007).	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The previous findings raised the question whether the differential pattern of p62 
distribution was dependent to the amount of its expression. To answer this query, melanocytes 
and melanoma cells were stably transfected with pLV-Cherry-p62 lentiviral vector for p62 
overexpression. This construct generates a cherry fluorescent protein fused to wild type form 
of human p62 protein. As demonstrated by protein immunoblots, the lentiviral infection 
conferred similar levels of ectopic p62 expression in both melanoma cells and melanocytes 
(Figure 11a). Unexpectedly, even a high expression of p62 in normal melanocytes did not 
change the diffuse pattern of p62 presented by these cells. On the other hand, the 
overexpression of p62 in metastatic melanoma cell line (SK-Mel-103) led to an increased 
number and size of protein aggregates (Figure 11b).  
 
 
 
 
 
 
Figure 10. Differential basal expression and cytosolic distribution of p62 in melanoma and 
melanocytes. Immunofluorescence staining of endogenous p62 (green signal) revealing cytosolic 
aggresomes in melanoma cells.	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Taken together, the increased levels and different cellular distribution of p62 in 
melanoma cells comparing to normal melanocytes suggest that p62 could play a relevant role 
in melanoma.   
 
 
4.1.3. P62 is transcriptionally-regulated in melanoma tumors 
 
Alteration in DNA copy number is a frequent reason of gene expression modification 
in cancer cells. In fact, DNA copy number variations are a common feature of melanoma 
tumors (Curtin et al., 2005).  
As previously shown in this study, melanoma specimens and cell lines express high 
levels of p62. To address whether the overexpression of p62 was related to SQSTM1 copy 
number variation, melanoma cell lines were submitted to high-resolution array comparative 
genomic hybridization (CGH). Genomic DNA of melanoma cells lines was extracted and 
hybridized against Human Genome CGH 44k microarrays. The cell lines chosen were SK-
Mel-28, SK-Mel-103, SK-Mel-173 and UACC-62 which present different genetic background 
(Table 2, page 46) and levels of p62 expression (Figure 9, page 69).  
Figure 11. Ectopic overexpression 
of derivatives of p62 (fused to the 
fluorescent cherry protein) 
showing that even after 
overexpression the distribution of 
p62 differs in melanoma cells and 
melanocytes. (a) Protein 
immunoblots against p62 and α -
tubulin showing similar levels of p62 
expression in melanocytes and SK-
Mel-103 melanoma cells after 
lentiviral transduction with the 
construct pLV-Cherry-p62. (b) 
Fluorescent microphotographs of 
indicated cells following ectopic 
overexpression of p62 demonstrating 
the accumulation of p62 aggregates 
only in melanoma cells.	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The Sequestosome 1 gene (SQSTM1) is located on chromosome 5q35 (base pair 
179,233,388 - 179,265,078). As shown in Figure 12, any of the cell lines studied by CGH 
presented amplification or gain of the SQSTM1 locus that could justify p62 overexpression. 
 
 
 
 
Figure 12. Absence of amplification of p62 genomic locus in melanoma cell lines. Comparative 
genomic hybridization analysis of 4 different melanoma cell lines demonstrated the absence of 
amplification of SQSTM1 locus. 
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For further elucidation of p62 regulation in melanoma, the levels of p62 protein and 
mRNA were compared in 10 randomly chosen human melanoma samples. Paraffined-
embedded sections of melanoma samples, including 2 VGP primary melanomas, 4 skin 
metastatic and 4 lymph node metastatic melanomas were submitted to p62 
immunohistochemistry for protein level detection. After that, cryosections of the same cases 
were used for total RNA extraction and submitted to RT-qPCR for p62 mRNA level 
detection. As shown in Figures 13a and 13b, a positive association between p62 protein and 
mRNA levels suggests a transcriptional regulation of SQSTM1gene in melanoma.  
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Figure 13. Transcriptionally-associated 
control of p62 in melanoma specimens. (a) 
Expression pattern of p62 protein visualized 
by immunohistochemistry on human samples 
corresponding to primary melanomas (M), 
skin melanoma metastases (SM) and lymph 
node melanoma metastases (NM). (b) The 
bar graph shows the relative expression of 
p62 mRNA obtained by RT-qPCR of the 
indicated melanoma specimens (n=3, mean ± 
SEM, P<0.0001).	  
b 
a 
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  Results	   	  
___________________________________________________________________________	  
73 
	  
For further elucidation of p62 regulation in melanoma, the levels of p62 protein and 
mRNA were compared in 10 randomly chosen human melanoma samples. Paraffined-
embedded sections of melanoma samples, including 2 VGP primary melanomas, 4 skin 
metastatic and 4 lymph node metastatic melanomas were submitted to p62 
immunohistochemistry for protein level detection. After that, cryosections of the same cases 
were used for total RNA extraction and submitted to RT-qPCR for p62 mRNA level 
detection. As shown in Figures 13a and 13b, a positive association between p62 protein and 
mRNA levels suggests a transcriptional regulation of SQSTM1gene in melanoma.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
M
1
M
2
SM
1
SM
2
SM
3
SM
4
N
M
1
N
M
2
N
M
3
N
M
4
2x 20x
2x 20x
2x 20x
2x 20x
2x 20x
2x 20x
2x 20x
2x 20x
2x 20x 2x 20x
Figure 13. Transcriptionally-associated 
control of p62 in melanoma specimens. (a) 
Expression pattern of p62 protein visualized 
by immunohistochemistry on human samples 
corresponding to primary melanomas (M), 
skin melanoma metastases (SM) and lymph 
node melanoma metastases (NM). (b) The 
bar graph shows the relative expression of 
p62 mRNA obtained by RT-qPCR of the 
indicated melanoma specimens (n=3, mean ± 
SEM, P<0.0001).	  
b 
a 
Results	   	  
___________________________________________________________________________
	   	  
74 
	  
Altogether, comparative genomic hybridization of melanoma cell lines and expression 
analyses of melanoma specimens support a transcriptional regulation of p62 without 
amplification of its genomic locus. 
 
 
4.1.4. P62 expression is induced during malignant transformation of melanocytes 
 
Several key genetic alterations governing melanoma initiation and progression have 
been identified. The most common proto-oncogenes involved in melanoma initiation are 
related to the activation of the mitogen-activated protein kinase pathway (MAPK). Mutations 
of RAS/MAPK pathway genes as BRAF and NRAS are detected in 40-60% and 10-20% of 
melanoma patients, respectively (Goel et al., 2006; Ribas et al., 2011). Moreover, Duran and 
coworkers have shown that the RAS oncogene leads to overexpression of p62 mRNA and 
protein levels in immortal embryo fibroblasts through the activation of the p62 promoter 
(Duran et al., 2008). Taking together, these observations presented in the literature address the 
question whether BRAF and RAS oncogenes could regulate p62 expression in melanocytic 
tumors.  
To answer this question, freshly isolated normal melanocytes were submitted to 
lentiviral-driven transduction of BRAFV600E, NRASQ61R and HRASG12V mutations. Non-
infected, control melanocytes (infected with FG12 vector) and melanocytes infected with 
BRAFV600E, NRASQ61R or HRASG12V were collected at days 4 and 6 post-infection for the 
detection of p62 mRNA and protein levels. As shown in Figure 14a, 4 to 6 days after 
infection, melanocytes expressing BRAFV600E, NRASQ61R and HRASG12V mutations entered into 
a nonproliferative state and suffered morphological features of senescence, including enlarged 
cytoplasm, nuclear size and extensive cytosolic vacuolization.  
Analyses by RT-qPCR (Figure 14b) and protein immunoblots (Figure 14c) did not 
show overexpression of p62 after infection with BRAFV600E, NRASQ61R or HRASG12V4 
mutations (P>0.05). Interestingly enough, these finding corroborates the previous results 
obtained by IHC (Figure 6, page 65 and Figure 7, page 67), whereby the expression of p62 
was negative in dermal nevi, benign lesions mostly composed by senescent melanocytes. 
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Figure 14. Absence of p62 upregulation in senescent melanocytes. (a) Microphotographs of 
non-infected (NI), control melanocytes (FG12) and melanocytes expressing BRAFV600E, NRASQ61R 
or HRASG12V mutations after 4 and 6 days of lentiviral infection showing morphological features of 
senescent phenotype. (b) The bar graph shows the relative expression of p62 mRNA of the 
indicated melanocytes, obtained by qPCR (n=3, mean ± SEM, P>0.05)  (c) Protein immunoblots 
against p62, Pan RAS and BRAF confirmed the overexpression of the indicated oncogenes but the 
absence of p62 upregulation in senescent melanocytes. α-tubulin was used as loading control. 
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Although BRAFV600E or NRASQ61R mutations are present in most of the melanoma 
tumors, the malignant transformation of melanocytes is invariably accompanied by additional 
genetic alterations as the silencing of tumor suppressor genes (Curtin et al., 2005; Denoyelle 
et al., 2006). In this study, the absence of p62 upregulation in cultured senescent melanocytes 
and dermal nevi specimens opened the question whether p62 overexpression is induced 
during the malignant transformation of melanocytes. 
To answer this query, conditional melanocyte-specific BrafV600E and 
BrafV600E/PtenloxP/loxP mice models were used for the analysis of p62 expression. Mice 
carrying BrafV600E mutation are able to form melanocytic lesions without metastatic capacity 
(Dankfort et al., 2009). On the other hand, BrafV600E mutation cooperates with Pten loss to 
induce malignant lesions and mice harboring such genetic alterations are able to form 
malignant melanomas with metastatic capacity (Dankfort et al., 2009). 
Tumor samples from both mice models were surgically extracted and the expression of 
p62 was assessed by immunohistochemical staining. Interestingly, the expression of p62 was 
higher in malignant melanomas specimen of BrafV600E/PtenloxP/loxP mice, than in benign 
melanocytic proliferation of the BrafV600 mice (Figure 15).  
 
 
 
 
 
 
 
In summary, the study of p62 expression in senescent melanocytes and in melanoma 
mice models suggest that p62 overexpression is a phenomenon associated to the malignant 
transformation of melanocytes. 
 
Figure 15. P62 overexpression is related to malignant transformation of melanocytes. 
Immunohistochemical staining for p62 (in pink) in melanocytic tumors of conditional melanocyte-
specific mice models showing increased expression of p62 in malignant melanocytic tumors 
(BrafV600E/PtenloxP/loxP) when compared to benign melanocytic tumors (BrafV600E).	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4.2. The function of Sequestosome1/p62 in melanoma cells     
 
4.2.1. Genetic inactivation of p62 triggers melanoma growth arrest  
 
Sequestosome1/p62 has been related to tumorigenesis in different types of cancer as 
indicated above (Duran et al., 2008; Mathew et al., 2009; Inami et al., 2011). Taking in 
consideration that p62 is overexpressed in malignant tumors of melanocytes, it was 
hypothesized that p62 could play a relevant role in melanoma cells.  
To address the function of p62 in melanoma, melanoma cell lines were submitted to 
genetic depletion of p62 by RNA interference (RNAi). First, to identify an adequate RNAi for 
p62 depletion, SK-Mel-103 melanoma cells were submitted to downregulation of endogenous 
p62 levels by lentiviral-driven transduction of 5 different p62 short harpirin RNA (p62 
shRNA). The infection of SK-Mel-103 cells with a scramble short harpirin RNA was used as 
control (control shRNA). After 6 days of infection, melanoma cells were collected for protein 
immunoblot analysis. As shown in Figure 16a and 16b, an efficient downregulation of p62 
protein was obtained with the shRNA constructs number 1, 3 and 5. The efficacy of p62 
deletion was also checked by direct immunofluorescence and visualized as a decrease of 
fluorescent signal in p62 shRNA cells (Figure 16c). The constructs 1 or 5 were then selected 
for the following experiments. 
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4.2. The function of Sequestosome1/p62 in melanoma cells     
 
4.2.1. Genetic inactivation of p62 triggers melanoma growth arrest  
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 Next, UACC-62 melanoma cells harboring the most common mutation found in 
melanoma patients (BRAFV600E) were depleted for p62 using shRNA constructs (Figure 17a). 
Intriguingly, proliferation assay demonstrated that UACC-62 melanoma cells responded to 
p62 shRNA with a significant inhibition of cell growth (Figures 17b and 17c). Indeed, 
UACC-62 cells infected with control shRNA and p62 shRNA were plated at low confluence 
for the analysis of the capacity to form colonies. After 20 days, the plates were stained with 
crystal violet and it was observed that the depletion of p62 decreased the capacity of colony 
formation by melanoma cells (Figure 17d).  
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Figure 16. Genetic depletion of p62 using RNAi in melanoma cells. Downregulation of 
endogenous p62 levels by lentiviral-driven transduction of shRNAs in SK-Mel-103 melanoma 
cells. (a) Protein immunoblots against p62 and α-tubulin showing efficient downregulation of p62 
in 3 out of 5 different p62 short harpirin RNA. (b) Microphotographs of melanoma cells 6 days 
after lentiviral infection with shRNA constructs. (c) Efficient depletion of p62 in SK-Mel-103 and 
UACC-62 melanoma cell lines confirmed by direct immunofluorescence 6 days after lentiviral 
infection.	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To confirm the influence of p62 in melanoma proliferation, 4 additional melanoma 
cell lines SK-Mel-28, SK-Mel-103, SK-Mel-173 and WM-164, harboring different mutational 
status (Table 2, page 46) were depleted for p62. The number of cells was quantified at day 0, 
2, 4 and 6 after infection. As represented in Figure 18, the relative number of p62 shRNA 
cells, comparing to control, decreased with the time, validating the results obtained with 
UACC-62 cell line. Indeed, it demonstrates that the effect of p62 depletion in cellular 
proliferation is independent of the genetic background presented by melanoma cells. 
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Figure 17. P62 genetic inactivation triggers melanoma growth arrest. (a) Protein immunoblots 
against p62 and α-tubulin showing an efficient downregulation of p62 in UACC-62 melanoma cells 
expressing p62 shRNA. (b) Corresponding proliferative curve of melanoma cells demonstrated an 
inhibition of cell growth after p62 depletion. Six days after lentiviral infection melanoma cells were 
seeded in 96-well optical bottom for quantification of total number of cells by automated high-
throughput confocal detection of DAPI-stained nuclei (n=3, mean ± SEM, P<0.05). (c) 
Representative microphotographs of UACC-62 melanoma cells 6 days after lentiviral infection for 
p62 downregulation. (d) Colony formation ability of UACC-62 melanoma cell line after p62 
downregulation. Cells were seeded at low density on day 6 after lentiviral transduction. Shown are 
representative scans of colonies visualized by crystal violet staining.	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Figure 18. The interference of p62 in melanoma proliferation is independent of the genetic 
background of the cells. (a) Protein immunoblots against p62 and α-tubulin showing an efficient 
downregulation of p62 in melanoma cells expressing p62 shRNA. (b) Representative 
microphotographs of melanomas cells on day 6 after lentiviral transduction demonstrating cell 
growth arrest after the depletion of p62. (c) Growth curves on days 0, 2, 4 and 6 after lentiviral 
transduction showing a relative decrease in cell number of p62 depleted cells (p62 shRNA), when 
compared to non infected (NI) and control cells. 	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Moreover, as shown in Figure 19a, the depletion of p62 was accompanied by 
morphological changes evocative of classical senescent phenotype, as cell enlargement, 
vacuolization and flattening. The morphological changes suffered by p62-depleted cells were 
also suggestive of cytoskeleton alterations. To address whether the depletion of p62 triggers a 
senescent mechanism, the expression of the senescence-induced β -galactosidase enzyme 
(SA-β-Gal), a commonly used senescence marker (Michaloglou et al. 2005), was evaluated. 
UACC-62 and SK-Mel-103 melanoma cells were depleted for p62 using shRNA constructs 
and submitted to Xgal staining. The increased of SA-β-Gal activity in p62 depleted cells 
demonstrated the senescent state of these cells (Figure 19b). 
 
 
 
 
Taken together, the results obtained by RNA interference technique prove that p62 is 
essential for melanoma proliferation, and its absence is responsible for inducing a 
nonproliferative state with senescent-like phenotype. 
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Figure 19. The absence of 
p62 expression is 
responsible for arresting 
melanoma cells with a 
senescent-like phenotype.  
(a) Representative 
microphotographs of the 
indicated melanoma cell 
lines after genetic depletion 
of p62 showing morphologic 
alterations suggestive of 
senescent phenotype. (b) 
Increased SA-β-Gal activity 
(blue staining) in melanoma 
cells after p62 depletion. 
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4.2.2. The requirement of p62 is tumor cell selective 
 
After addressing the relevance of p62 in melanoma cells, the next question was 
whether p62 could interfere with the proliferation of normal cells. Normal fibroblasts and 
melanocytes isolated from foreskin and UACC-62 melanoma cells were submitted to genetic 
depletion of p62 using RNA interference technique.  As shown by protein immunoblots, an 
efficient downregulation of p62 was acquired in melanoma and normal cells after lentiviral-
driven transduction of p62 shRNA (Figure 20a). Interestingly, after the depletion of p62, 
normal fibroblasts and melanocytes were still able to proliferate, meanwhile melanoma cells 
arrested. Unlike melanomas cells, normal fibroblasts and melanocytes did not suffer 
morphologic changes in the absence of p62 (Figure 20b). In fact, the senescence-associated β 
-galactosidase activity did not increase in normal cells depleted for p62 (P>0.05), but it 
increased in melanoma cells after p62 depletion (P=0.004) (Figures 20b and 20c).  
 
 
 
 
 
 
 
 
 
 
 
Figure 20. P62 depletion in normal melanocytes and fibroblats does not interfere with 
proliferative growth and morphologic changes. (a) Protein immunoblots against p62 and β-actin 
showing an efficient downregulation of p62 expression in melanoma cells, normal fibroblasts and 
melanocytes expressing p62 shRNA. (b) Representative microphotographics of cells on day 6 after 
lentiviral transduction showing increased SA-β-Gal activity (blue staining) in melanoma cells but 
not in normal cells after p62 depletion. (c) Corresponding quantification of SA-β-Gal activity after 
p62 depletion (n=3, mean ± SEM, P=0.004).	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In summary, the depletion of p62 did not trigger a senescent phenotype in normal 
cells, indicating a tumor cell selective requirement of p62 protein. 
 
4.2.3. P62 contributes to the invasive capacity of melanoma cells 
 
 Vertical growth phase melanomas, the invasive form of primary melanoma, showed 
elevated amount of p62 expression comparing to radial growth phase melanomas (Figure 7, 
page 67). Moreover, p62 depleted cells presented morphologic changes compatible with 
cytoskeleton remodeling (Figure 19, page 81). Since changes in cytoskeletal structure are 
involved in cellular adhesion and motility (Miyoshi et al., 2008), p62 could interfere with the 
invasive capacity of melanoma cells.  
To address the influence of p62 in invasion function, a Matrigel Matrix Invasion assay 
(MMI) was performed. The MMI works as a reconstituted basement membrane in vitro, being 
a useful way to study the invasion capacity of malignant cells. The Matrigel layer occludes 
the pores of the membrane, blocking non-invasive cells from migrating through the 
membrane. On the other hand, invasive cells are capable to detach themselves and invade 
through the Matrigel Matrix and the membrane pores.  
The extremely invasive melanoma cell line SK-Mel-103, isolated from metastatic 
melanoma, was submitted to lentiviral-driven transduction of control shRNA and p62 shRNA 
and plated in Matrigel transwell invasion chambers. Interestingly, after 24 hours of 
incubation, melanoma cells depleted to p62 lost invasion capacity. The quantification of 
melanoma cells above and below the membrane showed that p62 depleted cells invaded the 
reconstituted basement membrane 50% less than control cells (P<0.0001) (Figure 21). 
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Figure 21. Matrigel invasion assay showing that 
p62 favors melanoma invasion capacity. 
Invasiveness of SK-Mel-28 melanoma cells 
infected with control shRNA or p62 shRNA 
lentiviral constructs. Cells were plated in BioCoat 
Matrigel™ Invasion Chambers. Samples were 
analyzed 24h after plating in invasion chambers by 
counting DAPI+ nuclei. The experiment shows a 
decreased melanoma invasion capacity after p62 
depletion (n=3, mean ± SEM, P<0.0001). 	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Next, to test whether the overexpression of p62 could facilitate the invasion capacity 
of melanoma cells, a laborious skin reconstruct model was developed at Dr. Herlyn´s 
Laboratory, The Wistar Institute, Philadelphia. The skin reconstruct recapitulates the 
environment of melanoma cells and allows the study of melanoma invasion in a physiological 
system (Li et al., 2011; Brohem et al., 2011). 
The non-invasive melanoma cell line WM3211, isolated from primary radial growth 
phase melanoma, was submitted to lentiviral-driven transduction of a cherry fluorescent 
protein fused to p62 (pLV-mCherry-p62) for p62 overexpression. WM3211 cells infected 
with the vector pLV-mCherry were used as control. The stable infected melanoma cells were 
added to the epidermal layer of the artificial skin. After 18 days, skins were harvested and 
processed for H&E and immunohistochemical analysis of p62 and mCherry. Interestingly, 
only melanoma cells expressing high levels of p62 were able to invade the dermis; meanwhile 
control melanoma cells were restricted to the epidermis (Figure 22). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 22. Skin Reconstruct model showing that p62 favors melanoma invasion capacity. 
Representative pictures of skin reconstruct model made with the non-invasive WM3211 melanoma 
cell line. Skins were harvested after 18 days, processed for H&E staining and 
immunohistochemically analyzed for p62 and mCherry. The experiment demonstrates an increased 
invasion capacity of melanoma cells after ectopic overexpression of p62 (pLV-mCherry-p62), 
when compared to control cells (pLV-mCherry).	  
m
Ch
er
ry
p6
2
H&
E
pLV-­‐mCherry pLV-­‐mCherry-­‐p62
10x 10x
10x 10x
10x 10x
Results	   	  
___________________________________________________________________________
	   	  
84 
	  
Next, to test whether the overexpression of p62 could facilitate the invasion capacity 
of melanoma cells, a laborious skin reconstruct model was developed at Dr. Herlyn´s 
Laboratory, The Wistar Institute, Philadelphia. The skin reconstruct recapitulates the 
environment of melanoma cells and allows the study of melanoma invasion in a physiological 
system (Li et al., 2011; Brohem et al., 2011). 
The non-invasive melanoma cell line WM3211, isolated from primary radial growth 
phase melanoma, was submitted to lentiviral-driven transduction of a cherry fluorescent 
protein fused to p62 (pLV-mCherry-p62) for p62 overexpression. WM3211 cells infected 
with the vector pLV-mCherry were used as control. The stable infected melanoma cells were 
added to the epidermal layer of the artificial skin. After 18 days, skins were harvested and 
processed for H&E and immunohistochemical analysis of p62 and mCherry. Interestingly, 
only melanoma cells expressing high levels of p62 were able to invade the dermis; meanwhile 
control melanoma cells were restricted to the epidermis (Figure 22). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 22. Skin Reconstruct model showing that p62 favors melanoma invasion capacity. 
Representative pictures of skin reconstruct model made with the non-invasive WM3211 melanoma 
cell line. Skins were harvested after 18 days, processed for H&E staining and 
immunohistochemically analyzed for p62 and mCherry. The experiment demonstrates an increased 
invasion capacity of melanoma cells after ectopic overexpression of p62 (pLV-mCherry-p62), 
when compared to control cells (pLV-mCherry).	  
m
Ch
er
ry
p6
2
H&
E
pLV-­‐mCherry pLV-­‐mCherry-­‐p62
10x 10x
10x 10x
10x 10x
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  Results	   	  
___________________________________________________________________________	  
85 
	  
 Altogether, the downregulation of p62 leading to a reduced melanoma invasion 
capacity, combined to the overexpression of p62 leading to an increased melanoma invasion 
capacity corroborate to the relevance of p62 in melanoma progression. 
 
4.2.4. P62 depletion does not impair the formation of autophagosomes in melanoma cells 
 
 After having verified the relevance of p62 in melanoma proliferation and invasion 
capacity, the next question was the mechanism underlying the p62 requirement in melanoma 
cells.  
First of all, the involvement of p62 in autophagy was confirmed in melanoma cells. 
For that, SK-Mel-103 melanoma cells were stably transfected with the green fluorescent 
protein fused to wild type form of human LC3 (pLV-EGFP-LC3) and the cherry fluorescent 
protein fused to p62 (pLV-mCherry-p62). The cells generated were treated with Rapamycin, 
an autophagy stimulator by the inhibition of mTOR pathway (Raught et al., 2001) and with 
Chloroquine, an autophagy inhibitor that blocks lysosome–autophagosome fusion (Solomon 
et al., 2009). As represented in Figure 23a, after treatment with Rapamycin it could be 
observed few colocalization between p62 and LC3. Moreover, a strong colocalization of LC3 
and p62 was seen after blocking lysosome-autophagosome fusion by Chloroquine, confirming 
that p62 is involved in autophagy in melanoma cells. 
 The posttranslational modification of LC3 form I (LC3-I) to form II (LC3-II) is an 
indicative of autophagosome formation (Mehrpour et al., 2010). To test if the depletion of p62 
interferes with autophagosome formation, UACC-62 cells were depleted for p62, using 
shRNA constructs. After 3 and 6 days of infection, the levels of LC3-I and LC3-II were 
checked by protein immunoblots. As shown in Figures 23b and 23c, although there was a 
slight increase in total amount of LC3 protein, the downregulation of p62 did not interfere 
with the conversion of LC3-I to LC3-II.  
To confirm the previous result, melanoma cells SK-Mel-104 expressing GFP-LC3 
were submitted to lentiviral infection with control shRNA and p62 shRNA. After 7 days, the 
cells were treated with Rapamycin and Chloroquine during 7 hours. In fact, any difference of 
autophagosome formation, checked by green foci, was seen in melanoma cells after p62 
depletion (Figure 23d).  
Additionally, it was analyzed whether the absence of p62 could interfere with the 
accumulation of ubiquitinated (Ub) proteins. For that, SK-Mel-103 melanoma cells were 
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genetic depleted for p62 and ubiquitinaded proteins were checked by immunoblots. 
Surprisingly, the depletion of p62 was responsible for a decreasing of total Ub amount (Figure 
23e).  
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Figure 23. P62 depletion does not interfere with autophagosome formation in melanoma cells. 
(a) Representative fluorescent microphotographs of SK-Mel-103 melanoma cells expressing LC3 
(in green) and p62 (in cherry), before treatment and 7 hours after treatment with Rapamycin and 
Cloroquine (NT= non treated). (b) Protein immunoblots against LC3 and β -actin in SK-Mel-103 
melanoma cells expressing control shRNA and p62 shRNA. (c) Corresponding quantification of 
protein immunoblots showing that p62 downregulation did not interfere with the conversion of 
LC3-I to LC3-II (n=3, mean ± SEM, P>0.05). (d) Representative fluorescent microphotographs of 
SK-Mel-103 melanoma cells expressing EGFP-LC3 (in green) and treated with Rapamycin or 
Chloroquine showing no difference in autophagosome formation after p62 depletion (green foci). 
(e) Protein immunoblots against Ubiquitin and α-tubulin showing decreased Ub-proteins after p62 
downregulation.	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Altogether, these findings confirmed that p62 is involved in autophagy in melanoma 
cells however the depletion of p62 does not impair autophagosome formation. 
 
 
4.2.5. P62 is required for proper expression of survival, cell cycle and invasion 
modulators 
 
P62 protein is involved in protein degradation and activation of different cell signaling 
pathways (Puissant et al., 2012). Previous results of this study have shown that autophagy is 
still functional in the absence of p62. Thus, it was wondered whether specific targets or 
partners of p62 could not be shuttled to authopagosome degradation in the absence of p62. 
Moreover, the lack of p62 could interfere with different signaling pathways important for 
tumorigenesis in melanoma cells. 
To identify the molecular pathways associated with the inhibition of proliferation and 
invasion in p62-deficient melanoma cells, transcriptomic studies were performed. Melanoma 
cells were depleted for p62 and examined by microarray hybridization and gene expression 
analysis. SK-Mel-103 and UACC-62 cells were infected with p62 shRNA and control shRNA 
and collected at day 3 (early time point) and day 6 (late time point) post-infection. Total RNA 
was extracted and processed for hybridization. Functional analysis was carried out using Gene 
Set Enrichment Analysis (GSEA). The list of enriched pathways found in p62 depleted 
UACC-62 and SK-Mel-103 melanoma cells is represented in Figure 24, Supplemental Figures 
1 and 2 (pages 132-133).  
Interestingly, after the depletion of p62 many pathways involved in cell cycle control, 
DNA repair and DNA replication process were downregulated at early time point. Indeed, 
pathways involved in cellular motility and invasion, as adherent junctions, regulation of actin-
cytoskeleton, Rac-1 pathway and cell adhesion molecules were altered. Pathways related to 
cellular metabolism, proteosome degradation and membrane trafficking were also altered 
(Figure 24 and Supplemental Figures 1 and 2). Interestingly, NF-kB, mTOR and Keap1-Nrf2 
signaling pathways did not present statistical significant deregulation in melanoma cells 
depleted for p62. 
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To validate the results obtained by cDNA arrays, some genes were selected for protein 
immunoblot analysis. As shown in Figure 25, after the depletion of p62, many proteins 
involved in cell cycle as Cyclins, Aurora proteins and Survivin were downregulated. Indeed, 
epidermal growth factor receptor (EGFR) and High-Mobility Group A2 (HMGA2) protein 
were upregulated after p62 depletion.  
 
 
 
 
Figure 24. P62 depletion interferes with cell cycle and invasion functions. Altered pathways in 
SK-Mel-103 and UACC-62 cell lines at early (day 3) and late (day 6) time points after p62 
depletion. Red, green and gray indicate upregulation, downregulation and no significant 
deregulation, respectively. Intensity of colors indicates the degree of significance (dark: FDR < 
0.05; light: 0.05 < FDR < 0.25). 
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In summary, transcriptomic analysis provides information that p62 is required for the 
proper expression of survival, cell cycle modulators and genes involved in cell migration and 
adhesion, justifying why the depletion of p62 interferes with melanoma proliferation and 
invasion. 
 
 
4.3. The physiological relevance of Sequestosome 1/p62 in melanoma 
 
4.3.1. The absence of p62 compromises melanoma tumor growth in mouse xenografts 
 
 The depletion of p62 blocks melanoma cell proliferation in vitro. To establish whether 
p62 depletion affects the ability of melanoma cells to form solid tumors in vivo, mouse 
xenograft models were generated.   
SK-Mel-103 and UACC-62 melanoma cells were submitted to lentiviral-driven 
transduction of p62 shRNA and control shRNA. After 72 hours of lentiviral infection (before 
changes in cell morphology or proliferation), cells were collected and injected subcutaneously 
into the back region of athymic immunosuppressed mice (nude mice). A total of 9 nude mice 
were implanted with control cells (5 for UACC-62 and 4 for SK-Mel-103 cells) and 9 mice 
with p62-depleted cells (5 for UACC-62 and 4 for SK-Mel-103 cells). Growth of tumours was 
monitored for 4 weeks.  
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Figure 25. Validation of cDNA array data after p62 downregulation. Protein immunoblots 
against the indicated proteins on day 3 and 6 after lentiviral transduction with control and p62 
shRNA in UACC-62 melanoma cells confirming the results found by cDNA arrays. α-tubulin or β-
actin proteins were used as loading control.	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Figure 25. Validation of cDNA array data after p62 downregulation. Protein immunoblots 
against the indicated proteins on day 3 and 6 after lentiviral transduction with control and p62 
shRNA in UACC-62 melanoma cells confirming the results found by cDNA arrays. α-tubulin or β-
actin proteins were used as loading control.	  
Results	   	  
___________________________________________________________________________
	   	  
90 
	  
Importantly, melanoma control cells formed tumors that were visibly larger than the 
tumors formed by melanoma cells depleted for p62 (P<0.01) (Figure 26a). 
Immunohistochemical analysis of xenograft tumors confirmed the absence of p62 expression 
in the small tumors formed by p62-depleted cells (Figure 26b). Furthermore, cell flattening 
and morphological changes found in cultured p62-depleted cells were confirmed in vivo by an 
increase of cellular size of p62 shRNA tumor xenografts (P<0.0001) (Figure 26c).  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
In summary, experiments performed with mouse xenograft model suggest that p62 is 
necessary for tumor proliferation in vivo. 
c 
Figure 26. P62 depletion compromises tumor growth in mouse xenograft model. (a) Reduced 
tumorigenic potential of p62 depleted melanoma cells measured as a reduced growth of xenograft 
tumor (1.0x106 cells of the indicated cell lines) implanted subcutaneously in nude mice (P<0.01). 
(b) H&E and p62 immunohistochemical staining of xenograft tumors sections. (c) Quantification 
of cell perimeter of xenograft tumor sections showing increased size of p62 deficient melanoma 
cells in vivo (P<0.0001).	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4.3.2. P62 is associated with high proliferative index in human melanocytic tumors 
 
 The genetic depletion of p62 is responsible for melanoma cell arrest in vitro and in 
mouse xenograft model. To address the relation of p62 with a proliferative status in human 
melanoma specimens, the expression of p62 was compared to the expression of the 
proliferative marker Ki67. Consecutive sections of tissue microarrays of melanocytic tumors 
were submitted to p62 and Ki67 immunohistochemical staining. A total of 155 melanocytic 
tumors including 46 dermal nevi, 43 primary melanomas and 66 metastatic melanomas 
specimens were analyzed.  
Interestingly, high expression of p62 in melanocytic tumors was related to an 
increased proliferative index (P<0.0001). On the other hand, negative expression of p62 was 
related to a low proliferative index (P<0.0001) (Figure 27). These results corroborate the 
hypothesis that p62 is related to cellular proliferation in vivo. 
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Figure 27. P62 expression correlates with 
high proliferative status in melanocytic 
tumors. (a) Pictures of p62 and Ki67 
immunohistochemistry in consecutive sections 
of tissue microarrays of melanocytic tumors. 
(b) Corresponding quantification of p62 and 
Ki67 immunohistochemistry showing the 
relation between p62 expression and 
proliferative index. N indicates the total 
number of cases analyzed in each group 
(P<0.0001).	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4.3.3. The expression of p62 increases the risk for metastatic disease in melanoma 
patients  
 
 For additional evaluation of the physiological relevance of p62, 105 specimens of 
vertical growth phase melanomas were randomly selected for survival analyses. 
First, 105 melanoma samples were evaluated for the Breslow index and the presence 
of ulceration. P62 expression was evaluated by immunohistochemistry and classified as 
negative or positive. After the assessment of p62 expression, all clinical information was 
recompiled.   
Results of immunohistochemical analyses showed that p62 stained positive in 76.2% 
(80/105) of primary melanoma specimens. P62 expression in melanomas was heterogeneous 
with an inter- and intratumor variability. In the cases of melanomas associated to dermal nevi, 
a clear positive expression of p62 in melanoma cells in contrast with the absence of p62 
expression in nevi cells was observed. Surprisingly, nuclear expression of p62 was observed 
in 44.8% (47/105) of the VGP primary melanomas, some of them presenting the formation of 
big aggregates inside the nucleus (Figure 28). 
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Figure 28. Nuclear expression of p62 protein in melanoma cells. Pictures of p62 
immunohistochemistry in VGP melanoma specimen showing nuclear expression of p62 and the 
formation of p62 bodies inside the nucleus. 
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negative or positive. After the assessment of p62 expression, all clinical information was 
recompiled.   
Results of immunohistochemical analyses showed that p62 stained positive in 76.2% 
(80/105) of primary melanoma specimens. P62 expression in melanomas was heterogeneous 
with an inter- and intratumor variability. In the cases of melanomas associated to dermal nevi, 
a clear positive expression of p62 in melanoma cells in contrast with the absence of p62 
expression in nevi cells was observed. Surprisingly, nuclear expression of p62 was observed 
in 44.8% (47/105) of the VGP primary melanomas, some of them presenting the formation of 
big aggregates inside the nucleus (Figure 28). 
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Figure 28. Nuclear expression of p62 protein in melanoma cells. Pictures of p62 
immunohistochemistry in VGP melanoma specimen showing nuclear expression of p62 and the 
formation of p62 bodies inside the nucleus. 
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Clinical and histopathologic characteristics of the selected cases were analyzed. The 
age of the patients at diagnosis ranged from 25 to 99 years old (mean 58.51 years). Fifty-six 
patients were female and 49 male. All cases were confirmed as vertical growth phase 
melanomas, with Breslow ranging from 0.4 to x 19 mm (mean 3.66 mm) and 42% of the 
melanomas showing ulceration. Regarding the clinical staging at the moment of the diagnosis, 
25 patients were classified as stage I, 28 patients as stage IIA, 39 patients as stage IIB and 13 
patients as stage IIC. 
 The distribution of patients according to p62 expression is summarized in Table 9. 
Interestingly, the expression of p62 was related to greater tumor thickness. The mean of 
Breslow for p62 positive specimens was 3.99 mm, while 2.64 mm for p62 negative samples 
(P=0.05). The expression of p62 was also associated to a higher clinical stage (P=0.04). Most 
of the patients with undetectable p62 expression were classified at stage I (44%), while the 
majority of patients with detectable p62 expression were classified at stage IIB (40%). A 
superior prevalence of ulceration was found within melanomas expressing p62, however this 
difference was not statistical significant (44% versus 28%, P>0.05). Differences between 
distribution of sex and age were not significant. 
 
Table 9. Distribution of 105 patients according to p62 expression: 
Expression of p62 Negative  Positive  P value 
Number of patients N=25  N=80   
Women  N; % 13 52% 43 54% 0.878 
Age (years) Mean; SD 54.86 18.54 59.65 16.57 0.223 
With Ulceration  N; % 7 28% 35 44% 0.161 
Breslow (mm) Mean; SD 2.64 2.23 3.99 3.17 0.050 
Clinical Staging  N; %     0.040 
 I 11 44% 14 18%  
 IIA 6 24% 22 28%  
 IIB 7 28% 32 40%  
 IIC 1 4% 12 15%  
 
 
The relation between p62 expression in primary melanomas and patient outcome was 
evaluated using Kaplan–Meier survival curves and COX analysis.  
For survival curves, 105 patients were analysed. Four patients had to be excluded 
because of incomplete clinical information. Regarding disease free survival, from the total of 
101 patients, 57 had developed metastasis within five years of melanoma diagnosis. 
Interestingly, Kaplan–Meier survival curves and COX analysis showed that patients with 
positive p62 expression presented an increased risk for development of metastasis, with a 
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hazard ratio (HR) of 2.96 (P=0.022). Remarkable, adjusting by Breslow and T3 category (T≤ 
T3a stage or T>T3a stage) the expression of p62 was an independent prognostic factor for the 
development of metastasis in melanoma patients (P=0.034 and P=0.044, respectively) (Figure 
29 and Table 10). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 10. Multivariated Cox regression analysis of pathological and clinical factors: 
Disease Free Survival  
  HR 95%CI P  
p62  2.96 1.17 - 7.5 0.022 
Adjusting by Breslow 2.75 1.08 - 7.02 0.034 
 Clinical staging 2.51 0.97 - 6.53 0.058 
  T3 category 2.62 1.03 - 6.71 0.044 
 
Figure 29. Disease Free Survival curves of 101 melanoma patients subgrouped by p62 
expression. (a) Disease free survival curves subgrouped by p62 expression (p62clow0 = negative 
and p62clow1 = positive). (b) Disease free survival curves subgrouped by T3 category (T3a0 ≤ T3a 
stage and T3a1 > T3a stage) and p62 expression (p62clow0 = negative and p62clow1 = positive). 
Analysis time represents years of follow-up. The corresponding hazard ratios (HR) and 95% 
confidence intervals (95%CI) according to Cox regression analyses are shown in Table 10.	  
a 
b 
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Regarding overall survival, from the total of 101 patients, 39 had died from melanoma 
in the first 5 years of diagnostic. Kaplan–Meier survival curves and COX analysis showed 
that patients with negative p62 expression had a higher median overall survival than patients 
with p62 expression, however the log-rank section test was not significant (HR=1.69, 
P=0.289) (Figure 30 and Table 11). 
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 11. Multivariated Cox regression analysis of pathological and clinical factors: 
Overall Survival  
  HR 95%CI P  
p62  1.69 0.64 - 4.44 0.289 
Adjusting by Breslow 1.5 0.56 - 4.0 0.416 
 Clinical staging 0.96 0.36 - 2.6 0.939 
  T3 category 1.26 0.47 - 3.37 0.641 
Figure 30. Overall Survival curves of 101 melanoma patients subgrouped by p62 expression. 
(a) Overall survival curves subgrouped by p62 expression (p62clow0 = negative and p62clow1 = 
positive). (b) Overall survival curves subgrouped by T3 category (T3a0 ≤ T3a stage and T3a1 > T3a 
stage) and p62 expression (p62clow0 = negative and p62clow1 = positive). Analysis time represents 
years of follow-up. The corresponding hazard ratios (HR) and 95% confidence intervals (95%CI) 
according to Cox regression analyses are shown in Table 11. 
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In summary, clinical, pathological and survival analyses demonstrate that p62 
expression is involved in melanoma patient follow-up and corroborate previous findings that 
p62 is implicated in melanoma tumor progression. 
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5. DISCUSSION 
 
Melanoma is a complex cancer, which is aggressive and has a strong resistance to 
current available treatments. Despite all the studies generated in recent years, the mechanisms 
of melanoma progression remain not well understood. Sequestosome1/p62 is a 
multifunctional protein that promotes tumorigenesis by interfering with protein degradation 
machineries and activating pro-oncogenic signaling pathways (Duran et al., 2008; Mathew et 
al., 2009; Inami et al., 2011). Since one of the least understood aspects in melanoma is the 
modulation of protein degradation systems, p62 is an attractive candidate to be characterized 
in melanoma tumors.  
 
5.1. The expression of Sequestosome 1/p62 in melanocytic tumors 
 
During the last few years, some studies have identified the overexpression and 
accumulation of p62 in different human tumors (Thompson et al., 2003; Kitamura et al., 
2006; Duran et al., 2008). Nevertheless, no data about the expression of p62 in melanoma 
tumors are available in the literature. 
To address the expression of p62 in melanoma, tissue microarrays containing 
melanocytic lesions were immunohistochemically analyzed in this study. Surprisingly, p62 
was undetectable in any of the benign dermal nevi analyzed. Dysplastic nevi, a controversial 
lesion considered by some authors as a melanoma precursor and by others as a malignant 
neoplasm (Ackerman, 1988; Roth et al., 1991; Skender-Kalnenas et al., 1995), showed low 
expression of p62 in one-third of samples. Interestingly, the expression of p62 increases in 
malignant lesions of melanocytes. Primary melanoma samples (radial and vertical growth 
phase melanomas) express p62 more frequently than dysplastic nevi. Moreover, the frequency 
and intensity of p62 expression increase with the progression of melanoma. Vertical growth 
phase melanomas, which are primary tumors with metastatic capacity (Barnhill et al., 1993), 
and metastatic lesions, considered the last stage in tumor progression, show higher expression 
of p62 than early stage of melanoma tumors (RGP). Hence, analysis of p62 expression in 
melanocytic tumors suggests that its expression is related to melanoma progression. 
In addition, the comparison of p62 mRNA and protein levels between normal 
melanocytes and melanoma cell lines confirmed an overall upregulation of p62 in malignant 
cells.  Interestingly, not only the amount of p62 protein expression but also the pattern of its 
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distribution was different in normal melanocytes and melanoma cells. In this study, 
immunofluorescence analyses confirmed the presence of p62 cytoplasmic aggregates in 
melanoma cells. In fact, p62 positive bodies were found both in cultured melanoma cells and 
melanoma tissue specimens stained by immunofluorescence. On the other hand, normal 
melanocytes showed a weak and diffuse pattern of p62 expression into the cytoplasm. 
Moreover, the aggregate pattern of p62 presented by melanoma cells was independent of p62 
levels. Even increasing the expression of p62 in melanocytes to similar levels of those 
presented in melanoma, normal melanocytes cells were not able to form p62 cytosolic 
aggregates. 
The presence of p62 cytoplasmic aggregates has been identified in different types of 
human cells and diseases, as neurodegenerative diseases, hepatitis, myositis and cancer 
(Lamark et al., 2003; Nagaoka et al., 2004; Bjørkøy et al., 2005). Although the relevance of 
p62 in such cellular inclusions is not clear, latest studies indicate that p62 presents a 
protective effect against cell death (Babu et al., 2005; Bjørkøy et al., 2005). The differential 
levels and pattern of p62 distribution in normal melanocytes and melanoma cells 
demonstrated in this study could be a consequence of differential metabolism and oxidative 
stress presented by such cells. Elevated metabolism of melanoma cells might be responsible 
for an increased production of damaged/misfolded proteins that needed to be degraded 
(Moenner et al., 2007; Kirkin et al., 2009). Consequently, through the ability of p62 to 
sequester aggregated proteins and shuttle proteins for proteasomal or autophagosomal 
degradation, p62 accumulation may represent a melanoma cell’s attempt to rid itself of toxic 
substrates. 
In an attempt to understand the regulation of p62 intracellular levels, melanoma cell 
lines were submitted to comparative genomic hybridization. Although alterations in the 
number of gene copies are a common feature of melanoma tumors (Curtin et al., 2005), CGH 
analyses performed in this study failed to identify amplification or gain of SQSTM1 gene 
locus that could justify the upregulation of p62 in melanoma.  
The increased p62 mRNA levels in melanoma cells compared to normal melanocytes 
led the hypothesis that p62 is transcriptionally regulated in melanoma tumors. In fact, the 
strong correlation between p62 mRNA and protein levels found in human melanoma 
specimens corroborates this hypothesis.  
The transcriptional regulation of p62 was also described in others type of human 
tumors (Duran et al., 2008; Thompson et al., 2003). Nevertheless, a post-translational 
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regulation of p62 cannot be excluded in melanoma cells. As mentioned before, p62 protein is 
itself degraded by the autophagic machinery (Komatsu et al., 2007). Consequently, 
interferences in autophagy process could be a post-translational way to regulate the levels of 
p62 in melanoma. In fact, the deregulation of autophagy has been described in melanoma 
tumors (Checinska et al., 2011). While most authors support that autophagy is activated and 
necessary for melanoma progression (Hersey et al., 2008; Lazova et al., 2010; Han et al., 
2011; Ma et al., 2011), others believe that autophagy represent a tumor suppressor mechanism 
and its activity decreases with melanoma progression (Miracco et al., 2010). The observation 
made in this study that melanoma cells accumulate p62 aggregates after treatment with 
chloroquine, an inhibitor of lysosome–autophagosome fusion (Solomon et al., 2009), suggests 
that p62 could also be post-translationally regulated in melanoma tumors. 
Certain mechanisms of p62 regulation have been described in the literature. Duran and 
collaborators have shown that oncogenic RAS expression increases p62 mRNA levels 
through the activation of p62 promoter (Duran et al., 2008). Moreover, Galavotti and 
coworkers have demonstrated increased levels of p62 in HRASG12V transformed cells 
(Galavotti et al., 2012).  
Taking into account that the activation of the RAS/MEK/ERK pathway is a common 
feature of benign and malignant melanocytic tumors (Curtin et al., 2005), it was hypothesized 
in this study that BRAF or RAS mutations could regulate the expression of p62. Through 
lentiviral infection, normal melanocytes were transduced with the most frequently BRAF, 
NRAS and HRAS mutations found in melanocytic lesions. As already known, forced 
expression of such oncogenes in normal melanocytes led to a nonproliferative stage of the 
cells called senescence (Michaloglou et al., 2005; Denoyelle et al., 2006). Interestingly, the 
analyses of senescent melanocytes expressing BRAFV600E, NRASQ61R and HRASG12V mutations 
performed in this work failed to show upregulation of p62 mRNA and protein levels.  
In fact, the absence of p62 induction in senescent melanocytes corroborates the results 
obtained by IHC analysis of dermal nevi, which are benign lesions mostly composed by 
senescent melanocytes harboring BRAFV600E mutation (Pollock et al., 2003; Michaloglou et 
al., 2005). As mentioned before, all dermal nevi studied were negative for p62 expression. 
Although BRAFV600E mutation is one of the most important triggers for melanoma 
initiation, genetic alterations, as PTEN or p16INK4a loss of function, are needed for the 
malignant transformation of melanocytes (Tsao et al., 2004; Denoyelle et al., 2006; Dankort et 
al., 2009). The absence of p62 overexpression in cultured senescent melanocytes and dermal 
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nevi specimens open the question of whether p62 upregulation is related to the malignant 
transformation of melanocytes. To answer this question, established melanoma mice models 
(Dankfort et al., 2009) were used for the analysis of p62 expression in lesions harboring 
BrafV600E mutation and BrafV600E mutation associated to Pten loss. Interestingly, p62 was 
overexpressed in malignant tumors formed by BrafV600E/PtenloxP/loxP mice, meanwhile its 
expression was very low in benign lesions formed by BrafV600E mice.  
Taken together, the study of senescent melanocytes and melanoma mice model 
performed in this study propose that p62 upregulation is related to the malignant 
transformation of melanocytes. Corroborating the transforming potential of p62 protein, 
Duran and coworkers have shown that the downregulation of p62 reduces the capacity of 
prostate cancer cells to form colonies in soft agar, a marker of cellular transformation (Duran 
et al., 2011). Moreover, Takeuchi and collaborators have demonstrated that 3T3 fibroblasts 
expressing SQSTM1-ALK translocation were able to form solid tumors when injected in 
immunodeficient mice (Takeuchi et al., 2011). Although results herein suggest the 
transforming potential of p62, additional analyses are necessary to fully elucidate the role of 
p62 in malignant transformation of melanocytes. 
In summary, the upregulation of p62 in malignant cells, the presence of p62 
cytoplasmic aggregates in melanoma cells but not in normal melanocytes and the increased 
expression of p62 in late stages of melanoma progression indicate that p62 plays a relevant 
role in melanoma survival and progression. 
  
 
5.2. The function of Sequestosome 1/p62 in melanoma cells 
 
The different levels and distribution of p62 in normal melanocytes and melanoma cells 
shown here, together with its exclusive overexpression in malignant lesions, suggest a 
relevant function of p62 in melanoma tumors. To study the function of p62, melanoma cell 
lines were submitted to genetic depletion of p62 by RNA interference technique.  
The RNAi is a common technique used to determine the function of genes. For that, 
double-stranded RNAs are synthesized with sequences complementary to a target mRNA and 
introduced into the cells, promoting the degradation of mRNA. Consequently, RNAi 
promotes the posttranscriptional interruption of the expression of the target gene. The study of 
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effects and phenotypes obtained by RNAi introduction can thus elucidate the cellular role of 
the gene of interest (Shan et al., 2010).  
In total, five different melanoma cell lines were depleted for p62. Fascinatingly, the 
genetic depletion of p62 was responsible for the inhibition of melanoma proliferation in all 
cell lines studied. After 5 to 6 days without p62 expression, melanoma cells arrested and 
changed the morphology, adopting a senescent-like phenotype. In fact, melanoma cells 
depleted for p62 presented an increase senescence-induced β -galactosidase activity (SA-β-
Gal), a well-described marker for senescence (Michaloglou et al., 2005). Moreover, the effect 
of p62 depletion in cellular proliferation was independent of the genetic background presented 
by melanoma cells.  
Interestinlgy, the dependence of p62 seems to occur only in melamoma cells. Normal 
melanocytes and fibroblasts depleted for p62 were still able to proliferate in culture and did 
not change their morphology or SA-β-Gal activity. The tumor cell selective requirement of 
p62 shown in this study could be justified by a differential metabolism and proliferative rate 
presented by normal and tumor cells. 
Other studies have also described the influence of p62 in tumor growth. Many of them 
agree with results herein presented, that p62 is required for cellular proliferation (Mathew et 
al., 2009; Parkhitko et al., 2011; Duran et al., 2011). In fact, Duran and collaborators have 
shown that genetic depletion of p62 through RNAi reduces the proliferation of prostate cancer 
cells (Duran et al., 2011). However, other authors support that p62 restrain cellular 
proliferation (Linares et al, 2011; Galavotti et al., 2012). Opposite to Duran´s study, Galavotti 
and collaborators have described that the downregulation of p62 in glioblastoma stem cells 
promotes cell growth (Galavotti et al., 2012). Such contradictory results found in the literature 
suggest that the involvement of p62 in tumor proliferation might be tissue-specific. 
After establishing the requirement of p62 in melanoma proliferation, the next question 
of this study was the influence of p62 in melanoma invasion capacity. Since invasive forms of 
melanoma specimens (vertical growth phase melanomas) express higher levels of p62 protein 
than non-invasive primary melanomas (radial growth phase melanomas), p62 may be required 
for cellular invasion capacity. Furthermore, melanoma cells depleted for p62 present 
morphologic changes compatible with cytoskeleton remodeling that could promote alterations 
in cellular adhesion and motility.  
Fascinatingly, using Matrigel Matrix Invasion assay, this study demonstrated that the 
absence of p62 expression impairs the invasive capacity of highly metastatic melanoma cells 
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in vitro. Moreover, through a sophisticated artificial skin, which physiologically recapitulates 
the environment of melanoma cells (Li et al., 2011; Brohem et al., 2010), the overexpression 
of p62 turned non-invasive melanoma cells able to cross the basement membrane and invade 
the artificial dermis. These findings shown here confirm the recently published study of 
Galavotti and collaborators, where p62 contributes to the invasion capacity of glioblastoma 
multiforme cells (Galavotti et al., 2012).  
 
One of the most well described functions of p62 is its involvement in protein 
degradation (Bjørkøy et al., 2005; Bjørkøy et al., 2006; Kirkin et al., 2009). Since the absence 
of p62 interferes with the proliferative and invasion capacity of melanoma cells, to understand 
the mechanism underlying such phenotypic changes, proteolytic systems were analyzed in 
p62 depleted cells. 
Melanoma cells expressing green fluorescent protein fused to LC3 protein and cherry 
fluorescent protein fused to p62 were treated with an inductor (Rapamycin) or inhibitor 
(chloroquine) of autophagy.  
As described before, through the LIR domain p62 binds to LC3 protein located in the 
membrane of autophagosomes and shuttles ubiquitinated and/or aggregates of proteins to 
autophagosomal degradation (Watanabe et al., 2011). The co-localization of p62 with LC3 
protein after induction of autophagy, associated to an increased foci formation after inhibition 
of lysosome–autophagosome fusion (treatment with chloroquine) confirmed that p62 is 
involved in autophagy in melanoma cells.  
Melanoma cells were then depleted for p62 and the autophagosome formation capacity 
was checked through the formation of LC3 foci and the quantification of the isoform LC3-II 
(tightly bound to the autophagosomal membrane). In both approaches, the depletion of p62 
did not interfere with the autophagosome formation.  
Through its UBA domain, p62 is able to bind ubiquitinated proteins and delivers them 
to proteasomal or autophagosomal degradation (Seibenhener et al., 2007; Kirkin et al., 2009). 
Unexpectedly, immunoblots of p62 depleted cells performed in this study failed to show an 
accumulation of ubiquitinaded proteins. 
These results described above reveal that p62 is involved in autophagic degradation, 
however it is not required for the proper function of autophagy system. In fact, this result 
corroborates the study of Komatsu, which previously suggested that p62 knockout did not 
affect basal or starvation-induced autophagy (Komatsu et al., 2007).  
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Despite the fact that proteolytic systems are still functional in p62 depleted cells, the 
phenotypic changes found in such cells could be justified by a deficient delivery and 
degradation of specific partners of p62. Moreover, disturbance of proliferation and invasion 
capacity of melanoma cells could be justified by deregulation of intracellular signaling 
pathways, since p62 also works as an adaptor protein.  
To comprehend the mechanism whereby p62 interferes with melanoma progression, 
two different cell lines were submitted to transcriptomic analysis. Melanoma cells were 
submitted to p62 depletion through RNAi and changes in gene expression profile were 
analyzed at early and late time points. 
Transcriptomic analysis revealed broad changes in the expression profile of p62 
depleted cells and the consequent deregulation of different cellular pathways. Several 
pathways involved in cell cycle regulation, DNA replication and DNA repair were 
downregulated at early time point after p62 depletion. This finding not only supports the 
involvement of p62 in cell cycle (Linares et al, 2011) but also adds new information about its 
implication in DNA repair and replication processes.  Moreover, it also justifies why 
melanoma cells arrest in the absence of p62.  
Recently, Galavotti and colleagues have published the unique study that describes the 
influence of p62 in tumoral invasion (Galavotti et al., 2012). However, these authors have not 
fully elucidated the mechanism underlying such involvement. Tanscriptomic analyses herein 
performed demonstrate for the first time that p62 is involved in cellular motility and invasion 
through deregulation of actin-cytoskeleton and adherent junction pathways. Moreover, the 
RAC1 pathway that promotes cell-cell adhesion and regulates cell motility (Kimura et al 
2006; Sanz-Moreno et al., 2008) was also altered in p62 depleted cells. Interestingly, 
mutations in RAC1 gene were recently described in 9.2% of sun-exposed melanomas. Indeed, 
it was the third most frequent mutation, after BRAF and NRAS, in this type of cutaneous 
melanoma (Kraurhammer et al., 2012).  
Trancriptomic analyses performed in this study also demonstrated that p62 depletion 
alters metabolic and proteolytic pathways in melanoma cells, confirming previous published 
data (Seibenhener et al., 2007; Kirkin et al., 2009; Galavotti et al., 2012).  
The depletion of p62 in melanoma cells in the present study also led to downregulation 
of Survivin mRNA and protein levels. Survivin is a member of the inhibitor of apoptosis 
protein (IAP) family. Survivin protein is clearly associated with cancer and its expression is 
related to drug resistance and poor prognosis. When located in the nucleus, it is involved in 
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mitosis regulation. In the cytoplasm, Survivin inhibits apoptosis through the interaction with 
Caspase-9 (Zangemeister-Wittke et al., 2004). The overexpression of Survivin has been 
described in melanoma tumors (Alonso et al., 2004) and is associated with reduced survival in 
melanoma patients (Gradilone et al., 2003; Takeuchi et al., 2005). Recently, it was described 
that Survivin enhances the migration and invasion ability of melanocytic cells (McKenzie et 
al., 2010). Transcriptomic analyses performed in this work demonstrated for the first time a 
relation between p62 and Survivin expression. In fact, downregulation of Survivin protein 
may justify p62 interference with proliferation and invasion capacity of melanoma cells.  
The interruption of p62 expression was also responsible for the upregulation of 
HMGA2 protein. The HMGA family of proteins are architectural transcription factors that 
regulate the expression of numerous genes involved in cell growth, differentiation and cell 
death. This family of proteins consists of two members: HMGA1 and HMGA2. Usually, 
HMGAs are considered pro-oncogenic proteins. They can promote tumorigenesis and are 
upregulated in different tumors (Reeves, 2001; Young et al., 2007). Paradoxically, Narita and 
coworkers have described a novel role of HMGA proteins in cellular senescence. These 
authors found that HMGA accumulate on chromatin in senescent cells and promote 
proliferative arrest, thus acting as a tumor suppressor (Narita et al, 2006). Curiously, 
experiments performed in this study have shown that the depletion of p62 induces a 
senescence-like state of melanoma cells and produces overexpression of HMGA2 protein, 
corroborating the tumor suppressor role of HMGA2 proposed by Narita’s group. 
Surprisingly, the main signaling pathways regulated by p62 protein, NF-kB (Duran et 
al., 2008), mTOR (Duran et al., 2011) and Keap1-Nrf2 (Inami et al., 2011), were not altered 
in the transcriptomic experiment performed in this study. As mentioned before, the 
involvement of p62 in cancer is quite complex and its mechanism appears to be tissue-
specific. In fact, Moscat’s and Eileen White’s groups have found divergent data concerning 
NF-kB regulation by p62 (Duran et al., 2008; Mathew et al., 2009). In consequence, further 
analyses are required to fully dissect the relation between p62 and those signaling pathways in 
melanoma progression. 
In summary, alterations in cell cycle, metabolism and adhesion/motility pathways 
justify the inhibition of cellular proliferation, reduction of invasion capacity and morphologic 
changes suffered by p62 depleted melanoma cells. Thus, RNA interference and transcriptomic 
analyses confirm the relevance of p62 in melanoma progression. 
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5.3. The physiological relevance of Sequestosome 1/p62 in melanoma 
 
After having established the implication of p62 in melanoma progression using an in 
vitro approach, the next step of this work was to identify the physiological relevance of p62.  
To analyze if p62 interferes with tumor progression in vivo, mouse xenograft models 
were generated. Two different cell lines, harboring the BRAFV600E mutation or the NRASQ61R 
mutation respectively, were genetically depleted for p62 expression and subcutaneously 
introduced in immunodeficient mice. Confirming in vitro results, the depletion of p62 
inhibited tumor formation in these mice. Moreover, small tumors formed by p62 depleted 
cells showed an increased cell area, supporting the morphological changes observed in vitro. 
Despite its limitations, xenograft models are still an useful tool to determine clinical 
application of potential targets identified in basic research. Moreover, it has been used in 
preclinical drug development for the past 30 years (Kelland, 2004; Céspedes et al., 2006). In 
this study, the significant blockage of tumor progression in a xenograft model suggests that 
the inhibition of p62 is a promising strategy for melanoma treatment. Furthermore, the tumor 
cell-selective interference with proliferation, independent of the genetic background of 
melanoma cells, supports the use of p62 as therapeutic target. 
The relation of p62 with a proliferative status was also confirmed in vivo by a 
significant association between p62 expression and the proliferative marker Ki67 in human 
melanocytic tumors. 
For further characterization of the physiological relevance of p62 in melanoma 
patients, 105 primary vertical growth phase tumors were randomly selected for survival 
analyses. Immunohistochemical study of these 105 primary melanomas demonstrated a quite 
heterogeneous pattern of p62 expression, with a vast inter- and intratumoral variability. 
Whether this heterogeneity could reflect cellular subpopulations with different biological 
features, is an open question to be answered in the future. In addition, although nuclear 
localization of p62 has been only sporadically reported in the literature (Bjørkøy et al., 2005; 
Pankiv et al., 2009), herein, nearly half of melanoma specimens showed nuclear expression.  
 Interestingly, classification of 105 patients according to p62 expression demonstrated 
that p62 expression is associated to melanoma thickness, which is the most important 
histopathological prognostic factor in melanoma tumors (Balch et al., 2009). Furthermore, 
categorizing patients by TNM stages, high expression of p62 is related to an increased stage 
of disease. Correlation of p62 expression with ulceration, age and sex was not statistical 
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5.3. The physiological relevance of Sequestosome 1/p62 in melanoma 
 
After having established the implication of p62 in melanoma progression using an in 
vitro approach, the next step of this work was to identify the physiological relevance of p62.  
To analyze if p62 interferes with tumor progression in vivo, mouse xenograft models 
were generated. Two different cell lines, harboring the BRAFV600E mutation or the NRASQ61R 
mutation respectively, were genetically depleted for p62 expression and subcutaneously 
introduced in immunodeficient mice. Confirming in vitro results, the depletion of p62 
inhibited tumor formation in these mice. Moreover, small tumors formed by p62 depleted 
cells showed an increased cell area, supporting the morphological changes observed in vitro. 
Despite its limitations, xenograft models are still an useful tool to determine clinical 
application of potential targets identified in basic research. Moreover, it has been used in 
preclinical drug development for the past 30 years (Kelland, 2004; Céspedes et al., 2006). In 
this study, the significant blockage of tumor progression in a xenograft model suggests that 
the inhibition of p62 is a promising strategy for melanoma treatment. Furthermore, the tumor 
cell-selective interference with proliferation, independent of the genetic background of 
melanoma cells, supports the use of p62 as therapeutic target. 
The relation of p62 with a proliferative status was also confirmed in vivo by a 
significant association between p62 expression and the proliferative marker Ki67 in human 
melanocytic tumors. 
For further characterization of the physiological relevance of p62 in melanoma 
patients, 105 primary vertical growth phase tumors were randomly selected for survival 
analyses. Immunohistochemical study of these 105 primary melanomas demonstrated a quite 
heterogeneous pattern of p62 expression, with a vast inter- and intratumoral variability. 
Whether this heterogeneity could reflect cellular subpopulations with different biological 
features, is an open question to be answered in the future. In addition, although nuclear 
localization of p62 has been only sporadically reported in the literature (Bjørkøy et al., 2005; 
Pankiv et al., 2009), herein, nearly half of melanoma specimens showed nuclear expression.  
 Interestingly, classification of 105 patients according to p62 expression demonstrated 
that p62 expression is associated to melanoma thickness, which is the most important 
histopathological prognostic factor in melanoma tumors (Balch et al., 2009). Furthermore, 
categorizing patients by TNM stages, high expression of p62 is related to an increased stage 
of disease. Correlation of p62 expression with ulceration, age and sex was not statistical 
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significant. Altogether, these data indicate that p62 expression may predict an unfavorable 
outcome of melanoma patients. 
In fact, survival analyses performed in this study revealed that positive expression of 
p62 in primary melanoma is a predictive factor for the development of metastasis in the first 
five years after diagnosis. Patients with positive expression of p62 in primary lesions 
presented an increased risk for metastatic disease. The multivariated analysis for Breslow 
index showed that p62 is an independent prognostic factor. Additionally, a multivariable 
analysis including both tumor thickness and ulceration was performed categorizing patients 
by p62 expression and clinical staging less or more than T3a. Interestingly, p62 positive 
staining was an independent prognostic factor for the development of metastasis in these two 
categories of patients. The expression of p62 also increases the risk of death in melanoma 
patients, however overall survival analyses were not statistical significant. Since most of 
melanoma patients relapse within 5 years after diagnosis, disease free survival results support 
the biological function of p62 in tumor progression.  
 In summary, by combining in vitro experiments with tissue specimens and survival 
analyses, p62 was characterized as a new biomarker of the development and regulation of 
melanoma progression. Since melanoma is noted for its propensity for lethal metastasis and 
therapeutic resistance, the characterization of p62 as a promising target for melanoma 
treatment has broad clinical relevance. In addition, results herein generated through a 
multidisciplinary approach highlight the importance of translational research for the 
identification of new therapeutic strategies. 
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6. CONCLUSIONS 
 
Tissue expression patterns, in vitro experiments and survival analyses performed in 
this study support for the first time that Sequestosome1/p62 protein is required for melanoma 
progression. The results herein presented reveal Sequestosome1/p62 as a novel point of 
vulnerability for melanoma cells, thus representing a potential target for therapeutic 
intervention in melanoma patients. The main conclusions of this multidisciplinary study are 
listed below:  
 
1. P62 is overexpressed in melanoma cell lines and human melanoma specimens, 
particularly at invasive stages. In contrast, normal melanocytes express low levels of p62 
and dermal melanocytic nevi are virtually negative for p62 expression. The expression of p62 
in melanoma tumors seems to be transcriptionally regulated without amplification of its 
genomic locus. In addition, increased levels of p62 observed in transformed cells but not in 
senescent melanocytes suggest that p62 expression is upregulated during malignant 
transformation of melanocytes.  
 
2. Genetic depletion of p62 invariably leads to a senescence-like phenotype, inhibition of 
cell proliferation and loss of invasion capacity of melanoma cells. The requirement of p62 
appears to be tumor cell selective since normal melanocytes and fibroblasts do not suffer 
phenotypic changes after p62 depletion. Moreover, cDNA array analysis points to various 
cellular pathways related to cellular growth and invasion capacity as new targets of p62 in 
melanoma cells.  
 
3. The inhibition of cellular proliferation in p62 depleted melanoma cells translates into a 
significant blockage of tumor growth in mouse xenograft model. Furthermore, survival 
analysis corroborates the physiological relevance of p62 in melanoma progression, since the 
expression of p62 in primary tumors identifies an at-risk group of patients for the 
subsequent development of metastasis.  
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Supplemental Figure 1. Altered pathways in SK-Mel-103 and UACC-62 cell lines at early (day 3) 
and late (day 6) time points after p62 downregulation. Red, green and gray indicate upregulation, 
downregulation and no significant deregulation, respectively (FDR < 0.05). 
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Molecular Pathways
Control of Tumorigenesis and Chemoresistance by the
DEK Oncogene
Erica Riveiro-Falkenbach and María S. Soengas
Abstract
Slight modifications of chromatin dynamics can translate into small- and large-scale changes in DNA
replication and DNA repair. Similarly, promoter usage and accessibility are tightly dependent on chroma-
tin architecture. Consequently, it is perhaps not surprising that factors controlling chromatin organization
are frequently deregulated (directly or indirectly) in cancer cells. DEK is emerging as a novel class of DNA
topology modulators that can be both targets and effectors of protumorigenic events. The locus contain-
ing DEK at chromosome 6p22.3 is amplified or reorganized in multiple cancer types. In addition, DEK
can be subject to a variety of tumor-associated transcriptional and post-translational modifications. In
turn, DEK can favor cell transformation, at least in part by inhibiting cell differentiation and premature
senescence. More recently, DEK has also been linked to the resistance of malignant cells to apoptotic in-
ducers. Interestingly, a fraction of DEK can also bind RNA and affect alternative splicing, further illustrat-
ing the pleiotropic roles that this protein may exert in cancer cells. Here we will summarize the current
literature about the regulation and function(s) of DEK as a proto-oncogene. In addition, the translational
relevance of DEK as a putative diagnostic marker and candidate for drug development will be discussed.
Clin Cancer Res; 16(11); 2932–8. ©2010 AACR.
Background
DEK, a highly conserved nuclear factor and the only
member of its protein class, is preferentially expressed in
actively proliferating and malignant cells, where it can
reach up to 4 to 6 million copies per nucleus (1). DEK
was initially described as the target of a recurrent t(6;9)
translocation in a subset of acute myeloid leukemia
(AML) patients (2, 3). Subsequently, DEK has been shown
to promote tumorigenesis in a variety of cancer cell types,
at least in part by its ability to interfere with cell division
or DNA repair, inhibit cell differentiation, senescence and
apoptosis, and cooperate with transforming oncogenes
(Leave as such).
The bulk of DEK is bound to chromatin (1, 4, 5), prefer-
entially to euchromatic regions (6). However, DEK can also
be found within the nuclear matrix (7), or in interchroma-
tin granule clusters (8). The precise determinants that DEK
recognizes in the DNA are still under investigation.
Although DEK exhibits some sequence-specific DNA bind-
ing, it primarily seems to recognize structural features
(cruciform and supercoiled DNA; ref. 9). Two main
domains in DEK are responsible for its interaction with
DNA (see Fig. 1; ref. 10). Residues 87 to 187 are homolo-
gous to the scaffold attachment factor-box (SAF-box)
domain (11, 12) found in multiple nuclear proteins
(13). A second domain comprises residues 270 to 350 in
the carboxyl-terminal region of the DEK protein, which is
also responsible for multimerization (10).
Although the best known protumorigenic features of
DEK are related to DNA binding, a fraction of DEK (ap-
proximately 10%) is associated with RNA (1) and can
modulate RNA processing. Thus, DEK can affect 3′ splice
site discrimination by the splicing factor U2AF (14). In ad-
dition, DEK can interact with serine-arginine-rich (SR)
proteins (15) and other factors involved in exon-exon
junction complexes (16), although the functional rele-
vance of these interactions in cancer still needs to be
defined. Finally, DEK can also be secreted, particularly
by dying cells, and lead to the generation of autoimmune
antigens that might play a key role in juvenile rheumatoid
arthritis and other inflammatory diseases (17, 18).
The impact of DEK on mRNA splicing and autoimmu-
nity has been addressed by other reports (14, 17, 18). Here
we will focus primarily on the regulation and pro-
oncogenic roles of DEK that are dependent on its DNA-
associated functions.
Molecular Mechanisms of DEK Regulation
DEK has been shown to be upregulated in AML (2, 19,
20); retinoblastoma (21–23); glioblastoma (24);
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hepatocellular carcinoma (25); melanoma (26, 27); and
in an increasing list of other tumor types (20, 27–33).
However, the mechanisms leading to this preferential
accumulation of DEK in cancer cells are not completely
understood. No mutations have been reported in the cod-
ing sequence of human DEK. However, a variety of other
regulatory mechanisms have been identified at the DNA,
RNA, and protein levels (see Fig. 1).
Genomic reorganizations-DNA amplification
As indicated above, DEK was discovered by the identifi-
cation of the translocation t(6;9) (p23;q34) in a subset of
patients with AML, and was named on the basis of the
initials of the patient DK (2). The observation that this
chromosomal change was associated with an accelerated
tumor onset and poor prognosis prompted a series of
studies that ultimately support a causative role for DEK
in tumor development. Specifically, the t(6;9) transloca-
tion was found to result in an in-frame fusion between
nearly the entire DEK (missing just the last 25 amino
acids), and two thirds of the nucleoporin NUP214 on
chromosome 9 (Fig. 1). Although NUP214 (formally
known as CAN) localized at the nuclear pore, the DEK-
NUP214 fusion was found in the nucleoplasm (34).
Fig. 1. Schematic summary of DEK regulation and function. DEK expression can be regulated at the DNA, RNA, and protein levels. Genomic translocations
involving the 6p22.3 locus (where DEK maps) are frequent in a subset of AML. Amplifications and copy gains have been described in a variety of
tumors, including retinoblastoma, bladder cancer, and melanoma. In addition, DEK mRNA transcription can be induced by various transcription factors
(e.g., E2F-3, NF-Y, or YY1) whose expression and function are deregulated in multiple cancer cell types. In addition, acetylation, phosphorylation, and
ADP-ribosylation can alter the affinity of DEK for chromatin and chromatin remodeling factors. By its ability to impinge on chromatin topology, DEK
can influence DNA repair and DNA replication, as well as modulate the accessibility and occupancy of a still indeterminate number of promoters.
Interestingly, although DEK is best known for its DNA binding features, it should be noted that DEK can also interact with RNA and components of the
spliceosome. Ultimately, these functions favor tumor initiation, progression, and chemoresistance, at least in part by a concomitant blockade of
senescence, differentiation, and apoptosis. By virtue of its protumorigenic roles and tumor cell–selective expression, DEK may represent a new class of
drug targets and diagnostic markers.
Regulation and Function of the DEK Oncogene
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Amplifications and copy gains at the short arm of chromo-
some 6, encompassing the DEK gene, were also found in
the absence of translocations in a variety of malignancies,
particularly in bladder cancer (29) and retinoblastoma
(22, 23). Melanomas can also present with gains of the
chromosome 6p area (35). However, other mechanisms
of regulation of DEK may exist, as this protein can accu-
mulate to high levels in AML, melanomas, and other
tumors without specific amplifications or gains of the
DEK locus.
Transcriptional regulation
Analyses aimed at identifying regulatory elements with-
in the DEK promoter revealed binding sites for NF-Y and
YY1 at positions 170 and 135, respectively, from the tran-
scriptional starting site (36). NF-Y and YY1 are transcrip-
tion factors with well-documented roles in cellular
proliferation and transformation (37, 38), and thus could
provide a mechanistic link between DEK upregulation and
tumor development. Still, it remains unclear what the up-
stream modulators are that activate NF-Y and YY1 in order
to signal through DEK in the context of malignancies.
Additional insights about the transcriptional control of
DEK emerged from studies in virally induced pathologies.
Analyses of human papillomavirus (HPV)-positive cervi-
cal cancer cells indicated that DEK can be transcriptionally
activated by the E7 oncogene, a classical negative regula-
tor of the retinoblastoma (Rb) protein (39). These results
were confirmed by ectopic overexpression of E7 in prima-
ry human keratinocytes, and by the observation of DEK
upregulation in human cervical cancer specimens infected
with HPV (40, 41). Moreover, retinoblastoma and small
cell lung cancers, both associated with Rb loss, present
with high DEK levels (21). Consistent with Rb deficiency
favoring transcription via the E2F family of proteins (42),
chromatin immunoprecipitation assays showed that the
DEK promoter is bound by endogenous E2F-1 in tumor
cell lines (27). Mutation of E2F binding sites in the
DEK promoter abrogated transcriptional activation in
reporter assays (27). Therefore, tumor-associated E2F-1
activation may involve a concomitant activation of DEK
mRNA transcription.
Post-transcriptional modifications
Post-transcriptional modifications add an additional
layer of complexity in the regulation of DEK. For example,
DEK can be phosphorylated, ADP-ribosylated, or acetylat-
ed. Phosphorylation has been reported to inhibit the bind-
ing of DEK to DNA, but favor the interaction of this
protein with RNA splicing factors and potentially other
nuclear proteins (14, 43). Similarly, poly(ADP)ribosyla-
tion and acetylation may reduce the affinity of DEK for
DNA (44), but facilitate the interaction with other proteins
involved in chromatin remodeling (see below).
With regard to phosphorylation, multiple consensus
sites for casein kinase 2 (CK2) have been identified within
the DEK carboxy terminus (43). In actively proliferating
cells, DEK remains bound to DNA in a rather constant
manner throughout the cell cycle. Yet, at the G1 phase
there is a peak in DEK phosphorylation (43), but it is
unclear to what extent this phosphorylation affects cell
division. In line with this, DEK phosphorylation was
recently suggested to act as a switch to favor or inhibit
the association with proteins involved in chromatin
remodeling or RNA splicing. Thus, in Drosophila, CK2-
phosphorylated DEK can affect the deposition of histone
H3.3, at least in the context of the nuclear ecdysone recep-
tor (45). In overexpression studies, human DEK can also
bind CK2 and act as a histone chaperone (45). Intriguing-
ly, the fraction of phosphorylated, non-DNA-associated
DEK, was found to accumulate in apoptotic cells (44).
However, it is unclear whether this is the cause or conse-
quence of cell death, and which kinases are involved, as
CK2 may not be required in this process (44).
Another modification of DEK found to increase in
cells dying in response to genotoxic agents is poly(ADP-
ribosyl)ation (44). It has been proposed that this modifi-
cation results from the interaction of DEK with poly(ADP-
ribose) polymerase 1 (PARP1), likely to aid in DNA repair.
Poly(ADP ribosylated) DEK is displaced from chromatin
(46) and can be released into the extracellular space, where
it can generate reactive auto-antibodies (44). This conse-
quence of DEK modification may have important clinical
implications as accumulation of DEK-auto-antibodies is
found in synovial fluids of patients affected by juvenile
rheumatoid arthritis or juvenile idiopathic arthritis (44).
Therefore, deregulation of DEK's post-translational modi-
fications may be critical to the pathogenesis of inflamma-
tory diseases.
The affinity of DEK for DNA can also be reduced by
acetylation (8). This modification localizes DEK to nuclear
speckles or interchromatin granule clusters, which are
well-known for containing RNA-processing and transcrip-
tion factors (47). In contrast to phosphorylation that
involves mostly the C-terminus of DEK, acetylation appa-
rently affects lysines mapping within the first 70 amino
acids (8). Together, these results support domain-
specific modifications that may affect DEK conformation
and/or interaction with distinct partners.
In addition to the abovementioned regulation of DEK by
phosphorylation, acetylation, or ADP(ribosylation), it
should be mentioned that DEK-DNA interactions can be
modulated by a series of other chromatin-associated factors
such as histone deacetylases, methyltransferases (SET), his-
tone variants (H2A1.1), remodeling complexes (WSTF-
SNF2h), or death modulators (Daxx; refs. 45, 46, 48–50).
In summary, DEK is a very dynamic protein, which may
serve as a hub to recruit histones, histone modifiers and
chromatin remodeling factors, and modulate their
interaction with DNA. These activities of DEK depend on
various post-transcriptional modifications, which in turn
may respond to specific environmental or stress-related
signals. In light of the hypothesis, it has been suggested
that DEK could be one of the so-called “alarmins,”mole-
cules, that in the extracellular space, signal cell and tissue
damage (44).
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some 6, encompassing the DEK gene, were also found in
the absence of translocations in a variety of malignancies,
particularly in bladder cancer (29) and retinoblastoma
(22, 23). Melanomas can also present with gains of the
chromosome 6p area (35). However, other mechanisms
of regulation of DEK may exist, as this protein can accu-
mulate to high levels in AML, melanomas, and other
tumors without specific amplifications or gains of the
DEK locus.
Transcriptional regulation
Analyses aimed at identifying regulatory elements with-
in the DEK promoter revealed binding sites for NF-Y and
YY1 at positions 170 and 135, respectively, from the tran-
scriptional starting site (36). NF-Y and YY1 are transcrip-
tion factors with well-documented roles in cellular
proliferation and transformation (37, 38), and thus could
provide a mechanistic link between DEK upregulation and
tumor development. Still, it remains unclear what the up-
stream modulators are that activate NF-Y and YY1 in order
to signal through DEK in the context of malignancies.
Additional insights about the transcriptional control of
DEK emerged from studies in virally induced pathologies.
Analyses of human papillomavirus (HPV)-positive cervi-
cal cancer cells indicated that DEK can be transcriptionally
activated by the E7 oncogene, a classical negative regula-
tor of the retinoblastoma (Rb) protein (39). These results
were confirmed by ectopic overexpression of E7 in prima-
ry human keratinocytes, and by the observation of DEK
upregulation in human cervical cancer specimens infected
with HPV (40, 41). Moreover, retinoblastoma and small
cell lung cancers, both associated with Rb loss, present
with high DEK levels (21). Consistent with Rb deficiency
favoring transcription via the E2F family of proteins (42),
chromatin immunoprecipitation assays showed that the
DEK promoter is bound by endogenous E2F-1 in tumor
cell lines (27). Mutation of E2F binding sites in the
DEK promoter abrogated transcriptional activation in
reporter assays (27). Therefore, tumor-associated E2F-1
activation may involve a concomitant activation of DEK
mRNA transcription.
Post-transcriptional modifications
Post-transcriptional modifications add an additional
layer of complexity in the regulation of DEK. For example,
DEK can be phosphorylated, ADP-ribosylated, or acetylat-
ed. Phosphorylation has been reported to inhibit the bind-
ing of DEK to DNA, but favor the interaction of this
protein with RNA splicing factors and potentially other
nuclear proteins (14, 43). Similarly, poly(ADP)ribosyla-
tion and acetylation may reduce the affinity of DEK for
DNA (44), but facilitate the interaction with other proteins
involved in chromatin remodeling (see below).
With regard to phosphorylation, multiple consensus
sites for casein kinase 2 (CK2) have been identified within
the DEK carboxy terminus (43). In actively proliferating
cells, DEK remains bound to DNA in a rather constant
manner throughout the cell cycle. Yet, at the G1 phase
there is a peak in DEK phosphorylation (43), but it is
unclear to what extent this phosphorylation affects cell
division. In line with this, DEK phosphorylation was
recently suggested to act as a switch to favor or inhibit
the association with proteins involved in chromatin
remodeling or RNA splicing. Thus, in Drosophila, CK2-
phosphorylated DEK can affect the deposition of histone
H3.3, at least in the context of the nuclear ecdysone recep-
tor (45). In overexpression studies, human DEK can also
bind CK2 and act as a histone chaperone (45). Intriguing-
ly, the fraction of phosphorylated, non-DNA-associated
DEK, was found to accumulate in apoptotic cells (44).
However, it is unclear whether this is the cause or conse-
quence of cell death, and which kinases are involved, as
CK2 may not be required in this process (44).
Another modification of DEK found to increase in
cells dying in response to genotoxic agents is poly(ADP-
ribosyl)ation (44). It has been proposed that this modifi-
cation results from the interaction of DEK with poly(ADP-
ribose) polymerase 1 (PARP1), likely to aid in DNA repair.
Poly(ADP ribosylated) DEK is displaced from chromatin
(46) and can be released into the extracellular space, where
it can generate reactive auto-antibodies (44). This conse-
quence of DEK modification may have important clinical
implications as accumulation of DEK-auto-antibodies is
found in synovial fluids of patients affected by juvenile
rheumatoid arthritis or juvenile idiopathic arthritis (44).
Therefore, deregulation of DEK's post-translational modi-
fications may be critical to the pathogenesis of inflamma-
tory diseases.
The affinity of DEK for DNA can also be reduced by
acetylation (8). This modification localizes DEK to nuclear
speckles or interchromatin granule clusters, which are
well-known for containing RNA-processing and transcrip-
tion factors (47). In contrast to phosphorylation that
involves mostly the C-terminus of DEK, acetylation appa-
rently affects lysines mapping within the first 70 amino
acids (8). Together, these results support domain-
specific modifications that may affect DEK conformation
and/or interaction with distinct partners.
In addition to the abovementioned regulation of DEK by
phosphorylation, acetylation, or ADP(ribosylation), it
should be mentioned that DEK-DNA interactions can be
modulated by a series of other chromatin-associated factors
such as histone deacetylases, methyltransferases (SET), his-
tone variants (H2A1.1), remodeling complexes (WSTF-
SNF2h), or death modulators (Daxx; refs. 45, 46, 48–50).
In summary, DEK is a very dynamic protein, which may
serve as a hub to recruit histones, histone modifiers and
chromatin remodeling factors, and modulate their
interaction with DNA. These activities of DEK depend on
various post-transcriptional modifications, which in turn
may respond to specific environmental or stress-related
signals. In light of the hypothesis, it has been suggested
that DEK could be one of the so-called “alarmins,”mole-
cules, that in the extracellular space, signal cell and tissue
damage (44).
Riveiro-Falkenbach and Soengas
Clin Cancer Res; 16(11) June 1, 2010 Clinical Cancer Research2934
DEK in Tumor Progression and Drug Response
DEK-NUP214
From the initial discovery of the DEK-NUP214 fusion
protein in a subset of patients with AML, DEK has been
associated with tumor development. Yet, the precise mech-
anism of action of DEK-NUP214 in leukemogenesis has
remained elusive. It has been recently reported that in
malignant myeloid cells DEK-NUP214 expression corre-
lates with a general activation of protein synthesis and
increased the phosphorylation of eIF4E, a key factor in
translational initiation and a marker for translational
activity (51). In addition, in 293T cells, the DEK-
NUP214 fusion protein was found to have an impaired
ability to associate with histones and to be phosphory-
lated by CK2α and CK2β (51). If these results applied to
the situation in human tumors, they would provide a
molecular support for the hypothesis that the (refs. 6, 9)
(p23;q34) translocation modifies the chromatin binding
and remodeling activity of DEK.
DEK as a transcriptional modulator
Although it may be intuitive that the localization and
function of DEK can be affected by its fusion to the
nucleoporin NUP214 in AML, it is not clear how DEK ex-
erts its protumorigenic effects in cancers that do not exhi-
bit translocations of the 6p22-23 locus. It is plausible that
the high levels of DEK found in these tumor types result
in the occupancy of promoters and enhancers, which
in normal cells remain “DEK-free.” As indicated above,
phosphorylation, acetylation, or ADP(ribosylation) can af-
fect the affinity of DEK for DNA, and alter the stoichio-
metry of DNA-binding complexes. It is likely, although it
has not yet been explored in sufficient mechanistic detail,
that these post-translational DEK modifications are quan-
titatively and qualitatively different in benign and malig-
nant tissues. Given the intricate and dynamic nature of
chromatin, a comprehensive hierarchical map of these
modifications, and how specifically they impact on DEK
function and cellular fate, will undoubtedly pose a chal-
lenge. In fact, DEK can act as a transcriptional inducer or
inhibitor, depending on the specific gene, cell type, and
microenvironmental conditions. For example, DEK has
been detected in transcriptional repressor complexes bind-
ing to Daxx in U937T cells (52); as well as to P/CAF,
p300, or p65/nuclear factor-κB in HeLa cells (48, 53).
On the other hand, other studies also in HeLa cells, in-
dicate that DEK is largely excluded from heterochroma-
tin and can accumulate at promoter-enhancer regions of
select actively transcribed genes (54). Other activating
effects of DEK have been linked to the activation of the
transcription factor AP-2a (87MG or D17 astrocytoma
cells; ref. 55) or the nuclear splicing factor U2AF (HeLa;
ref. 14).
Inhibition of cellular senescence by DEK
In addition to assays aimed at uncovering DEK binding
partners, assessing cellular and environmental cues that af-
fect endogenous levels of DEK provided new insights on
the multiple processes in which DEK is an active player.
The first hint linking DEK to the proliferative status of cells
was provided by the repression of its mRNA in two condi-
tions: (i) HPV-positive cervical cancer cell lines undergo-
ing senescence-like cell-cycle arrest, and (ii) primary
keratinocytes and fibroblasts maintained for multiple pas-
sages in culture (and thus suffering telomere attrition).
Interestingly, in both settings, DEK overexpression exten-
ded cellular life span, supporting critical roles for DEK as
a senescence inhibitor (39).
As senescence bypass is an obligated hallmark of tumor
cells, DEK activation may represent a new class of the so-
called “tumor gatekeepers” (56). Proof for this hypothesis
has recently been provided by selective depletion of DEK
in melanoma cells by interfering short hairpin RNAs
(shRNA). In a subset of metastatic melanoma cell lines,
three independent DEK shRNAs prompted a progressive
abrogation of cell proliferation, accompanied by the char-
acteristic flattening, vacuolization, and acidic β-galactosidase
activity of senescent cells (26). Considering the large
number of genetic and epigenetic alterations that melano-
ma cells accumulate during their malignant transforma-
tion (57), it is remarkable that inhibiting the expression
of a single gene can drive them out of the cell cycle. It
also important to note that whereas human melanoma
specimens show high DEK protein expression, their
benign and senescent counterparts (nevi) are virtually
negative (26).
Inhibition of differentiation and facilitation of cellular
transformation by DEK
The interplay between DEK and the proliferative status
of cells was also shown in the context of cellular differen-
tiation. In human promyelocytic HL-60 cells or in human
foreskin keratinocytes, differentiation led to DEK downre-
gulation (41, 58). Moreover, mature cells from peripheral
blood were found to contain a 10 fold lower amount of
DEK than immature CD34-positive cells (59). Conversely,
when DEK is overexpressed, differentiation programs can
be counteracted, favoring oncogenic transformation. Thus,
in the presence of ectopic DEK, immortalized keratino-
cytes could shift from differentiation to a hyperprolifera-
tive state when reconstituted into artificial epidermal
rafts (41). Additionally, these DEK-expressing immortal-
ized keratinocytes had an enhanced capability to grow
in soft agar and form tumors in mice when transduced
with the HRAS, and HPV E6 and E7 oncogenes (40). Fur-
ther proof for an active protumorigenic role of DEK was
recently provided by elegant studies in mouse models.
DEK deficient mice were significantly more resistant than
their wild-type littermates to the induction of skin papillo-
mas in a classical 7,12-dimethyl-benz(a)anthracene
(DMBA)-12-O-tetradecanoylphorbol-13-acetate (TPA)
two-step carcinogenesis protocol (40). Whether DEK
knockout mice are also protected from the development
of metastatic tumors is an interesting question that
warrants further analysis.
Regulation and Function of the DEK Oncogene
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Apoptosis and chemosensitization by targeted
depletion of DEK
Although overexpression studies have identified a role
of DEK in favoring proliferation and blocking differentia-
tion, targeted knockdown is unraveling key functions of
DEK as a survival factor. DEK depletion in HeLa resulted
in the induction of apoptosis, at least in part, as a conse-
quence of the stabilization and activation of the tumor
suppressor p53 (60), and the deregulation of multiple
proteins with direct or indirect roles in cell viability
(61). Nevertheless, the extent to which DEK controls cell
survival is likely to depend on the genetic makeup of the
tumor cells. For example, DEK depletion did not lead to
an overt killing of melanoma cells (26). However, these
cells still paid a toll in the absence of DEK. A subset of
metastatic melanoma cells showed a progressive inhibi-
tion of cell-cycle progression upon DEK shRNA transduc-
tion, to ultimately stall into a senescence-like program
(26). Other melanoma lines continued to proliferate,
but became highly sensitive to genotoxic agents. Interest-
ingly, this chemosensitization by DEK shRNAs was found
independent on the functional status of p53. Instead, a
new function of DEK was identified in the transcriptional
control of the anti-apoptotic factor MCL-1 (26). MCL-1
upregulation is a general feature of aggressive cancers,
which also express high DEK levels. Therefore, it is tempt-
ing to speculate that the MCL-1 locus may be under the
control of DEK in multiple tumor types.
Clinical-Translational Advances
DEK as a tumor marker
Since its discovery as the target of the t(6;9) transloca-
tion in a subset of AML patients, DEK has been recurrent-
ly associated with tumor development. In fact, this
translocation has been suggested to be considered in
AML patient stratification (62). Chromosomal alterations
at the DEK locus are now known not to be a universal
feature of malignancy, even in AML (20). However, the
increasing list of tumor types showing high DEK protein
expression that can be easily detected by commercially
available antibodies raises the exciting possibility of using
DEK as a tumor marker. The finding that DEK expression
levels can distinguish benign nevi from malignant mela-
nomas (26) is a prime example of a clinically relevant
setting in which this protein may prove to be highly use-
ful. Moreover, as DEK may be present at higher levels in
immature cells than in their differentiated counterparts
(59), it could also aid in gauging the differentiation
potential of tumor cells. Whether DEK can mark stem
or tumor initiating cells is an interesting question that
merits further analysis.
DEK as drug target
Being an abundant and pleiotropic factor that binds
large stretches of chromatin, it could perhaps have been
expected that interfering with DEK functions would result
in intolerable side effects in normal cells. However, the
fact that DEK-deficient mice are viable whereas DEK-
depleted tumor cells enter into senescence or apoptosis
(40), supports a DEK-dependent “oncogenic addiction”
that could be exploited for drug design. From a transla-
tional point of view, it is also interesting that intratumoral
injection of DEK shRNAs can lead in the induction of
apoptotic features in mouse xenografts generated by Ras/
E6/E7-transformed human keratinocytes (40). The feasi-
bility and efficacy of sustained DEK downregulation has
yet to be proven in physiologically relevant tumor models
or clinical settings. However, the development of new
strategies for small interfering RNA (siRNA) delivery, and
the observation that normal cells may be less sensitive to
DEK downregulation than their hyperproliferative coun-
terparts (40), offers a window for therapeutic intervention.
The fact that DEK controls the resistance of tumor cells to
genotoxic agents (26, 44) could also be used as a guide for
a rational selection of compounds that may better syner-
gize with DEK-inhibitor agents. A proof of principle for
this hypothesis has been recently suggested in experimen-
tal models of melanoma (26). The observation that DEK is
released from apoptotic cells and generates auto-
antibodies may also provide an alternative to assess drug
efficacy in pharmacokinetic or pharmacodynamic studies
of pro-apoptotic agents.
The understanding of regulatory elements in the DEK
promoter has additional translational implications. Specif-
ically, the transcriptional control of DEK by E2F-1 (27)
may be relevant in the context of drug response. Thus,
anticancer agents that affect cell-cycle proliferation may
downregulate E2F-1 and, consequently, DEK expression
and the corresponding DEK-dependent functions.
In summary, the DEK oncogene is overexpressed in a
broad spectrum of cancers and plays an active role in
tumor initiation, maintenance, and drug response. There
are still many open questions about the regulation and
function of this protein, which will certainly keep research-
ers active in multiple disciplines. From a structural point
of view, it is unclear how DEK can bind chromatin in a
sequence unspecific manner but act at discrete sites in
the RNA [in fact the RNA-interacting domain(s) of DEK
are unknown]. Which of the reported post-transcriptional
modifications that might determine this differential DNA
versus RNA recognition are also not well understood. The
histone and chromatin modifiers, as well as the compo-
nents of the spliceosome that interact with and are affected
by DEK, need also to be better defined. Importantly, a
thorough genome-wide analysis is required to establish a
hierarchical map of DEK-dependent modulators of cell
proliferation and cell viability. The crosstalk between
DEK, p53, Rb, and the apoptotic machinery also deserves
attention, as this information may guide the development
of improved therapies. Although these questions are being
investigated, the available knowledge about the tumor-
selective expression and function of DEK can already be
funneled into clinical practice (in the form of diagnostic
markers, and as a platform for drug design). These results
illustrate how a multidisciplinary characterization of
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chromatin organizing factor can efficiently merge basic
and translational research in oncology.
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Abstract
Gain of chromosome 6p is a consistent feature of advanced
melanomas. However, the identity of putative oncogene(s)
associated with this amplification has remained elusive. The
chromatin remodeling factor DEK is an attractive candidate
as it maps to 6p (within common melanoma-amplified loci).
Moreover, DEK expression is increased in metastatic melano-
mas, although the functional relevance of this induction
remains unclear. Importantly, in other tumor types, DEK can
display various tumorigenic effects in part through its ability
to promote proliferation and inhibit p53-dependent apopto-
sis. Here, we report a generalized up-regulation of DEK
protein in aggressive melanoma cells and tumors. In addition,
we provide genetic and mechanistic evidence to support a key
role of DEK in the maintenance of malignant phenotypes of
melanoma cells. Specifically, we show that long-term DEK
down-regulation by independent short hairpin RNAs resulted
in premature senescence of a variety of melanoma cell lines.
Short-term abrogation of DEK expression was also function-
ally relevant, as it attenuated the traditional resistance of
melanomas to DNA-damaging agents. Unexpectedly, DEK
short hairpin RNA had no effect on p53 levels or p53-
dependent apoptosis. Instead, we identified a new role for
DEK in the transcriptional activation of the antiapoptotic
MCL-1. Other MCL-1–related factors such as BCL-2 or BCL-xL
were unaffected by changes in the endogenous levels of
DEK, indicating a selective effect of this gene on the apoptotic
machinery of melanoma cells. These results provide support
for DEK as a long sought-after oncogene mapping at
chromosome 6, with novel functions in melanoma prolifera-
tion and chemoresistance. [Cancer Res 2009;69(16):6405–13]
Introduction
Metastatic melanomas are invariably chemoresistant and carry a
grim prognosis (1). Complicating drug development, melanoma cells
accumulate a plethora of changes in gene expression with the
potential to unleash uncontrolled proliferation, evade senescence
programs, and inhibit death pathways at multiple levels (2). A
hierarchical mapping of these alterations (to distinguish central
nodes in tumor cell maintenance from inconsequential byproducts
of tumor development) has remained elusive. Equally unclear are the
mechanisms underlying common melanoma-associated events that
have been ascribed neither to mutations nor to genetic or epigenetic
alterations. This is particularly relevant for the antiapoptotic
members of the BCL-2 family (BCL-2, BCL-xL, and MCL-1). These
proteins are invariably overexpressed in melanoma cells and play
key roles in their chemoresistance (3). BCL-2 up-regulation may be a
consequence of MITF gene amplification (4). BCL-xL and MCL-1 can
be under the control of the mitogen-activated protein kinase or
nuclear factor-nB signaling cascades (5). However, neither MITF,
mitogen-activated protein kinase, nor nuclear factor-nB inhibition
abrogates the expression of these BCL-2 family members (6–8),
suggesting alternative, and yet unknown, mechanisms of regulation
of the apoptotic machinery in melanoma cells.
Alteration of chromosome 6 is one of the most consistent
cytogenetic changes in melanoma (9). In particular, gain of the 6p
arm is prevalent in different manifestations of the disease,
including cutaneous (both sun-exposed and non–sun-exposed),
acral, mucosal, and uveal melanomas (10, 11). Furthermore, tem-
poral clustering of karyotypic changes in melanoma indicates
that 6p gain may represent an early event in the acquisition of
chromosomal imbalances (12). Adding to the clinical relevance
of chromosome 6, 6p copy gains have been associated with poor
prognosis in ocular melanomas (11). Therefore, it has been long
suggested that this genomic region could contain one or multiple
pro-oncogenes (9, 13, 14). Although the minimal region of 6p gain
has not been described in melanoma, several reports in
retinoblastoma and bladder cancer have identified a narrow region
of gain in 6p22-23 (15–18). This region notably contains the
chromatin remodeling factor DEK.
DEK was originally discovered as the target of a chromosomal
translocation event [t(6;9)(p23;q34)] in a subset of acute myeloid
leukemias (19). Subsequent studies have repeatedly identified DEK
as a frequently overexpressed gene in several neoplasms (16, 20–22).
Furthermore, we and others have shown that DEK has effects on
mRNA splicing, transcriptional control, DNA damage repair,
differentiation, cell viability, and cell-to-cell signaling (23–31). Pro-
oncogenic roles of DEK are supported by its ability to inhibit p53-
mediated apoptosis (32), cooperate with the viral oncogenes E6
and E7 to overcome senescence (29), and promote HRAS-driven
keratinocyte transformation (28). The mechanism(s) through which
DEK mediates its effects, particularly in the context of cellular
oncogenes, is not well understood. DEK is a structurally unique
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DEK, indicating a selective effect of this gene on the apoptotic
machinery of melanoma cells. These results provide support
for DEK as a long sought-after oncogene mapping at
chromosome 6, with novel functions in melanoma prolifera-
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Figure 1. Overexpression of DEK in melanoma cell lines and tissue specimens. A, immunoblotting of a panel of metastatic melanoma lines and primary
foreskin-derived melanocytes (FM293 and FM298), with monoclonal (mAb ) and polyclonal (polyAb ) anti-DEK antibodies. B, monoclonal anti-DEK band densities
were quantified by densitometry, and relative DEK protein levels were normalized to FM293 melanocytes. Horizontal line, mean for each group. C, spectral karyotyping
analysis showing increased copy number at chromosome 6 (yellow boxes ) in SK-Mel-28 and SK-Mel-29, both expressing high levels of DEK (Figs. 1A and 2C ).
D, representative examples of DEK staining in benign nevi (top ) and melanoma lesions (bottom ) included in tissue microarrays. Right, higher-magnification views of
the indicated areas.
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protein (33) that binds preferentially to euchromatin, although it
can also be found within interchromatin granule clusters (34).
Consequently, it is unclear which DEK targets have a causative role
in tumor development and which are passengers of global changes
of chromatin architecture.
The contribution of DEK to melanoma progression and chemo-
resistance has yet to be analyzed. Increased DEK mRNA and
protein has been reported in a small number of melanoma cell
lines or tissues (21, 35). However, DEK function is highly dependent
on post-translational modifications (34, 36). Therefore, it is unclear
whether altered DEK expression is a generalized feature of ad-
vanced melanomas and whether this gene has a functional
contribution to melanoma cell maintenance and drug response.
To assess these questions, we used tissue microarrays to compare
the expression of DEK among benign nevi and malignant
melanoma specimens. In addition, the role of DEK was defined
in a panel of aggressive melanoma cell lines that recapitulate the
most frequent melanoma-associated defects. Our studies establish
DEK , a gene mapping to the genetically unstable 6p region, as the
first chromatin remodeling factor with dual and selective roles in
proliferation and apoptotic resistance in melanoma, acting
independently of classic tumor suppressor pathways.
Materials and Methods
Cells and reagents. Human melanocytes and melanoma lines were
isolated and cultured as described previously (6, 37). Doxorubicin
hydrochloride, cycloheximide, and 4¶,6-diamidino-2-phenylindole (DAPI)
were purchased from Sigma. Bortezomib was obtained from Millennium
Pharmaceuticals. z-VAD-fmk was purchased from Calbiochem. TW-37
synthesis and validation has been described elsewhere (38).
Figure 2. Induction of senescence-like cell
cycle arrest by long-term down-regulation
of DEK. A, total cell numbers estimated in
SK-Mel-28 (left) and SK-Mel-94 (right )
after infection with control shRNA or
shDEK-2 (shDEK )–expressing lentiviruses.
Bars, SE. B, melanoma cell lines were
transduced as in A . Fifteen days after
infection, cell cycle profile distribution was
analyzed by flow cytometry (top ), and
senescence features were determined by
senescence-associated h-galactosidase
activity (bottom, blue signal ). C, cells were
treated as in A . Whole-cell lysates were
processed for detection of the indicated
proteins by immunoblotting. NT, no
treatment.
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Extract preparation and gene expression analyses. Total cell lysates
were obtained by Laemmli extraction, separated by SDS-PAGE, and
transferred to Immobilon-P membranes (Millipore) for immunoblotting
(antibodies used in this study are listed in Supplementary Materials).
Protein expression was quantified using Scion image densitometry software
(Scion). Lentiviral-mediated modulation of DEK, MCL-1, BCL-2, and BCL-xL,
tissue microarrays, spectral karyotyping, and comparative genomic
hybridization procedures are described in Supplementary Information.
Cell proliferation and viability assays. Total cell numberswere estimated
at the indicated times by manual counting, and cell death rates were
determined by standard trypan blue exclusion assays (38). For flow cytometry
assays, cells were fixed in 70% ethanol, digested with 0.5 mg/mL RNase A, and
stained with 50 Ag/mL propidium iodide before analysis in a FACSCalibur
(Becton Dickinson Immunocytometry Systems). Data were fitted using
ModFit software (Verity Software). Senescence-associated h-galactosidase
staining was done as described previously (37). Nuclear condensation and
fragmentation were assessed by fluorescence microscopy after DAPI staining
using an Olympus BX-51 upright microscope.
Quantitative real-time reverse transcription-PCR. RNA purification
and real-time reverse transcription-PCR using a Bio-Rad iCycler (Bio-Rad)
were done essentially as described previously (37, 39) using the following
primers: mcl1 forward ATGCTTCGGAAACTGGACAT and reverse
TCCTGATGCCACCTTCTAGG and b-actin forward CGCCCAGCACGAT-
GAAA and reverse CCGCCGATCCACACAGA. The assay included a no-
template control and a standard curve of six dilutions for both mcl-1 and
b-actin . Results are given as the average F SE of three experiments, and
each sample was amplified and analyzed in triplicate.
Luciferase reporter gene assays. The human MCL-1 promoter reporter
plasmid 203/+10 was a generous gift of Douglas Cress (40). Cells were trans-
fected using Lipofectamine 2000 (Invitrogen) and the lysates were assayed
for firefly and Renilla luciferase activity using the Dual-Luciferase Reporter
Assay System (Promega). Luminescence was detected with a Tecan GENios
plate reader. Data are presented as the mean F SE of three experiments.
Statistics. Statistical analyses of cell death, quantitative real-time reverse
transcription-PCR, and luciferase reporter assays were done using a paired,
two-tailed Student’s t test.
Results
DEK protein overexpression in metastatic melanoma. We
hypothesized that gain of 6p in melanoma may function to
promote DEK overexpression. To this end, a panel of 16 metastatic
melanoma lines was selected to reflect the most common
melanoma-associated alterations in oncogenes or tumor suppres-
sors (see Supplementary Table S1). In parallel, primary human
foreskin-derived melanocytes were used as controls for normal
cells. Immunoblotting revealed a generalized high expression of
DEK, with an average 30-fold induction over the basal levels of
normal melanocytes (Fig. 1A and B).
Interestingly, spectral karyotyping confirmed that melanoma cell
lines with high DEK expression (SK-Mel-28 and -29) contained,
among other genetic abnormalities, an increased copy number
of chromosome 6 (Fig. 1C). However, large-scale chromosome 6p
amplifications are unlikely to be the sole mechanism underlying
DEK up-regulation. Thus, lines such as SK-Mel-103 or SK-Mel-147,
with moderate levels of DEK protein (Fig. 1A), had a normal copy
number of chromosome 6 defined by spectral karyotyping
(Supplementary Fig. S1A). Comparative genomic hybridization
showed focal gains at 6p22.3 but centromeric to DEK (Supple-
mentary Fig. S1B).
To validate the increased DEK protein expression found in cell
lines, an extensive immunohistochemical analysis was done on two
tissue microarrays, containing surgically removed melanocytic
lesions, each spotted in triplicate. Specifically, these tissue micro-
arrays included 87 primary melanomas and 115 metastatic
specimens. In addition, 3 dysplastic nevi, 7 benign nevi, and 5
biopsies of normal skin were included as reference. Notably, 90% of
the tumors analyzed showed clear positive DEK expression (10%
being very marked and 80% with moderate DEK levels; see
representative examples in Fig. 1D, bottom). Normal skin melano-
cytes and benign nevi showed no detectable DEK expression
(Fig. 1D, top ; results not shown). Therefore, these results support
a broad-spectrum up-regulation of DEK during melanoma
progression.
Long-term down-regulation of the endogenous DEK
expression in melanoma induces premature senescence.
Lentiviral vectors were used to transduce short hairpin RNAs
(shRNA) and down-regulate DEK in a stable manner. To avoid
complications of off-target effects, three independent shRNAs were
tested (see Supplementary Fig. S2). In 6 of 12 lines analyzed
(SK-Mel-28, SK-Mel-94, G-361, UACC-62, UACC-257, and MM576),
Figure 3. p53-independent induction of cell death by short-term inactivation
of DEK. A, SK-Mel-19 cells transduced with the indicated shRNAs were
treated with doxorubicin (Dox ) for 30 h, and cell death was determined
by DAPI staining and counting of condensed and fragmented nuclei.
B, fluorescence microscopy illustrating cell nuclear morphology after treatment
with 0.3 Ag/mL doxorubicin for 30 h in cells transduced with a control vector
(left) or shDEK-2 (right ). C, SK-Mel-19 cells transduced as in A were treated
with 0.2 Ag/mL doxorubicin, collected at the indicated times, and analyzed
by immunoblotting.
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DEK depletion led to a progressive cell cycle arrest, eventually
resulting in a near complete inhibition of cell proliferation as
determined by total cell counting (Fig. 2A) and flow cytometry
(Fig. 2B, top).
The reduction of cells in S phase of the cell cycle (Fig. 2B, top)
was accompanied by cell enlargement, flattening, and vacuolization
(Fig. 2B, bottom) reminiscent of classic senescent phenotypes (41).
In fact, staining for senescence-associated h-galactosidase activity
was positive in DEK-depleted melanoma cells (Fig. 2B, bottom).
Interestingly, cell cycle arrest and the acquisition of senescent-like
features occurred in cells expressing either wild-type p53 or
mutated p53 (e.g., SK-Mel-94 or SK-Mel-28, respectively; Fig. 2C).
Notably, DEK shRNAs did not affect the expression of p16INK4A
(Fig. 2C), a senescence-associated tumor suppressor. These results
show that DEK is required for the continued proliferation of
metastatic melanoma cells and point to novel p53 and p16 INK4A-
independent senescence programs.
Short-term down-regulation of DEK expression bypasses
melanoma chemoresistance. Recently, we have shown that DEK
can enhance resistance to DNA-damaging agents by promoting
efficient resolution of DNA damage foci (42). Therefore, we sought
to determine whether short term down-regulation of DEK
(therapeutically more feasible than sustained gene inactivation)
could contribute to the ability of melanoma cells to withstand
genotoxic agents. The anthracycline doxorubicin is a potent
antineoplastic agent in other tumor types but has only limited
efficacy against metastatic melanoma (8). This drug was selected
to treat cells with the highest levels of DEK, as they may be
more dependent on this protein for survival (see Fig. 3 for
SK-Mel-19 and Fig. 4 for SK-Mel-29; results with other cell lines are
discussed next). SK-Mel-19 was infected with a control shRNA
lentiviral vector, a vector expressing a single DEK-specific shRNA
(shDEK-1) or a vector expressing two distinct DEK-specific shRNAs
(shDEK-2). Two days after lentiviral infection, cells were treated
with increasing doses of doxorubicin and cell death was estimated
within 24 to 36 h after treatment. Relatively high levels of
doxorubicin were required to kill melanoma cells in the presence
of DEK (>0.2 Ag/mL; Fig. 3A). However, DEK depletion resulted in a
marked increase in doxorubicin-driven cell death, particularly on
dual-shRNA targeting (Fig. 3A). Importantly, the increased response
of DEK-depleted melanoma cells to doxorubicin was associated
with classic apoptotic features such as chromatin condensation
(Fig. 3B) and caspase processing (Fig. 3C). Therefore, although DEK
may not be the sole mediator of melanoma chemoresistance, our
results support a key role of this gene contributing to the
malignant features of melanoma cells.
DEK does not modulate p53 levels in melanoma cells. DEK
has been shown previously to mediate antiapoptotic effects
through destabilization of p53 protein and inhibition of p53
activity (23, 32). However, as with the case of long-term down-
regulation of DEK shown above (Fig. 2C), short-term expression of
DEK shRNA was not found to significantly affect total p53 levels
(Fig. 3C). Furthermore, the activation of p53 (detected by
phosphorylation of its serine 15) and the induction of p53 targets,
such as p21CIP1, were similar in DEK-expressing and DEK-deficient
melanoma cells (Fig. 3C).
DEK-knockdown cells have diminished MCL-1 expression.
Overexpression of antiapoptotic BCL-2 family members has been
associated with melanoma chemoresistance (3). Therefore, we
tested whether DEK could control BCL-2 family members.
Interestingly, DEK down-regulation with two different shRNAs led
Figure 4. Caspase-independent down-regulation of MCL-1 by DEK shRNA.
A, indicated melanoma cells were infected with either a control (Ctrl ) lentivirus
or one of three distinct vectors targeting DEK expression (shDEK-1, shDEK-2 ,
and shDEK-3 ). Ninety-six hours after infection, cells were collected and their
lysates were immunoblotted for DEK and MCL-1 expression. B, SK-Mel-19
cells transduced with the indicated shRNAs were treated with 0.2 Ag/mL
doxorubicin and collected for immunoblotting analyses. C, relative expression
of MCL-1 (left), BCL-2 (middle ), and BCL-xL (right ) following doxorubicin
treatment as estimated by band densitometry. Expression is shown relative to
that of untreated control-transduced cells. D, protein immunoblots in control
and shDEK-infected SK-Mel-19 cells treated with 0.2 Ag/mL doxorubicin alone
or with doxorubicin in the presence of 50 Amol/L of the pan-caspase inhibitor
z-VAD-fmk.
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DEK depletion led to a progressive cell cycle arrest, eventually
resulting in a near complete inhibition of cell proliferation as
determined by total cell counting (Fig. 2A) and flow cytometry
(Fig. 2B, top).
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In fact, staining for senescence-associated h-galactosidase activity
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mutated p53 (e.g., SK-Mel-94 or SK-Mel-28, respectively; Fig. 2C).
Notably, DEK shRNAs did not affect the expression of p16INK4A
(Fig. 2C), a senescence-associated tumor suppressor. These results
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metastatic melanoma cells and point to novel p53 and p16 INK4A-
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Short-term down-regulation of DEK expression bypasses
melanoma chemoresistance. Recently, we have shown that DEK
can enhance resistance to DNA-damaging agents by promoting
efficient resolution of DNA damage foci (42). Therefore, we sought
to determine whether short term down-regulation of DEK
(therapeutically more feasible than sustained gene inactivation)
could contribute to the ability of melanoma cells to withstand
genotoxic agents. The anthracycline doxorubicin is a potent
antineoplastic agent in other tumor types but has only limited
efficacy against metastatic melanoma (8). This drug was selected
to treat cells with the highest levels of DEK, as they may be
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SK-Mel-19 and Fig. 4 for SK-Mel-29; results with other cell lines are
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lentiviral vector, a vector expressing a single DEK-specific shRNA
(shDEK-1) or a vector expressing two distinct DEK-specific shRNAs
(shDEK-2). Two days after lentiviral infection, cells were treated
with increasing doses of doxorubicin and cell death was estimated
within 24 to 36 h after treatment. Relatively high levels of
doxorubicin were required to kill melanoma cells in the presence
of DEK (>0.2 Ag/mL; Fig. 3A). However, DEK depletion resulted in a
marked increase in doxorubicin-driven cell death, particularly on
dual-shRNA targeting (Fig. 3A). Importantly, the increased response
of DEK-depleted melanoma cells to doxorubicin was associated
with classic apoptotic features such as chromatin condensation
(Fig. 3B) and caspase processing (Fig. 3C). Therefore, although DEK
may not be the sole mediator of melanoma chemoresistance, our
results support a key role of this gene contributing to the
malignant features of melanoma cells.
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has been shown previously to mediate antiapoptotic effects
through destabilization of p53 protein and inhibition of p53
activity (23, 32). However, as with the case of long-term down-
regulation of DEK shown above (Fig. 2C), short-term expression of
DEK shRNA was not found to significantly affect total p53 levels
(Fig. 3C). Furthermore, the activation of p53 (detected by
phosphorylation of its serine 15) and the induction of p53 targets,
such as p21CIP1, were similar in DEK-expressing and DEK-deficient
melanoma cells (Fig. 3C).
DEK-knockdown cells have diminished MCL-1 expression.
Overexpression of antiapoptotic BCL-2 family members has been
associated with melanoma chemoresistance (3). Therefore, we
tested whether DEK could control BCL-2 family members.
Interestingly, DEK down-regulation with two different shRNAs led
Figure 4. Caspase-independent down-regulation of MCL-1 by DEK shRNA.
A, indicated melanoma cells were infected with either a control (Ctrl ) lentivirus
or one of three distinct vectors targeting DEK expression (shDEK-1, shDEK-2 ,
and shDEK-3 ). Ninety-six hours after infection, cells were collected and their
lysates were immunoblotted for DEK and MCL-1 expression. B, SK-Mel-19
cells transduced with the indicated shRNAs were treated with 0.2 Ag/mL
doxorubicin and collected for immunoblotting analyses. C, relative expression
of MCL-1 (left), BCL-2 (middle ), and BCL-xL (right ) following doxorubicin
treatment as estimated by band densitometry. Expression is shown relative to
that of untreated control-transduced cells. D, protein immunoblots in control
and shDEK-infected SK-Mel-19 cells treated with 0.2 Ag/mL doxorubicin alone
or with doxorubicin in the presence of 50 Amol/L of the pan-caspase inhibitor
z-VAD-fmk.
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to a drastic decrease in MCL-1 expression in SK-Mel-19, SK-Mel-29,
SK-Mel-5, and MM576 (Fig. 4A ; data not shown). Notably, DEK
shRNA did not alter BCL-2 or BCL-xL levels (Fig. 4B), suggesting
selective effects on the apoptotic machinery.
To further assess the requirement of DEK for high MCL-1
expression, DEK-depleted cells were treated with doxorubicin
(which induces MCL-1 levels in melanoma cells; Fig. 4B and C). As
shown in Fig. 4B , DEK shRNA cells ultimately expressed minimal
levels of MCL-1 after doxorubicin treatment (see quantification in
Fig. 4C). Again, the effects of DEK on the apoptotic machinery were
selective, as no changes in BCL-2 or BCL-xL levels were observed
before or after doxorubicin treatment (Fig. 4B and C). Importantly,
the reduction of MCL-1 expression in DEK-shRNA cells was not due
to proteolytic cleavage by apoptotic caspases (43). Thus, the pan-
caspase inhibitor z-VAD-fmk, although it eliminated caspase-3
cleavage, could not prevent MCL-1 down-regulation in shDEK-
treated cells (Fig. 4D).
Decreased MCL-1 in shDEK-treated cells is not due to
increased MCL-1 degradation. To determine if the decrease in
MCL-1 protein in DEK-knockdown cells was due to enhanced
proteasomal turnover, cells were treated with the proteasome
inhibitor bortezomib. As we reported previously (39, 44), bortezomib
induced a massive MCL-1 stabilization in control melanoma cells
within 2 to 3 h of treatment (Fig. 5A). A similar rate of MCL-1
accumulation was observed in shDEK-expressing melanoma cells
(Fig. 5B), although these cells have, as indicated above, intrinsically
lower basal levels of MCL-1 (note that MCL-1 immunoblots in
Fig. 5A were overexposed to favor the visualization of the endo-
genous low expression of MCL-1 in shRNA-DEK cells). Therefore,
the diminished MCL-1 levels in DEK-knockdown cells were not
due to increased proteosome-dependent MCL-1 degradation.
To assess the stability of MCL-1 protein in DEK-knockdown cells,
cycloheximide, a translational inhibitor, was used to inhibit de novo
MCL-1 synthesis. To better visualize the decrease in MCL-1
expression, cells were first pretreated with bortezomib to augment
MCL-1 levels. Bortezomib was subsequently removed, and cells
were incubated in cycloheximide and then processed for immu-
noblotting analysis (see Materials and Methods for additional
details). As shown in Fig. 5C and D , depletion of MCL-1 occurred
with similar kinetics in both control and shDEK-treated cells.
Novel role of DEK in MCL-1 transcription. Because DEK
was not affecting DEK protein stability, it could be controlling
Figure 5. Transcriptional control of MCL-1
by DEK. A, comparative analysis of MCL-1
protein down-regulation in SK-Mel-19 cells
transduced with control or DEK shRNAs
and treated for the indicated times with
25 nmol/L bortezomib (Bort ). BCL-2 and
h-actin are included as examples of
DEK-independent proteins and for loading
control, respectively. B, quantification
by densitometry of MCL-1 levels in A
depicted with respect to nontreated
control-infected cells. C and D, control or
shRNA-transduced SK-Mel-19 cells were
treated for 5 h with 25 nmol/L of the
proteasome inhibitor bortezomib. Cells
were then washed to remove bortezomib
and incubated with cycloheximide (CHX)
for the indicated times. Following
treatment, cells were collected and
processed for immunoblotting (C ) and
subsequent quantification by densitometry
(D ). E, MCL-1 mRNA expression of control
and shDEK-treated SK-Mel-19 cells
determined by quantitative real-time
reverse transcription-PCR. F, control and
shDEK-transduced SK-Mel-19 cells were
transfected with either the promoterless
pGL2 basic plasmid or a plasmid
expressing the firefly luciferase gene under
the control of the human MCL-1 promoter
(203/+10 bp). The average luciferase
activity of three experiments is shown
relative to that of control-transduced cells
transfected with the pGL2 basic plasmid.
Bars, SE. *, P < 0.05.
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to a drastic decrease in MCL-1 expression in SK-Mel-19, SK-Mel-29,
SK-Mel-5, and MM576 (Fig. 4A ; data not shown). Notably, DEK
shRNA did not alter BCL-2 or BCL-xL levels (Fig. 4B), suggesting
selective effects on the apoptotic machinery.
To further assess the requirement of DEK for high MCL-1
expression, DEK-depleted cells were treated with doxorubicin
(which induces MCL-1 levels in melanoma cells; Fig. 4B and C). As
shown in Fig. 4B , DEK shRNA cells ultimately expressed minimal
levels of MCL-1 after doxorubicin treatment (see quantification in
Fig. 4C). Again, the effects of DEK on the apoptotic machinery were
selective, as no changes in BCL-2 or BCL-xL levels were observed
before or after doxorubicin treatment (Fig. 4B and C). Importantly,
the reduction of MCL-1 expression in DEK-shRNA cells was not due
to proteolytic cleavage by apoptotic caspases (43). Thus, the pan-
caspase inhibitor z-VAD-fmk, although it eliminated caspase-3
cleavage, could not prevent MCL-1 down-regulation in shDEK-
treated cells (Fig. 4D).
Decreased MCL-1 in shDEK-treated cells is not due to
increased MCL-1 degradation. To determine if the decrease in
MCL-1 protein in DEK-knockdown cells was due to enhanced
proteasomal turnover, cells were treated with the proteasome
inhibitor bortezomib. As we reported previously (39, 44), bortezomib
induced a massive MCL-1 stabilization in control melanoma cells
within 2 to 3 h of treatment (Fig. 5A). A similar rate of MCL-1
accumulation was observed in shDEK-expressing melanoma cells
(Fig. 5B), although these cells have, as indicated above, intrinsically
lower basal levels of MCL-1 (note that MCL-1 immunoblots in
Fig. 5A were overexposed to favor the visualization of the endo-
genous low expression of MCL-1 in shRNA-DEK cells). Therefore,
the diminished MCL-1 levels in DEK-knockdown cells were not
due to increased proteosome-dependent MCL-1 degradation.
To assess the stability of MCL-1 protein in DEK-knockdown cells,
cycloheximide, a translational inhibitor, was used to inhibit de novo
MCL-1 synthesis. To better visualize the decrease in MCL-1
expression, cells were first pretreated with bortezomib to augment
MCL-1 levels. Bortezomib was subsequently removed, and cells
were incubated in cycloheximide and then processed for immu-
noblotting analysis (see Materials and Methods for additional
details). As shown in Fig. 5C and D , depletion of MCL-1 occurred
with similar kinetics in both control and shDEK-treated cells.
Novel role of DEK in MCL-1 transcription. Because DEK
was not affecting DEK protein stability, it could be controlling
Figure 5. Transcriptional control of MCL-1
by DEK. A, comparative analysis of MCL-1
protein down-regulation in SK-Mel-19 cells
transduced with control or DEK shRNAs
and treated for the indicated times with
25 nmol/L bortezomib (Bort ). BCL-2 and
h-actin are included as examples of
DEK-independent proteins and for loading
control, respectively. B, quantification
by densitometry of MCL-1 levels in A
depicted with respect to nontreated
control-infected cells. C and D, control or
shRNA-transduced SK-Mel-19 cells were
treated for 5 h with 25 nmol/L of the
proteasome inhibitor bortezomib. Cells
were then washed to remove bortezomib
and incubated with cycloheximide (CHX)
for the indicated times. Following
treatment, cells were collected and
processed for immunoblotting (C ) and
subsequent quantification by densitometry
(D ). E, MCL-1 mRNA expression of control
and shDEK-treated SK-Mel-19 cells
determined by quantitative real-time
reverse transcription-PCR. F, control and
shDEK-transduced SK-Mel-19 cells were
transfected with either the promoterless
pGL2 basic plasmid or a plasmid
expressing the firefly luciferase gene under
the control of the human MCL-1 promoter
(203/+10 bp). The average luciferase
activity of three experiments is shown
relative to that of control-transduced cells
transfected with the pGL2 basic plasmid.
Bars, SE. *, P < 0.05.
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its transcription. To this end, mRNA levels were estimated by
quantitative reverse transcription-PCR. As shown in Fig. 5E , DEK
down-regulation leads to a 50% reduction in MCL-1 mRNA. To
confirm the requirement of DEK for MCL-1 mRNA transcription, a
reporter construct driving luciferase expression under the control
of the proximal region of the human MCL-1 promoter was
transduced into either control or shDEK-transduced SK-Mel-19
cells (Fig. 5F). We found a 70% to 80% reduction in promoter
activity in MCL-1 in the absence of DEK (Fig. 5F). These results
show a new role for DEK in the transcriptional control of MCL-1 .
Functional implication of DEK-dependent MCL-1 expression.
To define the specific interplay between DEK and MCL-1 in the
enhancement of melanoma chemoresistance, we generated iso-
genic series of melanoma cell lines with differing levels of both
proteins and compared their response to doxorubicin. Additional
isogenic cell lines were generated to alter (positively and
negatively) the endogenous expression of BCL-xL. BCL-xL was
chosen as an example of an antiapoptotic BCL-2 factor that is not
under the control of DEK (Fig. 4B) but is also overexpressed in
melanoma cells (3).
To alter MCL-1 expression, we used two approaches. First, we
generated lentiviral vectors to drive MCl-1 from an ectopic
promoter that is not sensitive to DEK. Viral titers were selected
to restore MCL-1 levels to the basal conditions (Fig. 6A, left, inset).
Figure 6. Functional effect of the selective
regulation of BCL-2 family members by
DEK. A, restoration of MCL-1 levels using
lentiviral vectors coding for MCL-1 under
an exogenous promoter that is not
sensitive to DEK shRNA down-regulation
(left). Control infections were also done
with a vector expressing BCL-xL (right ).
Seventy-two hours after infection with
MCL-1 or BCL-xL lentiviruses, cells
were treated with the indicated
concentration of doxorubicin for 30 h.
Following treatment, cells were stained
with DAPI and apoptotic cells were counted
by fluorescence microscopy. B, inactivation
of MCL-1 (left) or BCL-xL (right ) with
the corresponding shRNAs. Insets,
shRNA-mediated knockdown of DEK and
either knockdown or overexpression of
BCL-xL and MCL-1 as determined by
immunoblotting. C, SK-Mel-19 cells were
transduced as in Fig. 3 and treated
with the BH3 mimetic TW-37 for 48 h and
then stained with trypan blue. Bars,
SE. D, fluorescence microscopy by
DAPI staining illustrating cell nuclear
morphology after treatment with 15 Amol/L
TW-37 in cells infected with a control
shRNA expressing vector (left ) or
shDEK-2 (right ). P values for the indicated
pair-wise comparisons were determined
by two-tailed Student’s t test.
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its transcription. To this end, mRNA levels were estimated by
quantitative reverse transcription-PCR. As shown in Fig. 5E , DEK
down-regulation leads to a 50% reduction in MCL-1 mRNA. To
confirm the requirement of DEK for MCL-1 mRNA transcription, a
reporter construct driving luciferase expression under the control
of the proximal region of the human MCL-1 promoter was
transduced into either control or shDEK-transduced SK-Mel-19
cells (Fig. 5F). We found a 70% to 80% reduction in promoter
activity in MCL-1 in the absence of DEK (Fig. 5F). These results
show a new role for DEK in the transcriptional control of MCL-1 .
Functional implication of DEK-dependent MCL-1 expression.
To define the specific interplay between DEK and MCL-1 in the
enhancement of melanoma chemoresistance, we generated iso-
genic series of melanoma cell lines with differing levels of both
proteins and compared their response to doxorubicin. Additional
isogenic cell lines were generated to alter (positively and
negatively) the endogenous expression of BCL-xL. BCL-xL was
chosen as an example of an antiapoptotic BCL-2 factor that is not
under the control of DEK (Fig. 4B) but is also overexpressed in
melanoma cells (3).
To alter MCL-1 expression, we used two approaches. First, we
generated lentiviral vectors to drive MCl-1 from an ectopic
promoter that is not sensitive to DEK. Viral titers were selected
to restore MCL-1 levels to the basal conditions (Fig. 6A, left, inset).
Figure 6. Functional effect of the selective
regulation of BCL-2 family members by
DEK. A, restoration of MCL-1 levels using
lentiviral vectors coding for MCL-1 under
an exogenous promoter that is not
sensitive to DEK shRNA down-regulation
(left). Control infections were also done
with a vector expressing BCL-xL (right ).
Seventy-two hours after infection with
MCL-1 or BCL-xL lentiviruses, cells
were treated with the indicated
concentration of doxorubicin for 30 h.
Following treatment, cells were stained
with DAPI and apoptotic cells were counted
by fluorescence microscopy. B, inactivation
of MCL-1 (left) or BCL-xL (right ) with
the corresponding shRNAs. Insets,
shRNA-mediated knockdown of DEK and
either knockdown or overexpression of
BCL-xL and MCL-1 as determined by
immunoblotting. C, SK-Mel-19 cells were
transduced as in Fig. 3 and treated
with the BH3 mimetic TW-37 for 48 h and
then stained with trypan blue. Bars,
SE. D, fluorescence microscopy by
DAPI staining illustrating cell nuclear
morphology after treatment with 15 Amol/L
TW-37 in cells infected with a control
shRNA expressing vector (left ) or
shDEK-2 (right ). P values for the indicated
pair-wise comparisons were determined
by two-tailed Student’s t test.
DEK, a Melanoma Oncogene at Chromosome 6
www.aacrjournals.org 6411 Cancer Res 2009; 69: (16). August 15, 2009
In a second set of experiments, the opposite strategy was tested
(Fig. 6B), that is, to abrogate MCL-1 mRNA and protein expression
with shRNAs that we have previously validated (6, 39, 44).
Interestingly, exogenous MCL-1 significantly protected DEK-
depleted melanoma cells, reducing the killing activity of doxoru-
bicin in half (Fig. 6A ; P = 0.014 for concentrations of doxorubicin of
0.25 Ag/mL). On the other hand, when MCL-1 was depleted, DEK
shRNA was not able to further enhance drug response (Fig. 6B, left ;
P = 0.441).
In contrast to MCL-1, altering BCL-xL levels by either over-
expression (Fig. 6A, right) or shRNAs (Fig. 6B, right) had no
significant effect on melanoma cell viability whether in the
presence or absence of DEK (see the corresponding P values in
Fig. 6A and B).
From the data presented above, it follows that DEK shRNA may
augment the therapeutic efficacy of small molecules, the antitumor
activity of which depends on MCL-1 inactivation. To examine this
possibility, we tested the small-molecule BH3 mimetic TW-37,
which we have shown previously to act primarily by inhibiting
MCL-1 (6, 38). Interestingly, DEK-depleted SK-Mel-19 cells were
significantly more sensitive to TW-37 treatment than their control
counterparts, showing an accelerated killing (Fig. 6C ; P = 0.011-
0.002) and induction of apoptotic-like features (see chromatin
condensation in Fig. 6D). These results provide proof-of-principle
for the development of rational therapies targeting DEK/MCL-1–
dependent mechanisms of cell survival in melanoma.
Discussion
In this study, we identified new roles for DEK in metastatic
melanoma cells. Despite the high degree of heterogeneity
characteristic of this tumor type, we found that the DEK protein
was invariably overexpressed in all 16 metastatic cell lines
investigated independent of their genetic background. Moreover,
high-throughput immunohistochemical analyses revealed a
marked expression of DEK in 90% of primary and metastatic
melanomas studied. In the same conditions, DEK expression in
normal skin and benign nevi was nearly undetectable. Importantly,
this high expression of DEK was not a simple byproduct of
melanoma development. Abrogation of endogenous DEK expres-
sion resulted in the disruption of characteristic malignant features
of melanomas. Thus, long-term expression of DEK shRNAs led to
cell cycle arrest with features of senescence. In turn, acute down-
regulation of DEK was sufficient to enhance the response to DNA
damaging agents and BH3 mimetics (doxorubicin and TW-37,
respectively). Our results additionally unveiled a previously
undescribed role for DEK in the regulation of a critical mediator
of chemoresistance, MCL-1.
The contribution of DEK to melanoma proliferation and drug
resistance provides mechanistic support for the long-suspected
presence of oncogene(s) mapping to the short arm of chromosome
6 (9, 13, 14). A complication in the identification of the putative
onocogene(s) in this region has been its high gene density (624
genes in the 6p21-23 interval). Moreover, this area is heavily
enriched in CpG islands; therefore, it can be subject to complex
epigenetic regulation. Interestingly, a common area of copy gain at
6p22-p23 in ocular melanomas (11) had also been reported in
bladder cancer and retinoblastoma (16–18). Of the 7 genes in this
region, only DEK was found to have a correlation between copy
gain and gene expression (18). Our spectral karyotyping and
comparative genomic hybridization analyses revealed duplications
of chromosome 6 in melanoma cell lines expressing high levels of
DEK. However, other mechanisms of regulation may favor DEK up-
regulation, as its expression can also be induced in cells with a
normal copy number at the DEK locus.
Considering the high number of mutations and alterations in
proliferative pathways that melanoma cells express, it is interesting
that down-regulation of a single gene (DEK) can ultimately drive
them into senescence-like cell cycle arrest. In fact, melanomas are
considered to be particularly efficient at overcoming premature
senescence, as this is one of the early barriers to melanocyte
transformation (45). Mechanisms that circumvent premature
senescence in melanomas are not well characterized. In fact, a
puzzling feature of this disease is that a large fraction of acquired
melanomas neither mutate nor delete p53 or p16INK4a, two tumor
suppressors with key roles in the induction of senescence programs
(2). Therefore, DEK overexpression may represent an alternative
mechanism to counteract the tumor suppressor activity of p53 and
p16 in melanoma cells. The precise effects of DEK in promoting
sustained proliferation will require further studies, but it is
tempting to speculate that it may cooperate with other oncogenes
mapping at chromosome 6p, such as c-MYC, which we have
recently shown to control melanoma senescence (46).
Although the requirement of sustained expression of DEK to
avoid premature senescence has implications for basic aspects of
melanoma, the new roles of DEK shown here in the control of
the apoptotic machinery are perhaps more significant from a
therapeutic perspective. Although DEK has been shown previously
to participate in the regulation of gene transcription (23–25, 30, 47),
promotion of MCL-1 expression is the first demonstration of a
transcriptional target of DEK directly contributing to an oncogenic
phenotype. The requirement of DEK for MCL-1 expression is
relevant as this protein has an intrinsically short half life (5); yet, it
is consistently accumulated in melanoma cells (3). In addition,
MCL-1 transcription can be inhibited by p53 (48), E2F1, or E2F2
(40), all of which are expressed in melanoma cells. Therefore, the
effects of DEK on MCL-1 transcription may serve to compensate
for negative regulatory signals intrinsically expressed in melanoma
cells. Furthermore, we and others have shown that MCL-1 is
essential for long-term survival of melanoma cells, and it is a
main determinant of their resistance to dacarbazine, BH3
mimetics, and inhibitors of MEK or the proteasome (6, 44, 49).
MCL-1 can also control melanoma cell survival under conditions of
anoikis (50). Thus, enhanced MCL-1 expression caused by DEK
overexpression may represent a major mechanism of melanoma
cell survival in response to chemotherapeutic agents and other
stress-inducing factors.
In conclusion, our results implicate overexpression of the 6p pro-
oncogene DEK as an extremely frequent event in metastatic
melanomas. Remarkably, this single event can have a dual effect on
melanoma cell proliferation and chemoresistance (preventing
senescence and inducing the antiapoptotic MCL-1, respectively).
Therefore, our results suggest that DEK may be a relevant target for
therapeutic intervention in this aggressive disease.
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In a second set of experiments, the opposite strategy was tested
(Fig. 6B), that is, to abrogate MCL-1 mRNA and protein expression
with shRNAs that we have previously validated (6, 39, 44).
Interestingly, exogenous MCL-1 significantly protected DEK-
depleted melanoma cells, reducing the killing activity of doxoru-
bicin in half (Fig. 6A ; P = 0.014 for concentrations of doxorubicin of
0.25 Ag/mL). On the other hand, when MCL-1 was depleted, DEK
shRNA was not able to further enhance drug response (Fig. 6B, left ;
P = 0.441).
In contrast to MCL-1, altering BCL-xL levels by either over-
expression (Fig. 6A, right) or shRNAs (Fig. 6B, right) had no
significant effect on melanoma cell viability whether in the
presence or absence of DEK (see the corresponding P values in
Fig. 6A and B).
From the data presented above, it follows that DEK shRNA may
augment the therapeutic efficacy of small molecules, the antitumor
activity of which depends on MCL-1 inactivation. To examine this
possibility, we tested the small-molecule BH3 mimetic TW-37,
which we have shown previously to act primarily by inhibiting
MCL-1 (6, 38). Interestingly, DEK-depleted SK-Mel-19 cells were
significantly more sensitive to TW-37 treatment than their control
counterparts, showing an accelerated killing (Fig. 6C ; P = 0.011-
0.002) and induction of apoptotic-like features (see chromatin
condensation in Fig. 6D). These results provide proof-of-principle
for the development of rational therapies targeting DEK/MCL-1–
dependent mechanisms of cell survival in melanoma.
Discussion
In this study, we identified new roles for DEK in metastatic
melanoma cells. Despite the high degree of heterogeneity
characteristic of this tumor type, we found that the DEK protein
was invariably overexpressed in all 16 metastatic cell lines
investigated independent of their genetic background. Moreover,
high-throughput immunohistochemical analyses revealed a
marked expression of DEK in 90% of primary and metastatic
melanomas studied. In the same conditions, DEK expression in
normal skin and benign nevi was nearly undetectable. Importantly,
this high expression of DEK was not a simple byproduct of
melanoma development. Abrogation of endogenous DEK expres-
sion resulted in the disruption of characteristic malignant features
of melanomas. Thus, long-term expression of DEK shRNAs led to
cell cycle arrest with features of senescence. In turn, acute down-
regulation of DEK was sufficient to enhance the response to DNA
damaging agents and BH3 mimetics (doxorubicin and TW-37,
respectively). Our results additionally unveiled a previously
undescribed role for DEK in the regulation of a critical mediator
of chemoresistance, MCL-1.
The contribution of DEK to melanoma proliferation and drug
resistance provides mechanistic support for the long-suspected
presence of oncogene(s) mapping to the short arm of chromosome
6 (9, 13, 14). A complication in the identification of the putative
onocogene(s) in this region has been its high gene density (624
genes in the 6p21-23 interval). Moreover, this area is heavily
enriched in CpG islands; therefore, it can be subject to complex
epigenetic regulation. Interestingly, a common area of copy gain at
6p22-p23 in ocular melanomas (11) had also been reported in
bladder cancer and retinoblastoma (16–18). Of the 7 genes in this
region, only DEK was found to have a correlation between copy
gain and gene expression (18). Our spectral karyotyping and
comparative genomic hybridization analyses revealed duplications
of chromosome 6 in melanoma cell lines expressing high levels of
DEK. However, other mechanisms of regulation may favor DEK up-
regulation, as its expression can also be induced in cells with a
normal copy number at the DEK locus.
Considering the high number of mutations and alterations in
proliferative pathways that melanoma cells express, it is interesting
that down-regulation of a single gene (DEK) can ultimately drive
them into senescence-like cell cycle arrest. In fact, melanomas are
considered to be particularly efficient at overcoming premature
senescence, as this is one of the early barriers to melanocyte
transformation (45). Mechanisms that circumvent premature
senescence in melanomas are not well characterized. In fact, a
puzzling feature of this disease is that a large fraction of acquired
melanomas neither mutate nor delete p53 or p16INK4a, two tumor
suppressors with key roles in the induction of senescence programs
(2). Therefore, DEK overexpression may represent an alternative
mechanism to counteract the tumor suppressor activity of p53 and
p16 in melanoma cells. The precise effects of DEK in promoting
sustained proliferation will require further studies, but it is
tempting to speculate that it may cooperate with other oncogenes
mapping at chromosome 6p, such as c-MYC, which we have
recently shown to control melanoma senescence (46).
Although the requirement of sustained expression of DEK to
avoid premature senescence has implications for basic aspects of
melanoma, the new roles of DEK shown here in the control of
the apoptotic machinery are perhaps more significant from a
therapeutic perspective. Although DEK has been shown previously
to participate in the regulation of gene transcription (23–25, 30, 47),
promotion of MCL-1 expression is the first demonstration of a
transcriptional target of DEK directly contributing to an oncogenic
phenotype. The requirement of DEK for MCL-1 expression is
relevant as this protein has an intrinsically short half life (5); yet, it
is consistently accumulated in melanoma cells (3). In addition,
MCL-1 transcription can be inhibited by p53 (48), E2F1, or E2F2
(40), all of which are expressed in melanoma cells. Therefore, the
effects of DEK on MCL-1 transcription may serve to compensate
for negative regulatory signals intrinsically expressed in melanoma
cells. Furthermore, we and others have shown that MCL-1 is
essential for long-term survival of melanoma cells, and it is a
main determinant of their resistance to dacarbazine, BH3
mimetics, and inhibitors of MEK or the proteasome (6, 44, 49).
MCL-1 can also control melanoma cell survival under conditions of
anoikis (50). Thus, enhanced MCL-1 expression caused by DEK
overexpression may represent a major mechanism of melanoma
cell survival in response to chemotherapeutic agents and other
stress-inducing factors.
In conclusion, our results implicate overexpression of the 6p pro-
oncogene DEK as an extremely frequent event in metastatic
melanomas. Remarkably, this single event can have a dual effect on
melanoma cell proliferation and chemoresistance (preventing
senescence and inducing the antiapoptotic MCL-1, respectively).
Therefore, our results suggest that DEK may be a relevant target for
therapeutic intervention in this aggressive disease.
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SUMMARY
Inappropriate drug delivery, secondary toxicities, and persistent chemo- and immunoresistance have tradi-
tionally compromised treatment response in melanoma. Using cellular systems and genetically engineered
mouse models, we show that melanoma cells retain an innate ability to recognize cytosolic double-stranded
RNA (dsRNA) and mount persistent stress response programs able to block tumor growth, even in highly
immunosuppressed backgrounds. The dsRNA mimic polyinosine-polycytidylic acid, coadministered with
polyethyleneimine as carrier, was identified as an unanticipated inducer of autophagy downstream of an
exacerbated endosomal maturation program. A concurrent activity of the dsRNA helicase MDA-5 driving
the proapoptotic protein NOXA resulted in an efficient autodigestion of melanoma cells. These results reveal
tractable links for therapeutic intervention among dsRNA helicases, endo/lysosomes, and apoptotic factors.
INTRODUCTION
Melanoma remains a prototype of solid cancers with increasing
incidence and extremely poor prognosis at advanced stages
(Jemal et al., 2008). Considerable effort has been devoted to
the identification of molecular determinants underlying mela-
noma chemo- and immunoresistance (Chin et al., 2006; Gray-
Schopfer et al., 2007). Still, the average survival of patients
with inoperable disseminated metastases is less than 10 months
(Tawbi and Kirkwood, 2007). High throughput histogenetic and
functional studies have revealed complex mechanisms associ-
ated with treatment failure (Fecher et al., 2008). These range
from increased expression of drug pumps and detoxification
enzymes to a pleiotropic potentiation of key survival pathways
(Fecher et al., 2008; Gray-Schopfer et al., 2007; Soengas and
Lowe, 2003). In addition, apoptotic programs involving the mito-
chondria, the endoplasmic reticulum, or death receptors are
invariably ineffective in vivo (Hersey and Zhang, 2008; Soengas
and Lowe, 2003). Consequently, current anticancer drugs either
do not reach their target(s) in a productive manner or have to be
SIGNIFICANCE
Melanoma cells accumulate multiple genetic and epigenetic alterations. Still, they still remain highly sensitive to dsRNA
mimics, shown here for the synthetic molecule pIC. However, the delivery vehicle is critical. PEI, a polycation that favors
endosomal uptake and cytosolic release, was able to shift the mode of action of pIC from a transient innocuous transcrip-
tional program to persistent cycles of fusion events involving a sequential recruitment of Rab7 (a small GTPase), LC3
(autophagosome marker), and lysosomes. A convergent mechanism of cellular stress was found driven by MDA-5 and
involving an efficient NOXA-dependent caspase activation. Selective antitumor activity of [pIC]PEI in vivo further supports
cytosolic dsRNA sensors as viable targets for drug development in melanoma.
Cancer Cell 16, 103–114, August 4, 2009 ª2009 Elsevier Inc. 103
Cancer Cell
Article
Targeted Activation of Innate Immunity
for Therapeutic Induction of Autophagy
and Apoptosis in Melanoma Cells
Damia` Tormo,1 Agnieszka Che˛cin´ska,1 Direna Alonso-Curbelo,1 Eva Pe´rez-Guijarro,1 Estela Can˜o´n,1
Erica Riveiro-Falkenbach,1 Tonantzin G. Calvo,1 Lionel Larribere,1 Diego Megı´as,2 Francisca Mulero,3
Miguel A. Piris,4 Rupesh Dash,5 Paola M. Barral,5 Jose´ L. Rodrı´guez-Peralto,6 Pablo Ortiz-Romero,6
Thomas Tu¨ting,7 Paul B. Fisher,5 and Marı´a S. Soengas1,*
1Melanoma Laboratory, Molecular Pathology Programme
2Confocal Microscopy and Cytometry Unit
3Molecular Imaging Unit
4Lymphoma Laboratory
Spanish National Cancer Research Centre (CNIO), Madrid 28049, Spain
5Department of Human and Molecular Genetics, VCU Institute of Molecular Medicine and VCU Massey Cancer Center,
Virginia Commonwealth University, School of Medicine, Richmond, VA 23298-0033, USA
6Hospital Universitario 12 de Octubre, Madrid 28041, Spain
7Laboratory of Experimental Dermatology, Department of Dermatology, University of Bonn, 53105 Bonn, Germany
*Correspondence: msoengas@cnio.es
DOI 10.1016/j.ccr.2009.07.004
SUMMARY
Inappropriate drug delivery, secondary toxicities, and persistent chemo- and immunoresistance have tradi-
tionally compromised treatment response in melanoma. Using cellular systems and genetically engineered
mouse models, we show that melanoma cells retain an innate ability to recognize cytosolic double-stranded
RNA (dsRNA) and mount persistent stress response programs able to block tumor growth, even in highly
immunosuppressed backgrounds. The dsRNA mimic polyinosine-polycytidylic acid, coadministered with
polyethyleneimine as carrier, was identified as an unanticipated inducer of autophagy downstream of an
exacerbated endosomal maturation program. A concurrent activity of the dsRNA helicase MDA-5 driving
the proapoptotic protein NOXA resulted in an efficient autodigestion of melanoma cells. These results reveal
tractable links for therapeutic intervention among dsRNA helicases, endo/lysosomes, and apoptotic factors.
INTRODUCTION
Melanoma remains a prototype of solid cancers with increasing
incidence and extremely poor prognosis at advanced stages
(Jemal et al., 2008). Considerable effort has been devoted to
the identification of molecular determinants underlying mela-
noma chemo- and immunoresistance (Chin et al., 2006; Gray-
Schopfer et al., 2007). Still, the average survival of patients
with inoperable disseminated metastases is less than 10 months
(Tawbi and Kirkwood, 2007). High throughput histogenetic and
functional studies have revealed complex mechanisms associ-
ated with treatment failure (Fecher et al., 2008). These range
from increased expression of drug pumps and detoxification
enzymes to a pleiotropic potentiation of key survival pathways
(Fecher et al., 2008; Gray-Schopfer et al., 2007; Soengas and
Lowe, 2003). In addition, apoptotic programs involving the mito-
chondria, the endoplasmic reticulum, or death receptors are
invariably ineffective in vivo (Hersey and Zhang, 2008; Soengas
and Lowe, 2003). Consequently, current anticancer drugs either
do not reach their target(s) in a productive manner or have to be
SIGNIFICANCE
Melanoma cells accumulate multiple genetic and epigenetic alterations. Still, they still remain highly sensitive to dsRNA
mimics, shown here for the synthetic molecule pIC. However, the delivery vehicle is critical. PEI, a polycation that favors
endosomal uptake and cytosolic release, was able to shift the mode of action of pIC from a transient innocuous transcrip-
tional program to persistent cycles of fusion events involving a sequential recruitment of Rab7 (a small GTPase), LC3
(autophagosome marker), and lysosomes. A convergent mechanism of cellular stress was found driven by MDA-5 and
involving an efficient NOXA-dependent caspase activation. Selective antitumor activity of [pIC]PEI in vivo further supports
cytosolic dsRNA sensors as viable targets for drug development in melanoma.
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administered at dosing schedules that result in unbearable toxic-
ities to normal cellular compartments (Tawbi and Kirkwood,
2007). Similarly, melanomas have an inherent ability to bypass
or overcome antitumoral activities of immunomodulators (Ilko-
vitch and Lopez, 2008; Tormo et al., 2006; Verma et al., 2008).
Autophagy, and in particular macroautophagy, which involves
the sequestration of bulk cytosolic components in autophago-
somes for subsequent lysosomal degradation (Xie and Klionsky,
2007), is an understudied process inmelanoma. The clinical rele-
vance of macroautophagy (herein referred to as autophagy for
simplicity) stems from its potential to protect cells against
a variety of intracellular and extracellular stress signals and favor
tumor development (Mathew et al., 2009; Mizushima et al.,
2008). Paradoxically, autophagy has also been associated with
cell death (Kroemer et al., 2009). Thus, excessive or persistent
autophagy can promote cell killing by depletion of key organelles
(e.g., endoplasmic reticulum or mitochondria), rewiring of
survival signals, deregulation of lysosomal enzymes, and/or acti-
vation of caspase-dependent apoptotic programs (Eisenberg-
Lerner et al., 2009; Hoyer-Hansen and Jaattela, 2008; Maiuri
et al., 2007; Xie and Klionsky, 2007). Given these pro- and anti-
apoptotic roles of autophagy, it is unclear whether this program
could be a viable target for drug development (Kroemer and
Levine, 2008; Rubinsztein et al., 2007; Scarlatti et al., 2009).
Autophagy genes can also have pleiotropic roles in the
immune system (Virgin and Levine, 2009). Thus, autophagy
can modulate antigen presentation, inhibit or potentiate inter-
feron responses, and display critical functions in the clearance
of intracellular viral and bacterial pathogens (Levine and Deretic,
2007; Sanjuan and Green, 2008). Typically, these responses are
engaged to protect infected cells or the host (Virgin and Levine,
2009). The precise mechanisms underlying this immune autoph-
agy are not well defined. Membrane-bound pattern recognition
receptors of the Toll-like receptor (TLR) family (particularly
TLR-3, TLR-4, and TLR-7) can favor pathogen sequestration
in autophagosomes (Delgado and Deretic, 2009; Levine and
Deretic, 2007). These TLRs have a restricted expression pattern,
being enriched in cells of the immune system, such as macro-
phages and dendritic cells (Paulos et al., 2007; Wenzel et al.,
2008). Whether melanoma cells have other sensors of viral path-
ogens that can be engaged to induce autophagy and cell death is
unknown.
Here, we have assessed the interplay between autophagy and
apoptosis in the context of tumor cell-selective elimination of
melanoma cells.
RESULTS
Identification of Autophagosome Inducers
in Melanoma Cells
Melanoma cells stably expressing the autophagosome marker
LC3 fused with GFP (Klionsky et al., 2008) were used to screen
for autophagy inducers among commercially available chemo-
therapeutic drugs and immunomodulators. To improve intracel-
lular delivery, cationic carriers, e.g., polyethyleneimine (PEI),
were added to DNA- or RNA-based agents (Bieber et al.,
2002). The initial screen was performed with the SK-Mel-103
cell line. Subsequent validation studies were performed using a
panel of nine human metastatic melanoma cell lines of diverse
genetic background (see Table S1 available online), as well as
the well-known B16 mouse melanoma cells. Primary skin mela-
nocytes, keratinocytes, and fibroblasts were included as con-
trols for normal cells. We also tested drug response in mouse
embryonic fibroblasts (MEFs) expressing or deficient for the
autophagy factor Atg5 to provide a genetically controlled model
to assess classical autophagy programs (Salazar et al., 2009).
Multiple drugs were found to promote focal GFP-LC3 fluores-
cence emission without significantly affecting cell viability (A.C.
and M.S.S., unpublished data). Among prodeath agents, the
classical double-stranded RNA (dsRNA) mimic polyinosine-pol-
ycytidylic acid (pIC; Wenzel et al., 2008) complexed with PEI
([pIC]PEI) induced a potent accumulation of GFP-LC3 foci (Fig-
ure 1A). About 50% of cells treated with low doses (0.5–1 mg/
ml) of [pIC]PEI showed GFP-LC3 staining within 2–4 hr. These
results were intriguing as pIC had been linked to autophagy in
immune cells (Delgado et al., 2008), but not in the context of
tumor cell death. Therefore, we focused on the identification of
the cellular machinery that sensed and executed the response
of melanoma cells to [pIC]PEI.
Consistent with autophagy, [pIC]PEI induced electrophoretic
mobility changesof theendogenousLC3,whicharecharacteristic
of lipidation of this protein during autophagy (Figure 1B). [pIC]PEI
also lead to LC3 foci formation in oncogenically transformed
MEFs, an activity that required Atg5 (Figure 1C, upper panels).
In fact, inhibition of LC3 redistribution in Atg5/ cells treated
with [pIC]PEI was as prominent as with rapamycin (Figure 1C),
a classical autophagy inducer (Noda and Ohsumi, 1998).
However, rapamycin and [pIC]PEI were not equivalent. LC3 foci
were transient inmelanoma treatedwith rapamycin, but sustained
with [pIC]PEI (Figure 1D). In addition, rapamycin, but not [pIC]PEI,
inhibited the mTOR pathway as visualized by monitoring the
expression of the phosphorylated S6 kinase (Figure 1E).
Electron microscopy provided independent evidence of auto-
phagosome/autolysosome formation driven by [pIC]PEI. Thus,
large mutivesicular structures (>500 nm diameter; Figure 1Fd)
were found following uptake of [pIC]PEI nanoparticles in mela-
noma cells (Figure 1Fb). This uptake was probably facilitated by
the known activity of PEI to coat geneticmaterial and favor endo-
cytosis (Boussif et al., 1995; Kopatz et al., 2004). Importantly,
neither naked pIC nor PEI alone was able to induce autophago-
some formation (see Figure S1 for representative examples).
Together, these results suggest an mTOR-independent autoph-
agy driven by pIC that requires an appropriate cellular delivery
method.
Selective Melanoma Cell Death after [pIC]PEI -Driven
Autophagy
Notably, in all melanoma cell lines tested in this study, the early
activation of autophagy by [pIC]PEI was invariably followed by
cell death (Figure 1G and Table S1). In contrast, melanocytes
retained their viability and did not display markers of autophagy
(Figures S2A–S2C). Interestingly, although complexed efficiently
with PEI, dsDNA, the immunogenic variant ds-BDNA (Ishii et al.,
2006), or other dsRNA molecules such as pA:U had no obvious
impact on melanoma physiology (Figure S2D and data not
shown). These results are consistent with the known superior
immunomodulatory efficacy of pIC over other dsRNA mimics
(Alexopoulou et al., 2001).
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Inhibition of Metastatic Melanoma Dissemination
by [pIC]PEI in Immunocompetent
and Immunosuppressed Mice
A detailed characterization of themechanism of action of [pIC]PEI
would not be meaningful without significant activity in vivo. To
this end, three tumor models were investigated. First, B16 mela-
noma cells were tested following subcutaneous or intravenous
inoculation in immunocompetent mice. In a second setting,
B16 or SK-Mel-103 cells expressing GFP (to allow for noninva-
sive imaging) were used in a surrogate model of lung metastasis
in SCID beige mice (Figures 2A–2D). These animals lack func-
tional B cells, T cells, and NK cells (Croy and Chapeau, 1990),
representing severely immunocompromised backgrounds,
which can be found in melanoma patients. As summarized in
Figures 2A–2D and Figures S3A–S3C, [pIC]PEI showed a consid-
erably stronger antimelanoma activity than naked pIC in all the
models tested, even in the highly immunosuppressed SCID
beige mice, in which pIC had virtually no effect.
The third system analyzed was the Tyr::NRASQ61K; INK4a/
ARF/ mice. These animals develop melanomas with key
features similar to the human disease (Ackermann et al., 2005).
A
B
D
E
F
G
C Figure 1. Induction of Autophagy by [pIC]PEI
Results in Melanoma Cell Death
(A) Fluorescence imaging of GFP-LC3 distribution in
SK-Mel-103 melanoma cells treated for 6 hr with 1 mg/ml
[pIC]PEI. Cells treated with PEI as single agent are shown
as reference controls.
(B) Changes in the electrophoretic mobility of the endoge-
nous LC3 in SK-Mel-103 treated for the indicated times
with pIC, [pIC]PEI, or vehicle control (PEI).
(C) Visualization of eGFP-LC3 distribution in wild-type or
Atg5/ MEFs treated for 8 hr with 25 nM Rapamycin
(Rap) or 1 mg/ml [pIC]PEI. pIC-treated cells are included
as controls (upper two rows). Bottom panels show quanti-
fication of the percentage of cells with focal GFP-LC3 at
the indicated times after treatment. Error bars correspond
to SEM of three independent experiments.
(D) Differential response of SK-Mel-103 melanoma cells to
rapamycin and [pIC]PEI determined by visualization of LC3-
GFP fluorescence (upper two rows) and bright-field
microscopy imaging (bottom row). Cells treated with
vehicle were included as controls.
(E) Immunoblots of total cell extracts isolated from SK-
Mel-103 cells treated as indicated and probed with anti-
bodies specific for phospho-S6 or tubulin.
(F) Transmission electron micrographs of melanoma cells
treated with [pIC]PEI. Arrows point to conjugates of pIC
and PEI being endocytosed into the treated cells. Note
the large multivesicular structures at late time points after
[pIC]PEI treatment (Fd).
(G) Murine B16 melanoma cells and the indicated human
melanoma cell lines compared for sensitivity to PEI and
pIC as single agents or in combination. Cell death was esti-
mated by trypan blue exclusion 24 and 48 hr after treat-
ment and presented asmeans ± SEMof three independent
experiments.
Here, again, the antitumor activity of [pIC]PEI
was significantly higher than that of pIC, as
determined by quantification of tumor number,
tumor size, metabolic activity, and histological
analyses (Figures 2E–2G and Figure S3D). Of
note, [pIC]PEI prolongs the progression-free survival (Figure 2E)
at dosing schedules without noticeable secondary toxicities
(see below). Together, these results support an efficient and
tumor cell-selective antitumor activity of [pIC]PEI.
Requirement of ATG5 for [pIC]PEI-Mediated Cell Death
Next, we investigated the molecular basis by which [pIC]PEI
mediates self-killing of melanoma cells. Electronic microscopy
(Figure 3A), real-time fluorescence analyses of GFP-LC3 distri-
bution (Movies S1 and S2), and Nomarski interference contrast
microscopy analyses (Movie S3) indicated that melanoma cell
death invariably followed the activation of classical autophago-
cytic vesicles (see Figure S4 for an example). To confirm that au-
tophagy is a key effector of [pIC]PEI action (and not a byproduct
of cellular stress), knockdown of key autophagy genes (Beclin1
and ATG7) was attempted in various melanoma cells. However,
transient or stable knockdown of these genes induced either
cellular senescence or cell death (A.C. and M.S.S., unpublished
data), as described in other systems (Hoyer-Hansen and Jaat-
tela, 2007; Mathew et al., 2009; Miller et al., 2008). This is consis-
tent with a basal rate of autophagy that can be visualized by
Cancer Cell
Endogenous dsRNA Sensors in Anticancer Therapy
Cancer Cell 16, 103–114, August 4, 2009 ª2009 Elsevier Inc. 105
Inhibition of Metastatic Melanoma Dissemination
by [pIC]PEI in Immunocompetent
and Immunosuppressed Mice
A detailed characterization of themechanism of action of [pIC]PEI
would not be meaningful without significant activity in vivo. To
this end, three tumor models were investigated. First, B16 mela-
noma cells were tested following subcutaneous or intravenous
inoculation in immunocompetent mice. In a second setting,
B16 or SK-Mel-103 cells expressing GFP (to allow for noninva-
sive imaging) were used in a surrogate model of lung metastasis
in SCID beige mice (Figures 2A–2D). These animals lack func-
tional B cells, T cells, and NK cells (Croy and Chapeau, 1990),
representing severely immunocompromised backgrounds,
which can be found in melanoma patients. As summarized in
Figures 2A–2D and Figures S3A–S3C, [pIC]PEI showed a consid-
erably stronger antimelanoma activity than naked pIC in all the
models tested, even in the highly immunosuppressed SCID
beige mice, in which pIC had virtually no effect.
The third system analyzed was the Tyr::NRASQ61K; INK4a/
ARF/ mice. These animals develop melanomas with key
features similar to the human disease (Ackermann et al., 2005).
A
B
D
E
F
G
C Figure 1. Induction of Autophagy by [pIC]PEI
Results in Melanoma Cell Death
(A) Fluorescence imaging of GFP-LC3 distribution in
SK-Mel-103 melanoma cells treated for 6 hr with 1 mg/ml
[pIC]PEI. Cells treated with PEI as single agent are shown
as reference controls.
(B) Changes in the electrophoretic mobility of the endoge-
nous LC3 in SK-Mel-103 treated for the indicated times
with pIC, [pIC]PEI, or vehicle control (PEI).
(C) Visualization of eGFP-LC3 distribution in wild-type or
Atg5/ MEFs treated for 8 hr with 25 nM Rapamycin
(Rap) or 1 mg/ml [pIC]PEI. pIC-treated cells are included
as controls (upper two rows). Bottom panels show quanti-
fication of the percentage of cells with focal GFP-LC3 at
the indicated times after treatment. Error bars correspond
to SEM of three independent experiments.
(D) Differential response of SK-Mel-103 melanoma cells to
rapamycin and [pIC]PEI determined by visualization of LC3-
GFP fluorescence (upper two rows) and bright-field
microscopy imaging (bottom row). Cells treated with
vehicle were included as controls.
(E) Immunoblots of total cell extracts isolated from SK-
Mel-103 cells treated as indicated and probed with anti-
bodies specific for phospho-S6 or tubulin.
(F) Transmission electron micrographs of melanoma cells
treated with [pIC]PEI. Arrows point to conjugates of pIC
and PEI being endocytosed into the treated cells. Note
the large multivesicular structures at late time points after
[pIC]PEI treatment (Fd).
(G) Murine B16 melanoma cells and the indicated human
melanoma cell lines compared for sensitivity to PEI and
pIC as single agents or in combination. Cell death was esti-
mated by trypan blue exclusion 24 and 48 hr after treat-
ment and presented asmeans ± SEMof three independent
experiments.
Here, again, the antitumor activity of [pIC]PEI
was significantly higher than that of pIC, as
determined by quantification of tumor number,
tumor size, metabolic activity, and histological
analyses (Figures 2E–2G and Figure S3D). Of
note, [pIC]PEI prolongs the progression-free survival (Figure 2E)
at dosing schedules without noticeable secondary toxicities
(see below). Together, these results support an efficient and
tumor cell-selective antitumor activity of [pIC]PEI.
Requirement of ATG5 for [pIC]PEI-Mediated Cell Death
Next, we investigated the molecular basis by which [pIC]PEI
mediates self-killing of melanoma cells. Electronic microscopy
(Figure 3A), real-time fluorescence analyses of GFP-LC3 distri-
bution (Movies S1 and S2), and Nomarski interference contrast
microscopy analyses (Movie S3) indicated that melanoma cell
death invariably followed the activation of classical autophago-
cytic vesicles (see Figure S4 for an example). To confirm that au-
tophagy is a key effector of [pIC]PEI action (and not a byproduct
of cellular stress), knockdown of key autophagy genes (Beclin1
and ATG7) was attempted in various melanoma cells. However,
transient or stable knockdown of these genes induced either
cellular senescence or cell death (A.C. and M.S.S., unpublished
data), as described in other systems (Hoyer-Hansen and Jaat-
tela, 2007; Mathew et al., 2009; Miller et al., 2008). This is consis-
tent with a basal rate of autophagy that can be visualized by
Cancer Cell
Endogenous dsRNA Sensors in Anticancer Therapy
Cancer Cell 16, 103–114, August 4, 2009 ª2009 Elsevier Inc. 105
monitoring LC3-GFP dynamics in untreatedmelanoma cells (see
Movie S1). Therefore, to avoid confounding results of testing
drug response in cells whose proliferative capacity and viability
is already severely compromised, [pIC]PEI-driven cell death
was determined in transformed wild-type and Atg5/ MEFs.
Although oncogenically transformed wild-type MEFs were less
sensitive to [pIC]PEI-mediated death than melanoma cells, they
were significantly more sensitive than their Atg5/ counterparts
(Figure 3B). However, it should be noted that Atg5/-trans-
formed MEFs died efficiently at high doses of [pIC]
PEI
(>1 mg/ml;
not shown), perhaps reflecting the dual roles of autophagy in
cell survival and cell death, as in immune cells (Virgin and Levine,
2009).
Requirement of Autophagosome-Lysosome Fusion
in [pIC]PEI -Mediated Cell Death
As indicated above, a defining ultrastructural feature of [pIC]PEI
treatment is the induction of large multivesicular structures
(Figure 1Fd). These vesicles could result from halted autophago-
somes in which lysosomes are either not recruited or dysfunc-
tional (Amaravadi et al., 2007; Ostenfeld et al., 2008). In this
scenario, autophagosomeswould grow in size as a consequence
of accumulation of improperly degraded material. Alternatively,
these vesicles could correspond to homotypic fusions among
large endosomes, subsequently recruiting multiple autophago-
somes (to generate hybrid structures, also referred to as amphi-
somes). To assess these possibilities, we transduced melanoma
cells with Cherry-GFP-LC3, which displays dual red-green fluo-
rescence in autophagosomes but loses GFP signal in the acidic
environment of autolysosomes (Tasdemir et al., 2008). We found
that [pIC]PEI, similar to rapamycin, induced autolysosomes in
melanoma cells (see ‘‘red-only’’ LC3 foci in Figure 3C). Support-
ing a lysosomal-dependent mode of action of [pIC]PEI, transient
treatment with the lysosomotropic agent chloroquine protected
melanoma cells against [pIC]PEI-driven cell death (Figure 3D),
without affecting the endosomal uptake of this dsRNA mimic
(as determined by colocalization of FluoRed-labeled [pIC]PEI
with GFP-fused early endosomal protein Rab5; Figure 3E).
Similar inhibitory effects were observed using the broad spec-
trum protease inhibitors E64d and pepstatin A and the vacuolar
ATPase blocker bafilomycin (Figure 3D).
To independently monitor lysosomal activity during [pIC]PEI
treatment, we assayed cells for the ability to process DQ-BSA
(a derivative of BSA whose green fluorescence is quenched
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Figure 2. Antimelanoma Activity of [pIC]PEI in
Mice
(A)–(D) are results from SCID Beige mice; (E)–(G) are
results from Tyr::RasQ61K 3 Ink4a/Arf/ mice.
(A) Representative images of lungs of mice 14 days
after intravenous inoculation of B16 melanoma cells
and treatment as indicated and photographed under
visible (Macro) or fluorescent (eGFP) light.
(B) Representation of the mean number of metastases
(±SEM) induced by B16 as indicated in (A). *p < 0.01
between PEI or pIC and [pIC]PEI treatment groups
(n = 5; generalized Mann-Whitney test).
(C) Lung colonization by eGFP-SK-Mel-103 in SCID
beige mice treated with the indicated agents and
assessed by fluorescence imaging and histological
analyses.
(D) Quantification of average number of external lung
nodules (±SEM) in the indicated treatment groups
shown in (C). *p < 0.01 between PEI, pIC, and [pIC]PEI
treatment groups (n = 5; generalized Mann-Whitney
test).
(E) Cohorts of Tyr::RasQ61K x Ink4a/Arf/ mice were
treated topically with a single dose of 200 mg DMBA
at 8 weeks of age. Upon appearance of pigmented
lesions of >1 mm diameter, mice were treated as indi-
cated. Control groups received PEI in 5%glucose. The
fraction of animals with tumors of <1mm diameter
(progression free survival) was represented by Kaplan-
Meier graphs.
(F) Average number of cutaneous melanocytic
neoplasms developing in each of the different treat-
ment groups. Scoring was performed every 5 days
and tumors were grouped by size as indicated.
(G) Representative transverse (left panels) and coronal
sections (right panels) of PET /CT fused images to
assess metabolic activity (18F-FDG incorporation) of
representative examples of mice treated as indicated.
Tumors are encircled with white dashed lines. The
asterisks mark animal hearts.
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monitoring LC3-GFP dynamics in untreatedmelanoma cells (see
Movie S1). Therefore, to avoid confounding results of testing
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with GFP-fused early endosomal protein Rab5; Figure 3E).
Similar inhibitory effects were observed using the broad spec-
trum protease inhibitors E64d and pepstatin A and the vacuolar
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lesions of >1 mm diameter, mice were treated as indi-
cated. Control groups received PEI in 5%glucose. The
fraction of animals with tumors of <1mm diameter
(progression free survival) was represented by Kaplan-
Meier graphs.
(F) Average number of cutaneous melanocytic
neoplasms developing in each of the different treat-
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(G) Representative transverse (left panels) and coronal
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unless cleaved by proteolytic enzymes). As shown in Figures 3F
and 3G, DQ-BSA was efficiently cleaved in the presence of
[pIC]PEI (note that DQ-BSA emission was detected at the lyso-
somes, as indicated by colocalization with Lysotracker red).
Dynamic Endosome Mobilization by [pIC]PEI
Having determined that autophagosomes fuse to active lyso-
somes in response to [pIC]PEI, we assessedwhether these organ-
elles interactedwith or were recruited to endosomes. First, endo-
somal dynamics were assessed in melanoma cells expressing
GFP fused to the late endosomal marker Rab7 (Luzio et al.,
2007). Basal endosome generation and resolution (i.e., progres-
sive reduction in size) was detected in untreated melanoma cells
(Figure S5, right panels; and Movie S4). [pIC]PEI treatment mark-
edly enhanced endosomal activity, inducing a sustained and
multiwave generation of endosomes (Figure S5, left panels;
and Movie S5). These endosomes were found to be filled with
lysosomes, as determined by dual imaging of GFP-Rab7 and
Lysotracker red (Figure 4A). Moreover, time-lapse microscopy
revealed fast kinetics of multiple recruitments of lysosomes to
GFP-Rab7-decorated endosomes (Movie S7; see also a sequen-
tial series of fusion events in Figure 4B). Importantly, as shown in
Figure 4A (right panels), endosome-lysosome fusion was signifi-
cantly inhibited if cellsoverexpressedRab7-T22N,aknowndomi-
nant-negative mutant of this protein (Gutierrez et al., 2004). In
total, these results uncovered a dynamic mobilization of endo/
lysosomal compartments in tumor cells treated with [pIC]PEI.
Generation and Resolution of [pIC]PEI-Driven
Amphisome Formation
To determine whether and when autophagosomes are recruited
to endosomes, we imaged melanoma cells simultaneously for
GFP-Rab7, Cherry-LC3, and Lysotracker blue at different time
points after [pIC]PEI addition. As shown in Figure 4C and
Figure S6A, the first event detected was generally the incorpora-
tion of Rab7 to the membrane of preexisting ‘‘empty’’ (early-
endosome) vesicles. LC3 was recruited afterwards usually start-
ing from an initial nucleation event, to ultimately decorate the
entire Rab7-positive vesicles. Lysotracker blue incorporation
into these endosome/autophagosome hybrids (amphisomes)
was found to be the last to occur. At this point, the corresponding
vesicle progressively diminished in size to ultimately become
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Figure 3. [pIC]PEI-Triggered Melanoma Cell Death
Is Driven by Autophagosome-Autolysosome
Formation
(A) Representative bright field (left and middle panels) and
electron microscope (right panel) micrographs of SK-Mel-
103 treated as indicated (30 hr).
(B) Transformed wild-type or Atg5/ MEFs treated with
low dose (0.2 mg/ml) of [pIC]PEI or control. Cell death was
estimated by trypan blue exclusion 48 hr after treatment
and presented as means of three independent experi-
ments.
(C) Confocal fluorescence images of SK-Mel-103 trans-
duced with Cherry-GFP-LC3 to detect autophagosomes
(red and green foci) and autolysosomes (red-only foci) after
treatment with [pIC]PEI, 25 nM Rapamycin (Rap), or solvent
control.
(D) Inhibitory effect of 100 mM bafilomycin (Bafil), 20 mM
chloroquine (Chlor), or 10 mg/ml pepstatin (PEP) on cell
death estimated by trypan blue exclusion 20 hr after treat-
ment with vehicle (white bars) or [pIC]PEI (black bars). Data
are indicated asmeans ± SEM of three independent exper-
iments.
(E) Confocal fluorescence images of SK-Mel-103 cells
stably transfected with eGFP-Rab5 and incubated with
[pIC]PEI labeled with FluoRed. Shown is the internalization
of [pIC]PEI by the melanoma cells in the presence or
absence of chloroquine.
(F) Confocal visualization of lysosomal-dependent proteol-
ysis upon cleavage and release of the fluorescent moiety of
DQ-BSA (green) in control or [pIC]PEI-treated SK-Mel-103.
Chloroquine is included to monitor DQ-BSA emission in
cells with blocked lysosomal activity. Cells were simulta-
neously imaged in the presence of Lysotracker red (LTR-
red) to visualize the lysosomal compartment.
(G) The DQ-BSA-Lysotracker colocalizationwas estimated
in a minimum of 150 cells in two independent experiments,
and it is expressed (as arbitrary fluorescence units) with
respect to control treated cells. Error bars correspond
to SEM.
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unless cleaved by proteolytic enzymes). As shown in Figures 3F
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tial series of fusion events in Figure 4B). Importantly, as shown in
Figure 4A (right panels), endosome-lysosome fusion was signifi-
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total, these results uncovered a dynamic mobilization of endo/
lysosomal compartments in tumor cells treated with [pIC]PEI.
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ing from an initial nucleation event, to ultimately decorate the
entire Rab7-positive vesicles. Lysotracker blue incorporation
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respect to control treated cells. Error bars correspond
to SEM.
Cancer Cell
Endogenous dsRNA Sensors in Anticancer Therapy
Cancer Cell 16, 103–114, August 4, 2009 ª2009 Elsevier Inc. 107
undetectable, indicating a bona fide autodegradative process
(Figure 4C and Figure S6, see arrows marking the Rab7 > LC3 >
Lysotracker sequence). The presence of Lysotracker did not
interfere with endosomal dynamics, as similar progressive
recruitment and internalization of LC3 to Rab7 endosomes was
found in its absence (Figure 4D).
[pIC]PEI Links Autophagy to Apoptotic Caspases
Notably, the sequential fusion events mentioned above for
a single vesicle were found to involve large numbers of endo-
somes and occur in a persistent manner throughout the entire
cytosol of treated cells (Figure S6). This was independent of
the imaging reagents used (see examples of cells imaged with
Lysotracker blue in Figure S6A or Lysotracker red in
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Figure 4. Generation and Resolution of Am-
phisomes upon [pIC]PEI Treatment
(A) SK-Mel-103 cells stably transfected with eGFP-
Rab7 wild-type or eGFP-Rab7 T22N were incu-
bated with [pIC]PEI for visualization of Rab7 (green
fluorescence) and Lysotracker red. Microphoto-
graphs were captured by confocal microscopy
10 hr after treatment with [pIC]PEI. Values in insets
correspond to the average area contained in
Rab7-decorated vesicles.
(B) Sequence of confocal microphotographs taken
at the indicated time intervals (in seconds) to illus-
trate the fusion to and incorporation of lysosomes
to Rab7-positive vesicles upon [pIC]PEI treatment.
(C) Real-time triple-imaging fluorescence micros-
copy of GFP-Rab7 wild-type, Cherry-LC3, and
Lysotracker blue (green, red, and blue fluores-
cence, respectively) in SK-Mel-103 cells treated
with [pIC]PEI. Images were taken at the indicated
time intervals (in minutes), 1 hr after treatment initi-
ation. Arrows mark the first sequence in which the
indicated markers appear visible.
(D) Incorporation of LC3 to the surface of Rab7
endosomal vesicles prior to internalization and
subsequent degradation. These endosome/LC3
hybrid structures (amphisomes) were visualized
by fluorescence real-time microscopy of SK-Mel-
103 cells expressing eGFP-Rab7 wild-type and
Cherry-LC3.
FigureS6B). Still, we foundaconsiderable
delay from the starting point of endosome
mobilization (2–5 hr), until final cellular
collapse (24–48 hr). Thus, we hypothe-
sized that cell demise required an addi-
tional, later event. Interestingly, cleaved
regulatory and effector caspases (casp-
8, 9, 7, and 3) were detected 15–20 hr
after [pIC]PEI treatment (Figure S7A).
Accordingly, caspase inhibitors (zVAD-
fmk, and to a lesser extent DEVD-CHO)
reduced [pIC]PEI-driven cell death (Fig-
ure S7B). Similarly, the sensitivity of
MEFs to [pIC]PEI was significantly reduced
in cells deficient for the apoptotic factors
Bax and Bak (Figure S7C, left panels).
Importantly, neither caspase inactivation
in melanoma cells nor BAX/BAK deficiency in MEFs prevented
the generation of GFP-LC3 foci (Figures S7B and S7C). Therefore,
[pIC]PEI is able to induce an early but persistent autophagy and
a late apoptotic program. This is in contrast to other systems
where caspases are the initiating death signals and autophagy
is induced to favor the clearance of partially degraded cytosolic
components (Kroemer and Levine, 2008).
Differential Gene Expression Induced by Naked
and PEI-Complexed pIC in Melanoma Cells
Next, we investigated the molecular sensor(s) of [pIC]PEI that
might link autophagy to apoptosis in a tumor cell-selective
manner. Using cDNA arrays, we found melanocytes to undergo
minimal changes in gene expression at early or late time points
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[pIC]PEI is able to induce an early but persistent autophagy and
a late apoptotic program. This is in contrast to other systems
where caspases are the initiating death signals and autophagy
is induced to favor the clearance of partially degraded cytosolic
components (Kroemer and Levine, 2008).
Differential Gene Expression Induced by Naked
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Next, we investigated the molecular sensor(s) of [pIC]PEI that
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manner. Using cDNA arrays, we found melanocytes to undergo
minimal changes in gene expression at early or late time points
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after treatment with pIC or [pIC]PEI. In contrast, melanoma cells
responded to both agents with substantial alterations of their
transcriptome (Figure S8A). Interestingly, while pIC induced
expected changes in interferon response genes, this response
was largely transient. In contrast, the effect of [pIC]PEI was sus-
tained and extended to additional transcripts (Figures S8A and
S8B). These results reveal key idiosyncratic differences between
melanocytes and melanoma cells regarding the uptake and
signaling to dsRNA mimics.
Qualitatively Different Activation of MDA-5 by pIC
in the Absence and Presence of PEI
The best known innate programs that control the sensing of long
dsRNA are (1) the Toll-like receptor 3, (2) the melanoma differen-
tiation-associated gene-5 (MDA-5)/interferon induced with heli-
case C domain 1 protein (IFIH1), and (3) the dsRNA-activated
protein kinase (PKR, also known as eIF2AK2) (Takeuchi and
Akira, 2008). Of these genes, MDA-5 showed the strongest
and most sustained induction by [pIC]PEI (Figure 5A). Moreover,
knockdown of TLR3 with independent siRNA or shRNA had no
impact on [pIC]PEI-driven cell death (Figure 5B). Therefore, we
focused on MDA-5 for further analyses. Protein immunoblotting
demonstrated a sustained activation of full-length MDA-5 by
[pIC]PEI (Figure 5C). In addition, an apoptosis-associated pro-
cessing of MDA-5 (Barral et al., 2007; Kovacsovics et al., 2002)
was found preferentially (and in a more sustained manner) in
[pIC]PEI-treated cells (Figure 5C). Of note, this induction and pro-
cessing of MDA-5 was not simply a consequence of activated
apoptotic programs. Treatment with bortezomib, a proteasome
inhibitor that engages intrinsic apoptotic pathways in melanoma
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Figure 5. MDA-5 Is a Sensor and Driver of
[pIC]PEI Cytotoxicity in Melanoma Cells
(A) Fold induction of the transcript levels of the
indicated pathogen-associated receptors relative
to nontreated cells. The IFIT-1 gene was used as
a reference for a classical IFN-responsive factor.
(B) Inhibition of TLR-3 expression by transient
transduction of siRNA (left panels) or stable infec-
tionwith lentivirus coding for shTLR3 (right panels).
Cell death was assessed by trypan blue exclusion
after treatment with vehicle (white bars) or [pIC]PEI
(black bars). Insets correspond to mRNA levels
detected by RT-PCR. Data are shown as means ±
SEM of three independent experiments.
(C) MDA-5 induction visualized by immunoblotting
in SK-Mel-28 and SK-Mel-147 treated with PEI,
pIC, or [pIC]PEI. Bortezomib was used as a control
for an effective death inducer. Full-length and
cleaved MDA-5 (MDA-5FL and MDA-5C, respec-
tively) are indicated with arrows. Asterisk corre-
sponds to a nonspecific band (not blocked by
MDA-5 shRNA; not shown).
(D) MDA-5 mRNA levels (left panel) and cell death
(right panels) in SK-Mel-103 infected with the
pLKO lentivirus expressing scrambled or MDA-5
shRNAs and treated as indicated. Data are shown
as means ± SEM of three independent experi-
ments. p < 0.05 between control and shMDA-5
cells in the presence of [pIC]PEI (two-tailed
Student’s t test).
(E) Inhibition of MDA-5 expression by transient
transduction of a second set of control and
MDA-5 siRNAs driven by the psi-vector frame
(see Experimental Procedures). Cell death in
control and [pIC]PEI-treated SK-Mel-103 (24 hr)
was determined by trypan blue exclusion and
plotted as means ± SEM of three independent
experiments. In the [pIC]PEI treatment group, p <
0.05 between control shRNA and shMDA-5-trans-
duced cells (two-tailed Student’s t test).
(F) Confocal visualization of GFP-LC3 in MeWo
melanoma cells infected with adenovirus control
or adenovirus MDA-5. [pIC]PEI was included as a
reference for autophagosome formation. Numbers
represent fraction of cells with eGFP-LC3 foci.
(G) Cell death resulting from adenovirus-driven
expression of MDA-5 in MeWo cells. The viral
concentration (in plate forming units [pfu]) is indi-
cated. Data correspond to means ± SEM of three
independent experiments.
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experiments. In the [pIC]PEI treatment group, p <
0.05 between control shRNA and shMDA-5-trans-
duced cells (two-tailed Student’s t test).
(F) Confocal visualization of GFP-LC3 in MeWo
melanoma cells infected with adenovirus control
or adenovirus MDA-5. [pIC]PEI was included as a
reference for autophagosome formation. Numbers
represent fraction of cells with eGFP-LC3 foci.
(G) Cell death resulting from adenovirus-driven
expression of MDA-5 in MeWo cells. The viral
concentration (in plate forming units [pfu]) is indi-
cated. Data correspond to means ± SEM of three
independent experiments.
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(Fernandez et al., 2005; Wolter et al., 2007), had no effect on
MDA-5 levels or processing (Figure 5C).
Downregulation of MDA-5 expression by siRNA (Figure 5D) or
shRNA (Figure 5E) reduced [pIC]PEI-driven cell death by 50%–
60%, providing evidence for a critical role of MDA-5 as sensor
and effector of this dsRNA mimic. Interestingly, although MDA-
5 needs interaction with dsRNA for full activation (Takeuchi and
Akira, 2008), ectopic expression of this protein is sufficient to
promote cell death in a subset of melanoma cells (e.g., MeWo
[Kang et al., 2004, 2002]). In these cells, MDA-5 was also found
to engage focal aggregation of LC3 (Figure 5F) prior to cell killing
(Figure 5G and data not shown). These results uncover a proau-
tophagy role of MDA-5. However, although MDA-5 may favor
autophagy, it is unlikely that this is the sole contribution of this
protein to [pIC]PEI-mediated cell death. Thus, MDA5-shRNA or
Mda-5/ MEFs could still engage autophagosome formation
after sustained treatment with [pIC]PEI (data not shown).
MDA-5-Driven NOXA-Dependent Cell Death
A main known role of endogenous MDA-5 is to elicit IFN
responses to blunt viral infection (Takeuchi and Akira, 2008).
IFN-a was secreted in [pIC]PEI-treated melanoma cells (data
not shown). However, IFN-a was a poor inducer of melanoma
cell death, even at doses 100 times higher than those secreted
by [pIC]PEI -treated cells (Figure S8C).
cDNAmicroarraydatageneratedabovewasanalyzed to identify
mediators of [pIC]PEI/MDA-5-driven melanoma cell death. Among
known proapoptotic factors, a strong and sustained upregulation
(up to 16-fold) of NOXA mRNA and protein levels was found
(Figures 6A–6D). Moreover, [pIC]PEI-mediated death induction
was reduced by 50%–60% when the NOXA level was reduced
using a shRNA (Figures 6E and 6F). Importantly, [pIC]PEI-driven
NOXA induction was significantly abrogated by MDA-5 shRNA
(Figure 6G). Therefore, these results uncover functional links
between dsRNA sensors and the apoptosis program via NOXA.
Other chemotherapeutic agents such as the proteasome
inhibitor bortezomib can also upregulate NOXA and kill mela-
noma cells deficient for Apaf-1 or other apoptotic modulators
(Fernandez et al., 2005; Qin et al., 2005). However, a main disad-
vantage of bortezomib is that it concomitantly induces various
antiapoptotic factors, including MCL-1, a NOXA antagonist
(Qin et al., 2006; Wolter et al., 2007). In contrast, no compensa-
tory accumulation ofMCL-1 protein was found in the response to
[pIC]PEI (Figures 6C and 6D).
A
C
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F
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D
B Figure 6. [pIC]PEI Engages Apoptosis via NOXA
Independently of the Status of p53 or without
Inducing Compensatory MCL-1 Activation
(A) Heat map of log2 ratio values of the indicated genes
after pIC or [pIC]PEI treatment of SK-Mel-103 and calcu-
lated with respect to control (PEI)-incubated cells.
(B) Immunoblots of total cell extracts isolated from
SK-Mel-103 treated for 24 and 48 hr with pIC, [pIC]PEI, or
Bortezomib for the relative levels of NOXA, p53, and anti-
apoptotic Bcl-2 and Bcl-xL proteins.
(C) SK-Mel-28 and SK-Mel-147 (expressing p53 L145A
and p53 wild-type, respectively) were treated with PEI,
pIC, [pIC]PEI, or 25 nM Bortezomib. Shown are the relative
levels of NOXA and MCL-1 protein at different time points
after treatment.
(D) Quantification of the levels of Mcl-1 and NOXA in
SK-Mel-28 after each treatment and represented with
respect to control untreated cells.
(E) NOXA protein expression in melanoma SK-Mel-103
treated for 24 hr with pIC or [pIC]PEI 2 days after infection
with a lentiviral vector expressing inactive shRNA (sh
Ctrl) or shRNA for NOXA.
(F) Death rates (±SEM) of control and NOXA shRNA trans-
duced SK-Mel-103 melanoma cells and incubated with
pIC or [pIC]PEI for 24 hr.
(G) Inhibitory effect of MDA-5 downregulation on NOXA
induction by [pIC]PEI determined in SK-Mel transduced
with control or MDA5 shRNAs. Data is represented as
means ± SEM of four independent experiments. Levels
of NOXA were quantified by densitometry of the corre-
sponding immunoblots and plotted with respect to
untreated controls.
(H) Immunoblots of total cell extracts isolated from SK-
Mel-103 treated for 24 hr with vehicle or [pIC]PEI in the
presence or absence of chloroquine and probed for the
detection of MDA-5 (full-length and cleaved forms) and
NOXA.
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(Fernandez et al., 2005; Wolter et al., 2007), had no effect on
MDA-5 levels or processing (Figure 5C).
Downregulation of MDA-5 expression by siRNA (Figure 5D) or
shRNA (Figure 5E) reduced [pIC]PEI-driven cell death by 50%–
60%, providing evidence for a critical role of MDA-5 as sensor
and effector of this dsRNA mimic. Interestingly, although MDA-
5 needs interaction with dsRNA for full activation (Takeuchi and
Akira, 2008), ectopic expression of this protein is sufficient to
promote cell death in a subset of melanoma cells (e.g., MeWo
[Kang et al., 2004, 2002]). In these cells, MDA-5 was also found
to engage focal aggregation of LC3 (Figure 5F) prior to cell killing
(Figure 5G and data not shown). These results uncover a proau-
tophagy role of MDA-5. However, although MDA-5 may favor
autophagy, it is unlikely that this is the sole contribution of this
protein to [pIC]PEI-mediated cell death. Thus, MDA5-shRNA or
Mda-5/ MEFs could still engage autophagosome formation
after sustained treatment with [pIC]PEI (data not shown).
MDA-5-Driven NOXA-Dependent Cell Death
A main known role of endogenous MDA-5 is to elicit IFN
responses to blunt viral infection (Takeuchi and Akira, 2008).
IFN-a was secreted in [pIC]PEI-treated melanoma cells (data
not shown). However, IFN-a was a poor inducer of melanoma
cell death, even at doses 100 times higher than those secreted
by [pIC]PEI -treated cells (Figure S8C).
cDNAmicroarraydatageneratedabovewasanalyzed to identify
mediators of [pIC]PEI/MDA-5-driven melanoma cell death. Among
known proapoptotic factors, a strong and sustained upregulation
(up to 16-fold) of NOXA mRNA and protein levels was found
(Figures 6A–6D). Moreover, [pIC]PEI-mediated death induction
was reduced by 50%–60% when the NOXA level was reduced
using a shRNA (Figures 6E and 6F). Importantly, [pIC]PEI-driven
NOXA induction was significantly abrogated by MDA-5 shRNA
(Figure 6G). Therefore, these results uncover functional links
between dsRNA sensors and the apoptosis program via NOXA.
Other chemotherapeutic agents such as the proteasome
inhibitor bortezomib can also upregulate NOXA and kill mela-
noma cells deficient for Apaf-1 or other apoptotic modulators
(Fernandez et al., 2005; Qin et al., 2005). However, a main disad-
vantage of bortezomib is that it concomitantly induces various
antiapoptotic factors, including MCL-1, a NOXA antagonist
(Qin et al., 2006; Wolter et al., 2007). In contrast, no compensa-
tory accumulation ofMCL-1 protein was found in the response to
[pIC]PEI (Figures 6C and 6D).
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after pIC or [pIC]PEI treatment of SK-Mel-103 and calcu-
lated with respect to control (PEI)-incubated cells.
(B) Immunoblots of total cell extracts isolated from
SK-Mel-103 treated for 24 and 48 hr with pIC, [pIC]PEI, or
Bortezomib for the relative levels of NOXA, p53, and anti-
apoptotic Bcl-2 and Bcl-xL proteins.
(C) SK-Mel-28 and SK-Mel-147 (expressing p53 L145A
and p53 wild-type, respectively) were treated with PEI,
pIC, [pIC]PEI, or 25 nM Bortezomib. Shown are the relative
levels of NOXA and MCL-1 protein at different time points
after treatment.
(D) Quantification of the levels of Mcl-1 and NOXA in
SK-Mel-28 after each treatment and represented with
respect to control untreated cells.
(E) NOXA protein expression in melanoma SK-Mel-103
treated for 24 hr with pIC or [pIC]PEI 2 days after infection
with a lentiviral vector expressing inactive shRNA (sh
Ctrl) or shRNA for NOXA.
(F) Death rates (±SEM) of control and NOXA shRNA trans-
duced SK-Mel-103 melanoma cells and incubated with
pIC or [pIC]PEI for 24 hr.
(G) Inhibitory effect of MDA-5 downregulation on NOXA
induction by [pIC]PEI determined in SK-Mel transduced
with control or MDA5 shRNAs. Data is represented as
means ± SEM of four independent experiments. Levels
of NOXA were quantified by densitometry of the corre-
sponding immunoblots and plotted with respect to
untreated controls.
(H) Immunoblots of total cell extracts isolated from SK-
Mel-103 treated for 24 hr with vehicle or [pIC]PEI in the
presence or absence of chloroquine and probed for the
detection of MDA-5 (full-length and cleaved forms) and
NOXA.
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Importantly, the induction of MDA-5 and NOXA by [pIC]PEI was
found to occur even when lysosome activity was blocked by
chloroquine or by cathepsin inhibitors (Figure 6H and Figure S7D
and data not shown). Thus, NOXA can be activated indepen-
dently of the autophagy program. From a therapeutic perspec-
tive, it was interesting to note that cDNA arrays failed to identify
changes in NOXA expression in melanocytes (data not shown).
Similarly, MDA-5 and NOXA were not upregulated in skin fibro-
blasts (Figure S8D), which also showed increased resistance to
[pIC]PEI in culture (Figure S8E) and no obvious signs of toxicity
in biopsies from treated animals (Figure S8F; note also lack of
toxicity to other organs).
[pIC]PEI-Mediated Therapeutic Effects In Vivo: MDA-5
Requirement, LC3 Foci Formation, and NOXA Induction
Next, we investigated the dependency on MDA-5 and the dual
activation of autophagosome and apoptotic markers identified
above by [pIC]PEI in vivo. Available antibodies against MDA-5
cannot distinguish full length from processed forms of this
protein. In the absence of current Mda-5-deficient mouse mela-
noma models, we decided to take advantage of homozygous
knockout MEFs for the Mda-5 gene. As shown in Figure 7A,
transformed Mda-5/ MEFs were significantly more resistant
to [pIC]PEI than their wild-type counterparts, both in tissue
culture systems and when grown as xenografts in mice.
Selective antibodies for LC3 and NOXA were used to visualize
autophagosome formation and activation of NOXA by [pIC]PEI in
human melanoma xenografts. Although sporadic stainings for
LC3 or NOXA were detected in vehicle-treated SK-Mel-103
xenografts, the total number of positive cells and the corre-
sponding signal intensity of NOXA or LC3 per individual cell
were noticeably stronger in the [pIC]PEI-treated specimens
(Figure 7B). The animal model used (SCID beige) is highly immu-
nodeficient. Therefore, these results serve as the proof-of-prin-
ciple for the ability of [pIC]PEI to bypass the requirement for
immune effectors and drive tumor cell death by a coordinated
autophagy/apoptosis mechanism.
DISCUSSION
Melanomas accumulate a plethora of genetic and epigenetic
alterations that contribute to the limited efficacy of current anti-
cancer treatments (Chin et al., 2006; Soengas and Lowe,
2003). However, here we have shown that melanoma cells retain
the ability to sense and respond to mimetics of viral dsRNA and
that this feature can be exploited therapeutically. Specifically,
A
C
B Figure 7. Defining the Mode of Action of
[pIC]PEI In Vivo
(A) Response of oncogenically transformed wild-
type (+/+) or Mda-5/ (/) MEFs, measured as
time-dependent changes in tumor size (±SEM)
upon treatment with naked pIC (V) or [pIC]PEI.
Shown are p values for comparative analyses
between the indicated treatment groups (n = 10,
generalized Mann-Whitney test). Inset bar graphs
corresponds to death rates (±SEM; n = 3) of the
indicated cell populations 24 hr after treatment in
culture with 1 mg/ml [pIC]PEI.
(B) SK-Mel-103 GFP-LC3 melanoma cells
implanted subcutaneously into SCID beige mice
were left to grow to 6–8 mm diameter and then
treated with PEI or [pIC]PEI. Paraffin-embedded
sections were stained for LC3 or NOXA antibodies.
For LC3, high magnification photographs are also
included to show the formation of foci character-
istic of autophagosomes.
(C) Model summarizing main results of this study.
A transient activation of IFN and other antiviral
stress response factors by naked pIC (1) can be
shifted into a sustained stress program when this
dsRNA mimic is delivered to cells with PEI (2).
PEI packs pIC into nanoparticles and favors both
its endosomal uptake and delivery to the cytosol
for subsequent activation of the helicase MDA-5
(3). In addition to favor endosomal swelling, PEI
has been described to favor endosome-endo-
some fusion. Within 2–3 hr after incubation with
[pIC]PEI melanoma cells undergo massive ultra-
structural changes in the endosomal compartment
(4). These changes involve a sustained and cyclic
Rab7 > LC3 > Lysotracker sequence of fusion
events, revealing an active generation and resolution of endosome-autophagosome-lysosome hybrids (5). AlthoughMDA-5 can facilitate autophagosome forma-
tion, a main function of this protein described here is the induction of the proapoptotic factor NOXA (6). NOXA is per se a poor apoptotic inducer, but can lower the
threshold for caspase processing. Sustained lysosomal-dependent degradative process together with the activation of apoptotic caspases can ultimately
converge in efficient tumor cell death (7). Importantly, we demonstrate a potent anti-melanoma activity of [pIC]PEI in various animal models, at concentrations
with no obvious toxicity to normal cellular compartments.
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Importantly, the induction of MDA-5 and NOXA by [pIC]PEI was
found to occur even when lysosome activity was blocked by
chloroquine or by cathepsin inhibitors (Figure 6H and Figure S7D
and data not shown). Thus, NOXA can be activated indepen-
dently of the autophagy program. From a therapeutic perspec-
tive, it was interesting to note that cDNA arrays failed to identify
changes in NOXA expression in melanocytes (data not shown).
Similarly, MDA-5 and NOXA were not upregulated in skin fibro-
blasts (Figure S8D), which also showed increased resistance to
[pIC]PEI in culture (Figure S8E) and no obvious signs of toxicity
in biopsies from treated animals (Figure S8F; note also lack of
toxicity to other organs).
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Next, we investigated the dependency on MDA-5 and the dual
activation of autophagosome and apoptotic markers identified
above by [pIC]PEI in vivo. Available antibodies against MDA-5
cannot distinguish full length from processed forms of this
protein. In the absence of current Mda-5-deficient mouse mela-
noma models, we decided to take advantage of homozygous
knockout MEFs for the Mda-5 gene. As shown in Figure 7A,
transformed Mda-5/ MEFs were significantly more resistant
to [pIC]PEI than their wild-type counterparts, both in tissue
culture systems and when grown as xenografts in mice.
Selective antibodies for LC3 and NOXA were used to visualize
autophagosome formation and activation of NOXA by [pIC]PEI in
human melanoma xenografts. Although sporadic stainings for
LC3 or NOXA were detected in vehicle-treated SK-Mel-103
xenografts, the total number of positive cells and the corre-
sponding signal intensity of NOXA or LC3 per individual cell
were noticeably stronger in the [pIC]PEI-treated specimens
(Figure 7B). The animal model used (SCID beige) is highly immu-
nodeficient. Therefore, these results serve as the proof-of-prin-
ciple for the ability of [pIC]PEI to bypass the requirement for
immune effectors and drive tumor cell death by a coordinated
autophagy/apoptosis mechanism.
DISCUSSION
Melanomas accumulate a plethora of genetic and epigenetic
alterations that contribute to the limited efficacy of current anti-
cancer treatments (Chin et al., 2006; Soengas and Lowe,
2003). However, here we have shown that melanoma cells retain
the ability to sense and respond to mimetics of viral dsRNA and
that this feature can be exploited therapeutically. Specifically,
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(A) Response of oncogenically transformed wild-
type (+/+) or Mda-5/ (/) MEFs, measured as
time-dependent changes in tumor size (±SEM)
upon treatment with naked pIC (V) or [pIC]PEI.
Shown are p values for comparative analyses
between the indicated treatment groups (n = 10,
generalized Mann-Whitney test). Inset bar graphs
corresponds to death rates (±SEM; n = 3) of the
indicated cell populations 24 hr after treatment in
culture with 1 mg/ml [pIC]PEI.
(B) SK-Mel-103 GFP-LC3 melanoma cells
implanted subcutaneously into SCID beige mice
were left to grow to 6–8 mm diameter and then
treated with PEI or [pIC]PEI. Paraffin-embedded
sections were stained for LC3 or NOXA antibodies.
For LC3, high magnification photographs are also
included to show the formation of foci character-
istic of autophagosomes.
(C) Model summarizing main results of this study.
A transient activation of IFN and other antiviral
stress response factors by naked pIC (1) can be
shifted into a sustained stress program when this
dsRNA mimic is delivered to cells with PEI (2).
PEI packs pIC into nanoparticles and favors both
its endosomal uptake and delivery to the cytosol
for subsequent activation of the helicase MDA-5
(3). In addition to favor endosomal swelling, PEI
has been described to favor endosome-endo-
some fusion. Within 2–3 hr after incubation with
[pIC]PEI melanoma cells undergo massive ultra-
structural changes in the endosomal compartment
(4). These changes involve a sustained and cyclic
Rab7 > LC3 > Lysotracker sequence of fusion
events, revealing an active generation and resolution of endosome-autophagosome-lysosome hybrids (5). AlthoughMDA-5 can facilitate autophagosome forma-
tion, a main function of this protein described here is the induction of the proapoptotic factor NOXA (6). NOXA is per se a poor apoptotic inducer, but can lower the
threshold for caspase processing. Sustained lysosomal-dependent degradative process together with the activation of apoptotic caspases can ultimately
converge in efficient tumor cell death (7). Importantly, we demonstrate a potent anti-melanoma activity of [pIC]PEI in various animal models, at concentrations
with no obvious toxicity to normal cellular compartments.
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our results revealed tractable points of crosstalk between innate
sensors of dsRNA, endo/lysosomal compartments, and tumor
cell death.
Given the ability of melanoma cells to deactivate death
programs (Gray-Schopfer et al., 2007), it is intriguing that they
remain sensitive to lysosomal-dependent autodegradative
mechanisms. This is particularly relevant because autophagy
has been abundantly linked to cytoprotection in innate and
acquired immune responses (Levine and Deretic, 2007; Sanjuan
and Green, 2008; Virgin and Levine, 2009). Activation of auto-
phagosomes by TLR3 has also been reported for naked dsRNA
in macrophages, but in this case, for protection of the host at
both the cellular and organismal levels (Delgado et al., 2008).
In the melanoma cells studied here, however, TLR3 was found
dispensable for [pIC]PEI-driven autophagy or apoptotic induc-
tion, perhaps reflecting inherent differences in TLR3 expression
between professional immune cells and melanomas.
An intriguing feature of the response of melanoma cells to
[pIC]PEI was a considerable time lag from the detection of the first
series of endosome-autophagosome-lysosome fusions (within
an hour of treatment) to the final cellular collapse (24–48 hr). It
is therefore conceivable that autophagy is engaged in response
to [pIC]PEI as an initial mechanism of protection, which is later
shifted into a prodeath program (see model in Figure 7C).
Thus, autophagy could be engaged to resolve an exacerbated
endocytosis driven by pIC complexed to PEI (Boussif et al.,
1995; Kopatz et al., 2004). Endocytic recruitment of autophago-
somes could initially help tumor cells to maintain a ‘‘clean’’
cytosol. Intraendocytic degradation would prevent leakage or
the accumulation of partially degraded autophagocytic struc-
tures, and/or damaged lysosomes, which could be potentially
lethal to cells (Kroemer and Jaattela, 2005). However, the phys-
ical concentration of autophagosomes and lysosomes within
endocytic vesicles may also provide a point of vulnerability of
melanoma cells. Recurrent cycles of endo/lysosome genera-
tion-degradation could lower the threshold for the activation of
death programs (i.e., by depleting ATP and/or key proteins or
organelles required for cell maintenance) as described in other
systems (Eisenberg-Lerner et al., 2009). In fact, amain difference
between [pIC]PEI (which kills melanoma cells) and rapamycin
(innocuous to melanoma cells) is the sustainability of the endoly-
sosome-autophagosome fusion events. An additional defining
feature of [pIC]PEI not shared by rapamycin or by other chemo-
therapeutic agents is the ability to engage a potent wave of proa-
poptotic events driven, at least in part, by the MDA-5 dsRNA
sensor (see Figure 7C).
MDA-5, a helicase now considered as a first line of defense
against viral dsRNA (Kato et al., 2006), was first described as a
melanoma differentiation-associated gene (Kang et al., 2002).
It was noted that MDA-5 had proapoptotic activities when
expressed ectopically at high levels (Kang et al., 2004; Kovac-
sovics et al., 2002). However, even forced expression of MDA-
5 was rather inefficient in tumor cells with hyperactivated RAS/
MEK/ERK pathway (Lin et al., 2006), as is the case of melanomas
(Gray-Schopfer et al., 2007). Therefore, it was unclear how to
drive a sustained activation of the endogenous MDA-5 protein.
Moreover, the identity of death-inducing targets of MDA-5
remains unclear (Takeuchi and Akira, 2008). We showed that
endogenousMDA-5 can in fact be induced to kill melanoma cells
(with pIC delivered appropriately to the cytosol). Further, we
uncovered roles of MDA-5 beyond the activation of IFN-driven
immune responses. Specifically, we showed the ability of
MDA-5 to drive autophagosome formation and NOXA activation.
Still, our data also suggest that additional death inducers acti-
vated by [pIC]PEI are likely to act in parallel or in concert with
MDA-5 and NOXA (i.e., depletion of these proteins do not
completely abrogate the antitumoral activity of [pIC]PEI). In this
context, the cDNA arrays performed here indicate that [pIC]PEI
can selectively induce a variety of stress kinases with proauto-
phagic and proapoptotic activity (D.T. and M.S.S., unpublished
data).
From a therapeutic perspective, perhaps one the most unex-
pected findings in this study is the cell-autonomous anti-tumoral
activity of [pIC]PEI. pIC has been used formore than four decades
as a synthetic dsRNA mimic to boost the immune system in an
IFN-dependent manner (Field et al., 1967). Unfortunately, clinical
trials with naked pIC showed poor pIC stability and IFN induction
and no detectable antitumor effect in melanoma (Robinson et al.,
1976). Complexes with low molecular weight poly-L-lysine,
carboxymethylcellulose, liposomes, or PEI have been reported
to favor pIC’s therapeutic activity via IFN-dependent immune
responses (Fujimura et al., 2006; Levine et al., 1979). Our results
show that PEI significantly enhances the ability of pIC to induce
melanoma cells to express classical IFN-a targets. However, we
also show that IFN, per se, does not recapitulate the anti-mela-
noma activity of [pIC]PEI in cultured cells. Moreover, [pIC]PEI
can display an efficient anti-melanoma activity in animals with
defective NK, T, or B cell signaling, a condition common of mela-
noma patients (Kirkwood et al., 2008; Wenzel et al., 2008). In
addition to the xenografts in immunosuppressed and immuno-
deficient mice, our results in two additional in vivo models
(MDA-5-deficient cells and autochthonous cutaneous mela-
nomas generated in the Tyr::NRASQ61K; INK4a/ARF/ mice)
further emphasized the physiological relevance of our data. Alto-
gether, our results provide the proof of principle for dsRNA
sensors as therapeutic targets to overcome the inherent resis-
tance of melanoma cells to current anticancer treatments.
EXPERIMENTAL PROCEDURES
Treatment, Imaging, and Expression Analyses in Cultured Cells
The human and mouse metastatic melanoma cell lines used in this study are
described in the Supplemental Experimental Procedures. Normal human
melanocytes and fibroblasts were isolated from anonymous discarded fore-
skins as previously reported (Wolter et al., 2007), using protocols approved
by the University of Michigan and the Instituto Carlos III-CNIO ethics commit-
tees. Wild-type and Atg5- or Bax/Bak-deficient MEFs have been described
before (Kuma et al., 2004; Lindsten et al., 2000). Oncogenically transformed
derivatives of these cells, expressing HRASG12V and the SV40 large T antigen,
were a kind gift of G. Velasco (Universidad Complutense,Madrid, Spain). Infor-
mation on PEI-complexed pIC, pharmacological inhibitors of apoptosis and
autophagy, and other reagents and techniques used here to assess cell death
and cell viability are described in the Supplemental Experimental Procedures.
Details on transmission electron microscopy, confocal and fluorescence
microscopy, protein immunoblotting, lentiviral mediated RNA interference,
and cDNA microarray expression profiling are also described in the Supple-
mental Experimental Procedures. Full data sets corresponding to the cDNA
arrays reported in this study in melanocytes and SK-Mel-103 cells were
deposited to the Gene Expression Omnibus database (with accession
numbers GSE16337 and GSE14445, respectively).
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our results revealed tractable points of crosstalk between innate
sensors of dsRNA, endo/lysosomal compartments, and tumor
cell death.
Given the ability of melanoma cells to deactivate death
programs (Gray-Schopfer et al., 2007), it is intriguing that they
remain sensitive to lysosomal-dependent autodegradative
mechanisms. This is particularly relevant because autophagy
has been abundantly linked to cytoprotection in innate and
acquired immune responses (Levine and Deretic, 2007; Sanjuan
and Green, 2008; Virgin and Levine, 2009). Activation of auto-
phagosomes by TLR3 has also been reported for naked dsRNA
in macrophages, but in this case, for protection of the host at
both the cellular and organismal levels (Delgado et al., 2008).
In the melanoma cells studied here, however, TLR3 was found
dispensable for [pIC]PEI-driven autophagy or apoptotic induc-
tion, perhaps reflecting inherent differences in TLR3 expression
between professional immune cells and melanomas.
An intriguing feature of the response of melanoma cells to
[pIC]PEI was a considerable time lag from the detection of the first
series of endosome-autophagosome-lysosome fusions (within
an hour of treatment) to the final cellular collapse (24–48 hr). It
is therefore conceivable that autophagy is engaged in response
to [pIC]PEI as an initial mechanism of protection, which is later
shifted into a prodeath program (see model in Figure 7C).
Thus, autophagy could be engaged to resolve an exacerbated
endocytosis driven by pIC complexed to PEI (Boussif et al.,
1995; Kopatz et al., 2004). Endocytic recruitment of autophago-
somes could initially help tumor cells to maintain a ‘‘clean’’
cytosol. Intraendocytic degradation would prevent leakage or
the accumulation of partially degraded autophagocytic struc-
tures, and/or damaged lysosomes, which could be potentially
lethal to cells (Kroemer and Jaattela, 2005). However, the phys-
ical concentration of autophagosomes and lysosomes within
endocytic vesicles may also provide a point of vulnerability of
melanoma cells. Recurrent cycles of endo/lysosome genera-
tion-degradation could lower the threshold for the activation of
death programs (i.e., by depleting ATP and/or key proteins or
organelles required for cell maintenance) as described in other
systems (Eisenberg-Lerner et al., 2009). In fact, amain difference
between [pIC]PEI (which kills melanoma cells) and rapamycin
(innocuous to melanoma cells) is the sustainability of the endoly-
sosome-autophagosome fusion events. An additional defining
feature of [pIC]PEI not shared by rapamycin or by other chemo-
therapeutic agents is the ability to engage a potent wave of proa-
poptotic events driven, at least in part, by the MDA-5 dsRNA
sensor (see Figure 7C).
MDA-5, a helicase now considered as a first line of defense
against viral dsRNA (Kato et al., 2006), was first described as a
melanoma differentiation-associated gene (Kang et al., 2002).
It was noted that MDA-5 had proapoptotic activities when
expressed ectopically at high levels (Kang et al., 2004; Kovac-
sovics et al., 2002). However, even forced expression of MDA-
5 was rather inefficient in tumor cells with hyperactivated RAS/
MEK/ERK pathway (Lin et al., 2006), as is the case of melanomas
(Gray-Schopfer et al., 2007). Therefore, it was unclear how to
drive a sustained activation of the endogenous MDA-5 protein.
Moreover, the identity of death-inducing targets of MDA-5
remains unclear (Takeuchi and Akira, 2008). We showed that
endogenousMDA-5 can in fact be induced to kill melanoma cells
(with pIC delivered appropriately to the cytosol). Further, we
uncovered roles of MDA-5 beyond the activation of IFN-driven
immune responses. Specifically, we showed the ability of
MDA-5 to drive autophagosome formation and NOXA activation.
Still, our data also suggest that additional death inducers acti-
vated by [pIC]PEI are likely to act in parallel or in concert with
MDA-5 and NOXA (i.e., depletion of these proteins do not
completely abrogate the antitumoral activity of [pIC]PEI). In this
context, the cDNA arrays performed here indicate that [pIC]PEI
can selectively induce a variety of stress kinases with proauto-
phagic and proapoptotic activity (D.T. and M.S.S., unpublished
data).
From a therapeutic perspective, perhaps one the most unex-
pected findings in this study is the cell-autonomous anti-tumoral
activity of [pIC]PEI. pIC has been used formore than four decades
as a synthetic dsRNA mimic to boost the immune system in an
IFN-dependent manner (Field et al., 1967). Unfortunately, clinical
trials with naked pIC showed poor pIC stability and IFN induction
and no detectable antitumor effect in melanoma (Robinson et al.,
1976). Complexes with low molecular weight poly-L-lysine,
carboxymethylcellulose, liposomes, or PEI have been reported
to favor pIC’s therapeutic activity via IFN-dependent immune
responses (Fujimura et al., 2006; Levine et al., 1979). Our results
show that PEI significantly enhances the ability of pIC to induce
melanoma cells to express classical IFN-a targets. However, we
also show that IFN, per se, does not recapitulate the anti-mela-
noma activity of [pIC]PEI in cultured cells. Moreover, [pIC]PEI
can display an efficient anti-melanoma activity in animals with
defective NK, T, or B cell signaling, a condition common of mela-
noma patients (Kirkwood et al., 2008; Wenzel et al., 2008). In
addition to the xenografts in immunosuppressed and immuno-
deficient mice, our results in two additional in vivo models
(MDA-5-deficient cells and autochthonous cutaneous mela-
nomas generated in the Tyr::NRASQ61K; INK4a/ARF/ mice)
further emphasized the physiological relevance of our data. Alto-
gether, our results provide the proof of principle for dsRNA
sensors as therapeutic targets to overcome the inherent resis-
tance of melanoma cells to current anticancer treatments.
EXPERIMENTAL PROCEDURES
Treatment, Imaging, and Expression Analyses in Cultured Cells
The human and mouse metastatic melanoma cell lines used in this study are
described in the Supplemental Experimental Procedures. Normal human
melanocytes and fibroblasts were isolated from anonymous discarded fore-
skins as previously reported (Wolter et al., 2007), using protocols approved
by the University of Michigan and the Instituto Carlos III-CNIO ethics commit-
tees. Wild-type and Atg5- or Bax/Bak-deficient MEFs have been described
before (Kuma et al., 2004; Lindsten et al., 2000). Oncogenically transformed
derivatives of these cells, expressing HRASG12V and the SV40 large T antigen,
were a kind gift of G. Velasco (Universidad Complutense,Madrid, Spain). Infor-
mation on PEI-complexed pIC, pharmacological inhibitors of apoptosis and
autophagy, and other reagents and techniques used here to assess cell death
and cell viability are described in the Supplemental Experimental Procedures.
Details on transmission electron microscopy, confocal and fluorescence
microscopy, protein immunoblotting, lentiviral mediated RNA interference,
and cDNA microarray expression profiling are also described in the Supple-
mental Experimental Procedures. Full data sets corresponding to the cDNA
arrays reported in this study in melanocytes and SK-Mel-103 cells were
deposited to the Gene Expression Omnibus database (with accession
numbers GSE16337 and GSE14445, respectively).
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Treatment Response In Vivo
All experiments in mouse models were performed in accordance with institu-
tionally approved protocols by the University of Michigan Unit for Laboratory
Animal Medicine Committee and the Instituto Carlos III-CNIO ethics
committee. Generation and treatment of autochthonous melanomas in the
Tyr::N-RasQ61K/; Ink4a/Arf/mice and the analysis of melanoma xenografts
in C57BL/6 and in the immunosuppressed SCID beige mice are summarized
in the Supplemental Experimental Procedures.
Histopathological and Immunohistochemical Analyses
Tumors or tissue sections from the indicated treatment groups were fixed in
10% buffered formalin, embedded in paraffin, and routinely stained with
hematoxylin and eosin. Alternatively, tumors were immunostained with the
NOXA antibody (Calbiochem) and LC3 antibody (Cell Signaling). Slides were
digitalized with Dotslide (Olympus).
Statistical Analyses
Viability data are expressed as means ± SEM and statistical analysis of the
differences was determined by the two-tailed Student’s t test. For statistical
evaluation of tumor growth andmetastasis in vivo, the generalizedMann-Whit-
ney test was used to compare the values of continuous variables between two
groups. p values of < 0.05 were considered significant.
SUPPLEMENTAL DATA
Supplemental Data include Supplemental Experimental Procedures, eight
figures, one table, and seven movies and can be found with this article online
at http://www.cell.com/cancer-cell/supplemental/S1535-6108(09)00217-7.
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committee. Generation and treatment of autochthonous melanomas in the
Tyr::N-RasQ61K/; Ink4a/Arf/mice and the analysis of melanoma xenografts
in C57BL/6 and in the immunosuppressed SCID beige mice are summarized
in the Supplemental Experimental Procedures.
Histopathological and Immunohistochemical Analyses
Tumors or tissue sections from the indicated treatment groups were fixed in
10% buffered formalin, embedded in paraffin, and routinely stained with
hematoxylin and eosin. Alternatively, tumors were immunostained with the
NOXA antibody (Calbiochem) and LC3 antibody (Cell Signaling). Slides were
digitalized with Dotslide (Olympus).
Statistical Analyses
Viability data are expressed as means ± SEM and statistical analysis of the
differences was determined by the two-tailed Student’s t test. For statistical
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